https://www.hirudotherapysociety.org/en/research/tardy-predictive-factors-for-thrombosis-and-major-bleeding-in-an-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tardy-predictive-factors-for-thrombosis-and-major-bleeding-in-an-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tardy-predictive-factors-for-thrombosis-and-major-bleeding-in-an-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tardy-predictive-factors-for-thrombosis-and-major-bleeding-in-an-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mazur-ornatins-potent-glycoprotein-iib-iiia-antagonists-and-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mazur-ornatins-potent-glycoprotein-iib-iiia-antagonists-and-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mazur-ornatins-potent-glycoprotein-iib-iiia-antagonists-and-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mazur-ornatins-potent-glycoprotein-iib-iiia-antagonists-and-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nowak-thrombin-induced-tumour-growth-pharmacological-control-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nowak-thrombin-induced-tumour-growth-pharmacological-control-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nowak-thrombin-induced-tumour-growth-pharmacological-control-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nowak-thrombin-induced-tumour-growth-pharmacological-control-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aeberli-macrophage-migration-inhibitory-factor-and-glucocorticoid-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aeberli-macrophage-migration-inhibitory-factor-and-glucocorticoid-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aeberli-macrophage-migration-inhibitory-factor-and-glucocorticoid-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aeberli-macrophage-migration-inhibitory-factor-and-glucocorticoid-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/de-leeches-in-the-intensive-care-unit-nursing-care-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/de-leeches-in-the-intensive-care-unit-nursing-care-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/de-leeches-in-the-intensive-care-unit-nursing-care-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/de-leeches-in-the-intensive-care-unit-nursing-care-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ni-decrease-of-hirudin-degradation-by-deleting-the-kex1-gene-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ni-decrease-of-hirudin-degradation-by-deleting-the-kex1-gene-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ni-decrease-of-hirudin-degradation-by-deleting-the-kex1-gene-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ni-decrease-of-hirudin-degradation-by-deleting-the-kex1-gene-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leech-peptide-based-immunotherapy-of-experimental-autoimmune-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leech-peptide-based-immunotherapy-of-experimental-autoimmune-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leech-peptide-based-immunotherapy-of-experimental-autoimmune-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leech-peptide-based-immunotherapy-of-experimental-autoimmune-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hoffman-reduced-argatroban-doses-after-coronary-artery-bypass-graft-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hoffman-reduced-argatroban-doses-after-coronary-artery-bypass-graft-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hoffman-reduced-argatroban-doses-after-coronary-artery-bypass-graft-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hoffman-reduced-argatroban-doses-after-coronary-artery-bypass-graft-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guo-a-recombinant-peptide-hirudin-potentiates-the-inhibitory-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guo-a-recombinant-peptide-hirudin-potentiates-the-inhibitory-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guo-a-recombinant-peptide-hirudin-potentiates-the-inhibitory-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guo-a-recombinant-peptide-hirudin-potentiates-the-inhibitory-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hursting-argatroban-anticoagulation-in-renal-dysfunction-a-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hursting-argatroban-anticoagulation-in-renal-dysfunction-a-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hursting-argatroban-anticoagulation-in-renal-dysfunction-a-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hursting-argatroban-anticoagulation-in-renal-dysfunction-a-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hirbawi-role-of-the-acidic-hirudin-like-cooh-terminal-amino-acid-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hirbawi-role-of-the-acidic-hirudin-like-cooh-terminal-amino-acid-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hirbawi-role-of-the-acidic-hirudin-like-cooh-terminal-amino-acid-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hirbawi-role-of-the-acidic-hirudin-like-cooh-terminal-amino-acid-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kalimuthu-nonarterialized-venous-replantation-of-part-of-amputated-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kalimuthu-nonarterialized-venous-replantation-of-part-of-amputated-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kalimuthu-nonarterialized-venous-replantation-of-part-of-amputated-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kalimuthu-nonarterialized-venous-replantation-of-part-of-amputated-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hursting-reducing-harm-associated-with-anticoagulation-practical-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hursting-reducing-harm-associated-with-anticoagulation-practical-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hursting-reducing-harm-associated-with-anticoagulation-practical-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hursting-reducing-harm-associated-with-anticoagulation-practical-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tardyponcet-extremely-low-doses-of-lepirudin-in-a-patient-with-heparin-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tardyponcet-extremely-low-doses-of-lepirudin-in-a-patient-with-heparin-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tardyponcet-extremely-low-doses-of-lepirudin-in-a-patient-with-heparin-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tardyponcet-extremely-low-doses-of-lepirudin-in-a-patient-with-heparin-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/genzen-prolonged-elevation-of-plasma-argatroban-in-a-cardiac-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/genzen-prolonged-elevation-of-plasma-argatroban-in-a-cardiac-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/genzen-prolonged-elevation-of-plasma-argatroban-in-a-cardiac-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/genzen-prolonged-elevation-of-plasma-argatroban-in-a-cardiac-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/saugel-argatroban-therapy-for-heparin-induced-thrombocytopenia-in-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/saugel-argatroban-therapy-for-heparin-induced-thrombocytopenia-in-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/saugel-argatroban-therapy-for-heparin-induced-thrombocytopenia-in-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/saugel-argatroban-therapy-for-heparin-induced-thrombocytopenia-in-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/draenert-management-of-venous-thrombosis-in-fibular-free-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/draenert-management-of-venous-thrombosis-in-fibular-free-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/draenert-management-of-venous-thrombosis-in-fibular-free-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/draenert-management-of-venous-thrombosis-in-fibular-free-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schenker-paradoxical-interactions-between-modifiers-and-elastase-2-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schenker-paradoxical-interactions-between-modifiers-and-elastase-2-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schenker-paradoxical-interactions-between-modifiers-and-elastase-2-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schenker-paradoxical-interactions-between-modifiers-and-elastase-2-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/valnickova-flexibility-of-the-thrombin-activatable-fibrinolysis-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/valnickova-flexibility-of-the-thrombin-activatable-fibrinolysis-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/valnickova-flexibility-of-the-thrombin-activatable-fibrinolysis-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/valnickova-flexibility-of-the-thrombin-activatable-fibrinolysis-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/karadag-a-case-of-irritant-contact-dermatitis-with-leech-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/karadag-a-case-of-irritant-contact-dermatitis-with-leech-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/karadag-a-case-of-irritant-contact-dermatitis-with-leech-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/karadag-a-case-of-irritant-contact-dermatitis-with-leech-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rana-redesigning-allosteric-activation-in-an-enzyme-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rana-redesigning-allosteric-activation-in-an-enzyme-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rana-redesigning-allosteric-activation-in-an-enzyme-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rana-redesigning-allosteric-activation-in-an-enzyme-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sommers-sensitive-detection-of-oversulfated-chondroitin-sulfate-in-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sommers-sensitive-detection-of-oversulfated-chondroitin-sulfate-in-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sommers-sensitive-detection-of-oversulfated-chondroitin-sulfate-in-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sommers-sensitive-detection-of-oversulfated-chondroitin-sulfate-in-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kang-highly-sensitive-potentiometric-strip-test-for-detecting-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kang-highly-sensitive-potentiometric-strip-test-for-detecting-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kang-highly-sensitive-potentiometric-strip-test-for-detecting-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kang-highly-sensitive-potentiometric-strip-test-for-detecting-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ong-reversal-of-transfusion-dependence-by-tumor-necrosis-factor-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ong-reversal-of-transfusion-dependence-by-tumor-necrosis-factor-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ong-reversal-of-transfusion-dependence-by-tumor-necrosis-factor-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ong-reversal-of-transfusion-dependence-by-tumor-necrosis-factor-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/palmerini-prognostic-value-of-the-syntax-score-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/palmerini-prognostic-value-of-the-syntax-score-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/palmerini-prognostic-value-of-the-syntax-score-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/palmerini-prognostic-value-of-the-syntax-score-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baber-how-serious-a-problem-is-bleeding-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baber-how-serious-a-problem-is-bleeding-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baber-how-serious-a-problem-is-bleeding-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baber-how-serious-a-problem-is-bleeding-in-patients-with-acute-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zang-identification-of-heparin-samples-that-contain-impurities-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zang-identification-of-heparin-samples-that-contain-impurities-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zang-identification-of-heparin-samples-that-contain-impurities-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zang-identification-of-heparin-samples-that-contain-impurities-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aich-competitive-inhibition-of-heparinase-by-persulfonated-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aich-competitive-inhibition-of-heparinase-by-persulfonated-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aich-competitive-inhibition-of-heparinase-by-persulfonated-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aich-competitive-inhibition-of-heparinase-by-persulfonated-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/montpas-anaphylactoid-reactions-associated-with-contaminated-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/montpas-anaphylactoid-reactions-associated-with-contaminated-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/montpas-anaphylactoid-reactions-associated-with-contaminated-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/montpas-anaphylactoid-reactions-associated-with-contaminated-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clark-the-rcpch-care-pathway-for-children-at-risk-of-anaphylaxis-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clark-the-rcpch-care-pathway-for-children-at-risk-of-anaphylaxis-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clark-the-rcpch-care-pathway-for-children-at-risk-of-anaphylaxis-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clark-the-rcpch-care-pathway-for-children-at-risk-of-anaphylaxis-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ausen-flaps-pedicled-on-the-superficial-temporal-artery-and-vein-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ausen-flaps-pedicled-on-the-superficial-temporal-artery-and-vein-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ausen-flaps-pedicled-on-the-superficial-temporal-artery-and-vein-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ausen-flaps-pedicled-on-the-superficial-temporal-artery-and-vein-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gray-interactions-of-oversulfated-chondroitin-sulfate-oscs-from-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gray-interactions-of-oversulfated-chondroitin-sulfate-oscs-from-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gray-interactions-of-oversulfated-chondroitin-sulfate-oscs-from-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gray-interactions-of-oversulfated-chondroitin-sulfate-oscs-from-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/acharji-prognostic-significance-of-elevated-baseline-troponin-in-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/acharji-prognostic-significance-of-elevated-baseline-troponin-in-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/acharji-prognostic-significance-of-elevated-baseline-troponin-in-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/acharji-prognostic-significance-of-elevated-baseline-troponin-in-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bates-clinical-experience-with-argatroban-for-heparin-induced-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bates-clinical-experience-with-argatroban-for-heparin-induced-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bates-clinical-experience-with-argatroban-for-heparin-induced-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bates-clinical-experience-with-argatroban-for-heparin-induced-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/volpi-agarose-gel-electrophoresis-for-the-quality-assurance-and-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/volpi-agarose-gel-electrophoresis-for-the-quality-assurance-and-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/volpi-agarose-gel-electrophoresis-for-the-quality-assurance-and-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/volpi-agarose-gel-electrophoresis-for-the-quality-assurance-and-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chess-case-study-contamination-of-heparin-with-oversulfated-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chess-case-study-contamination-of-heparin-with-oversulfated-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chess-case-study-contamination-of-heparin-with-oversulfated-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chess-case-study-contamination-of-heparin-with-oversulfated-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/beccati-identification-of-a-novel-structure-in-heparin-generated-by-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/beccati-identification-of-a-novel-structure-in-heparin-generated-by-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/beccati-identification-of-a-novel-structure-in-heparin-generated-by-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/beccati-identification-of-a-novel-structure-in-heparin-generated-by-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/volpi-electrophoresis-for-the-analysis-of-heparin-purity-and-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/volpi-electrophoresis-for-the-analysis-of-heparin-purity-and-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/volpi-electrophoresis-for-the-analysis-of-heparin-purity-and-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/volpi-electrophoresis-for-the-analysis-of-heparin-purity-and-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-total-scalp-replantation-salvaged-by-changing-the-recipient-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-total-scalp-replantation-salvaged-by-changing-the-recipient-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-total-scalp-replantation-salvaged-by-changing-the-recipient-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-total-scalp-replantation-salvaged-by-changing-the-recipient-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nikolsky-outcomes-of-patients-with-prior-coronary-artery-bypass-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nikolsky-outcomes-of-patients-with-prior-coronary-artery-bypass-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nikolsky-outcomes-of-patients-with-prior-coronary-artery-bypass-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nikolsky-outcomes-of-patients-with-prior-coronary-artery-bypass-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hedlund-the-heparin-recall-of-2008-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hedlund-the-heparin-recall-of-2008-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hedlund-the-heparin-recall-of-2008-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hedlund-the-heparin-recall-of-2008-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/medina-strategies-to-increase-flap-survival-in-nasal-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/medina-strategies-to-increase-flap-survival-in-nasal-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/medina-strategies-to-increase-flap-survival-in-nasal-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/medina-strategies-to-increase-flap-survival-in-nasal-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/boyle-the-complete-n-terminal-extension-of-heparin-cofactor-ii-is-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/boyle-the-complete-n-terminal-extension-of-heparin-cofactor-ii-is-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/boyle-the-complete-n-terminal-extension-of-heparin-cofactor-ii-is-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/boyle-the-complete-n-terminal-extension-of-heparin-cofactor-ii-is-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/seymour-decorsin-a-potent-glycoprotein-iib-iiia-antagonist-and-1990 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/seymour-decorsin-a-potent-glycoprotein-iib-iiia-antagonist-and-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/seymour-decorsin-a-potent-glycoprotein-iib-iiia-antagonist-and-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/seymour-decorsin-a-potent-glycoprotein-iib-iiia-antagonist-and-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nemes-high-throughput-differentiation-of-heparin-from-other-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nemes-high-throughput-differentiation-of-heparin-from-other-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nemes-high-throughput-differentiation-of-heparin-from-other-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nemes-high-throughput-differentiation-of-heparin-from-other-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ye-characterization-of-currently-marketed-heparin-products-key-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ye-characterization-of-currently-marketed-heparin-products-key-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ye-characterization-of-currently-marketed-heparin-products-key-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ye-characterization-of-currently-marketed-heparin-products-key-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yang-annexin-a1-potential-for-glucocorticoid-sparing-in-ra-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yang-annexin-a1-potential-for-glucocorticoid-sparing-in-ra-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yang-annexin-a1-potential-for-glucocorticoid-sparing-in-ra-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yang-annexin-a1-potential-for-glucocorticoid-sparing-in-ra-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kashiwagi-quantitative-analysis-of-hemodynamics-of-congested-island-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kashiwagi-quantitative-analysis-of-hemodynamics-of-congested-island-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kashiwagi-quantitative-analysis-of-hemodynamics-of-congested-island-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kashiwagi-quantitative-analysis-of-hemodynamics-of-congested-island-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-method-to-detect-contaminants-in-heparin-using-radical-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-method-to-detect-contaminants-in-heparin-using-radical-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-method-to-detect-contaminants-in-heparin-using-radical-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-method-to-detect-contaminants-in-heparin-using-radical-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/valgimigli-scientific-foundation-and-possible-implications-for-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/valgimigli-scientific-foundation-and-possible-implications-for-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/valgimigli-scientific-foundation-and-possible-implications-for-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/valgimigli-scientific-foundation-and-possible-implications-for-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hopkins-morphological-and-molecular-characterization-of-a-new-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hopkins-morphological-and-molecular-characterization-of-a-new-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hopkins-morphological-and-molecular-characterization-of-a-new-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hopkins-morphological-and-molecular-characterization-of-a-new-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bae-identification-of-lactoferrin-as-a-human-dedifferentiation-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bae-identification-of-lactoferrin-as-a-human-dedifferentiation-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bae-identification-of-lactoferrin-as-a-human-dedifferentiation-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bae-identification-of-lactoferrin-as-a-human-dedifferentiation-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhou-oversulfated-chondroitin-sulfate-binds-to-chemokines-and-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhou-oversulfated-chondroitin-sulfate-binds-to-chemokines-and-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhou-oversulfated-chondroitin-sulfate-binds-to-chemokines-and-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhou-oversulfated-chondroitin-sulfate-binds-to-chemokines-and-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/eades-gilz-a-new-link-between-the-hypothalamic-pituitary-adrenal-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/eades-gilz-a-new-link-between-the-hypothalamic-pituitary-adrenal-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/eades-gilz-a-new-link-between-the-hypothalamic-pituitary-adrenal-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/eades-gilz-a-new-link-between-the-hypothalamic-pituitary-adrenal-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaiser-contaminated-heparin-and-outcomes-after-cardiac-surgery-a-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaiser-contaminated-heparin-and-outcomes-after-cardiac-surgery-a-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaiser-contaminated-heparin-and-outcomes-after-cardiac-surgery-a-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaiser-contaminated-heparin-and-outcomes-after-cardiac-surgery-a-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clemmensen-multinational-non-interventional-study-of-patients-with-st-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clemmensen-multinational-non-interventional-study-of-patients-with-st-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clemmensen-multinational-non-interventional-study-of-patients-with-st-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clemmensen-multinational-non-interventional-study-of-patients-with-st-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goto-prognostic-value-of-angiographic-lesion-complexity-in-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goto-prognostic-value-of-angiographic-lesion-complexity-in-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goto-prognostic-value-of-angiographic-lesion-complexity-in-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goto-prognostic-value-of-angiographic-lesion-complexity-in-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/valgimigli-design-and-rationale-for-the-minimizing-adverse-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/valgimigli-design-and-rationale-for-the-minimizing-adverse-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/valgimigli-design-and-rationale-for-the-minimizing-adverse-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/valgimigli-design-and-rationale-for-the-minimizing-adverse-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/capodanno-bivalirudin-for-acute-coronary-syndromes-premises-promises-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/capodanno-bivalirudin-for-acute-coronary-syndromes-premises-promises-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/capodanno-bivalirudin-for-acute-coronary-syndromes-premises-promises-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/capodanno-bivalirudin-for-acute-coronary-syndromes-premises-promises-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xin-improving-the-bioactivity-of-rhirudin-with-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xin-improving-the-bioactivity-of-rhirudin-with-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xin-improving-the-bioactivity-of-rhirudin-with-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xin-improving-the-bioactivity-of-rhirudin-with-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/navarese-comprehensive-meta-analysis-of-safety-and-efficacy-of-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/navarese-comprehensive-meta-analysis-of-safety-and-efficacy-of-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/navarese-comprehensive-meta-analysis-of-safety-and-efficacy-of-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/navarese-comprehensive-meta-analysis-of-safety-and-efficacy-of-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mirakian-management-of-allergy-to-penicillins-and-other-beta-lactams-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mirakian-management-of-allergy-to-penicillins-and-other-beta-lactams-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mirakian-management-of-allergy-to-penicillins-and-other-beta-lactams-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mirakian-management-of-allergy-to-penicillins-and-other-beta-lactams-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/verdoia-bivalirudin-as-compared-to-unfractionated-heparin-in-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/verdoia-bivalirudin-as-compared-to-unfractionated-heparin-in-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/verdoia-bivalirudin-as-compared-to-unfractionated-heparin-in-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/verdoia-bivalirudin-as-compared-to-unfractionated-heparin-in-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/one-hour-screening-of-adulterated-heparin-by-simplified-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/one-hour-screening-of-adulterated-heparin-by-simplified-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/one-hour-screening-of-adulterated-heparin-by-simplified-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/one-hour-screening-of-adulterated-heparin-by-simplified-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/asgari-rational-design-of-stable-and-functional-hirudin-iii-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/asgari-rational-design-of-stable-and-functional-hirudin-iii-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/asgari-rational-design-of-stable-and-functional-hirudin-iii-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/asgari-rational-design-of-stable-and-functional-hirudin-iii-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sugg-the-reverse-superficial-sural-artery-flap-revisited-for-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sugg-the-reverse-superficial-sural-artery-flap-revisited-for-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sugg-the-reverse-superficial-sural-artery-flap-revisited-for-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sugg-the-reverse-superficial-sural-artery-flap-revisited-for-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/turner-safety-of-live-attenuated-influenza-vaccine-in-young-people-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/turner-safety-of-live-attenuated-influenza-vaccine-in-young-people-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/turner-safety-of-live-attenuated-influenza-vaccine-in-young-people-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/turner-safety-of-live-attenuated-influenza-vaccine-in-young-people-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baylan-reverse-posterior-interosseous-flap-for-defects-of-the-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baylan-reverse-posterior-interosseous-flap-for-defects-of-the-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baylan-reverse-posterior-interosseous-flap-for-defects-of-the-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baylan-reverse-posterior-interosseous-flap-for-defects-of-the-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/borthwick-the-il-1-cytokine-family-and-its-role-in-inflammation-and-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/borthwick-the-il-1-cytokine-family-and-its-role-in-inflammation-and-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/borthwick-the-il-1-cytokine-family-and-its-role-in-inflammation-and-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/borthwick-the-il-1-cytokine-family-and-its-role-in-inflammation-and-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/laine-potential-mechanism-of-acute-stent-thrombosis-with-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/laine-potential-mechanism-of-acute-stent-thrombosis-with-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/laine-potential-mechanism-of-acute-stent-thrombosis-with-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/laine-potential-mechanism-of-acute-stent-thrombosis-with-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rothenberger-determining-the-appropriate-number-and-duration-of-leech-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rothenberger-determining-the-appropriate-number-and-duration-of-leech-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rothenberger-determining-the-appropriate-number-and-duration-of-leech-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rothenberger-determining-the-appropriate-number-and-duration-of-leech-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ewan-prescribing-an-adrenaline-auto-injector-personalized-care-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ewan-prescribing-an-adrenaline-auto-injector-personalized-care-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ewan-prescribing-an-adrenaline-auto-injector-personalized-care-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ewan-prescribing-an-adrenaline-auto-injector-personalized-care-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/linke-effect-of-valve-design-and-anticoagulation-strategy-on-30-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/linke-effect-of-valve-design-and-anticoagulation-strategy-on-30-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/linke-effect-of-valve-design-and-anticoagulation-strategy-on-30-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/linke-effect-of-valve-design-and-anticoagulation-strategy-on-30-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/capodanno-antithrombotic-strategies-in-valvular-and-structural-heart-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/capodanno-antithrombotic-strategies-in-valvular-and-structural-heart-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/capodanno-antithrombotic-strategies-in-valvular-and-structural-heart-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/capodanno-antithrombotic-strategies-in-valvular-and-structural-heart-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wipfli-assessment-of-fibrin-polymerization-during-bivalirudin-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wipfli-assessment-of-fibrin-polymerization-during-bivalirudin-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wipfli-assessment-of-fibrin-polymerization-during-bivalirudin-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wipfli-assessment-of-fibrin-polymerization-during-bivalirudin-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/de-antithrombotic-strategies-in-the-catheterization-laboratory-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/de-antithrombotic-strategies-in-the-catheterization-laboratory-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/de-antithrombotic-strategies-in-the-catheterization-laboratory-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/de-antithrombotic-strategies-in-the-catheterization-laboratory-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clarke-heightened-autoantibody-immune-response-to-citrullinated-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clarke-heightened-autoantibody-immune-response-to-citrullinated-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clarke-heightened-autoantibody-immune-response-to-citrullinated-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clarke-heightened-autoantibody-immune-response-to-citrullinated-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hassen-management-of-refractory-bleeding-post-cardiopulmonary-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hassen-management-of-refractory-bleeding-post-cardiopulmonary-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hassen-management-of-refractory-bleeding-post-cardiopulmonary-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hassen-management-of-refractory-bleeding-post-cardiopulmonary-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/villablanca-bivalirudin-versus-heparin-in-patients-undergoing-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/villablanca-bivalirudin-versus-heparin-in-patients-undergoing-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/villablanca-bivalirudin-versus-heparin-in-patients-undergoing-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/villablanca-bivalirudin-versus-heparin-in-patients-undergoing-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/minhas-periprocedural-anticoagulation-in-transcatheter-aortic-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/minhas-periprocedural-anticoagulation-in-transcatheter-aortic-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/minhas-periprocedural-anticoagulation-in-transcatheter-aortic-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/minhas-periprocedural-anticoagulation-in-transcatheter-aortic-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/patel-stroke-after-transcatheter-aortic-valve-replacement-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/patel-stroke-after-transcatheter-aortic-valve-replacement-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/patel-stroke-after-transcatheter-aortic-valve-replacement-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/patel-stroke-after-transcatheter-aortic-valve-replacement-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nxfchrenberg-efficacy-and-safety-of-bivalirudin-for-percutaneous-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nxfchrenberg-efficacy-and-safety-of-bivalirudin-for-percutaneous-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nxfchrenberg-efficacy-and-safety-of-bivalirudin-for-percutaneous-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nxfchrenberg-efficacy-and-safety-of-bivalirudin-for-percutaneous-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/burke-exploring-the-difference-in-post-procedural-stroke-rates-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/burke-exploring-the-difference-in-post-procedural-stroke-rates-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/burke-exploring-the-difference-in-post-procedural-stroke-rates-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/burke-exploring-the-difference-in-post-procedural-stroke-rates-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wu-effect-of-astragali-radix-on-growth-immunity-and-related-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wu-effect-of-astragali-radix-on-growth-immunity-and-related-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wu-effect-of-astragali-radix-on-growth-immunity-and-related-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wu-effect-of-astragali-radix-on-growth-immunity-and-related-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shi-effects-of-cu-enrichment-and-release-on-growth-internal-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shi-effects-of-cu-enrichment-and-release-on-growth-internal-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shi-effects-of-cu-enrichment-and-release-on-growth-internal-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shi-effects-of-cu-enrichment-and-release-on-growth-internal-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nijenhuis-usefulness-of-clopidogrel-loading-in-patients-who-underwent-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nijenhuis-usefulness-of-clopidogrel-loading-in-patients-who-underwent-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nijenhuis-usefulness-of-clopidogrel-loading-in-patients-who-underwent-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nijenhuis-usefulness-of-clopidogrel-loading-in-patients-who-underwent-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mendoza-equine-pythiosis-in-costa-rica-report-of-39-cases-1986 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mendoza-equine-pythiosis-in-costa-rica-report-of-39-cases-1986 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mendoza-equine-pythiosis-in-costa-rica-report-of-39-cases-1986 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mendoza-equine-pythiosis-in-costa-rica-report-of-39-cases-1986 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wang-leeches-attenuate-blood-hyperviscosity-and-related-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wang-leeches-attenuate-blood-hyperviscosity-and-related-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wang-leeches-attenuate-blood-hyperviscosity-and-related-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wang-leeches-attenuate-blood-hyperviscosity-and-related-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schxfcpke-revacept-a-novel-inhibitor-of-platelet-adhesion-in-patients-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schxfcpke-revacept-a-novel-inhibitor-of-platelet-adhesion-in-patients-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schxfcpke-revacept-a-novel-inhibitor-of-platelet-adhesion-in-patients-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schxfcpke-revacept-a-novel-inhibitor-of-platelet-adhesion-in-patients-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-linear-peptides-containing-d-leucine-with-neuroprotective-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-linear-peptides-containing-d-leucine-with-neuroprotective-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-linear-peptides-containing-d-leucine-with-neuroprotective-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-linear-peptides-containing-d-leucine-with-neuroprotective-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mendes-crude-heparin-preparations-unveil-the-presence-of-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mendes-crude-heparin-preparations-unveil-the-presence-of-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mendes-crude-heparin-preparations-unveil-the-presence-of-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mendes-crude-heparin-preparations-unveil-the-presence-of-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wang-effects-of-17-e2-on-growth-and-gonad-development-of-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wang-effects-of-17-e2-on-growth-and-gonad-development-of-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wang-effects-of-17-e2-on-growth-and-gonad-development-of-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wang-effects-of-17-e2-on-growth-and-gonad-development-of-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goel-impact-of-diabetes-mellitus-on-short-term-vascular-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goel-impact-of-diabetes-mellitus-on-short-term-vascular-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goel-impact-of-diabetes-mellitus-on-short-term-vascular-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goel-impact-of-diabetes-mellitus-on-short-term-vascular-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zheng-buzangtongluo-decoction-improved-hindlimb-ischemia-by-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zheng-buzangtongluo-decoction-improved-hindlimb-ischemia-by-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zheng-buzangtongluo-decoction-improved-hindlimb-ischemia-by-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zheng-buzangtongluo-decoction-improved-hindlimb-ischemia-by-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cairns-loss-of-elk1-has-differential-effects-on-age-dependent-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cairns-loss-of-elk1-has-differential-effects-on-age-dependent-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cairns-loss-of-elk1-has-differential-effects-on-age-dependent-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cairns-loss-of-elk1-has-differential-effects-on-age-dependent-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/camaj-the-importance-of-the-heart-team-evaluation-before-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/camaj-the-importance-of-the-heart-team-evaluation-before-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/camaj-the-importance-of-the-heart-team-evaluation-before-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/camaj-the-importance-of-the-heart-team-evaluation-before-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hu-a-peptide-inhibitor-of-macrophage-migration-in-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hu-a-peptide-inhibitor-of-macrophage-migration-in-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hu-a-peptide-inhibitor-of-macrophage-migration-in-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hu-a-peptide-inhibitor-of-macrophage-migration-in-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/luo-metabolomics-based-study-reveals-the-effect-of-lead-pb-in-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/luo-metabolomics-based-study-reveals-the-effect-of-lead-pb-in-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/luo-metabolomics-based-study-reveals-the-effect-of-lead-pb-in-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/luo-metabolomics-based-study-reveals-the-effect-of-lead-pb-in-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zheng-serum-metabolomic-profiles-reveal-the-impact-of-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zheng-serum-metabolomic-profiles-reveal-the-impact-of-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zheng-serum-metabolomic-profiles-reveal-the-impact-of-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zheng-serum-metabolomic-profiles-reveal-the-impact-of-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jiang-purification-and-characterization-of-a-novel-fibrinolytic-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jiang-purification-and-characterization-of-a-novel-fibrinolytic-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jiang-purification-and-characterization-of-a-novel-fibrinolytic-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jiang-purification-and-characterization-of-a-novel-fibrinolytic-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baker-lack-of-association-between-clinical-and-ultrasound-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baker-lack-of-association-between-clinical-and-ultrasound-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baker-lack-of-association-between-clinical-and-ultrasound-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baker-lack-of-association-between-clinical-and-ultrasound-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bi-preparation-and-application-of-nanosensor-in-safeguarding-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bi-preparation-and-application-of-nanosensor-in-safeguarding-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bi-preparation-and-application-of-nanosensor-in-safeguarding-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bi-preparation-and-application-of-nanosensor-in-safeguarding-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hardy-effects-of-time-interval-since-blood-draw-and-of-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hardy-effects-of-time-interval-since-blood-draw-and-of-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hardy-effects-of-time-interval-since-blood-draw-and-of-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hardy-effects-of-time-interval-since-blood-draw-and-of-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bxernthaler-supplemental-fibrinogen-restores-platelet-inhibitor-induced-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bxernthaler-supplemental-fibrinogen-restores-platelet-inhibitor-induced-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bxernthaler-supplemental-fibrinogen-restores-platelet-inhibitor-induced-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bxernthaler-supplemental-fibrinogen-restores-platelet-inhibitor-induced-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ehrmann-assessment-of-platelet-biology-in-equine-patients-with-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ehrmann-assessment-of-platelet-biology-in-equine-patients-with-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ehrmann-assessment-of-platelet-biology-in-equine-patients-with-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ehrmann-assessment-of-platelet-biology-in-equine-patients-with-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhao-a-novel-oncotherapy-strategy-direct-thrombin-inhibitors-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhao-a-novel-oncotherapy-strategy-direct-thrombin-inhibitors-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhao-a-novel-oncotherapy-strategy-direct-thrombin-inhibitors-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhao-a-novel-oncotherapy-strategy-direct-thrombin-inhibitors-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/boissiere-flap-venous-congestion-and-salvage-techniques-a-systematic-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/boissiere-flap-venous-congestion-and-salvage-techniques-a-systematic-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/boissiere-flap-venous-congestion-and-salvage-techniques-a-systematic-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/boissiere-flap-venous-congestion-and-salvage-techniques-a-systematic-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chandrasekhar-incidence-predictors-and-outcomes-associated-with-acute-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chandrasekhar-incidence-predictors-and-outcomes-associated-with-acute-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chandrasekhar-incidence-predictors-and-outcomes-associated-with-acute-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chandrasekhar-incidence-predictors-and-outcomes-associated-with-acute-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/razuk-impact-of-anemia-on-short-term-outcomes-after-tavr-a-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/razuk-impact-of-anemia-on-short-term-outcomes-after-tavr-a-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/razuk-impact-of-anemia-on-short-term-outcomes-after-tavr-a-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/razuk-impact-of-anemia-on-short-term-outcomes-after-tavr-a-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tugulan-heparin-induced-thrombocytopenia-after-mitral-valve-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tugulan-heparin-induced-thrombocytopenia-after-mitral-valve-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tugulan-heparin-induced-thrombocytopenia-after-mitral-valve-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tugulan-heparin-induced-thrombocytopenia-after-mitral-valve-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leech-bsaci-2021-guideline-for-the-management-of-egg-allergy-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leech-bsaci-2021-guideline-for-the-management-of-egg-allergy-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leech-bsaci-2021-guideline-for-the-management-of-egg-allergy-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leech-bsaci-2021-guideline-for-the-management-of-egg-allergy-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/faour-reperfusion-after-fibrinolytic-therapy-raft-an-open-label-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/faour-reperfusion-after-fibrinolytic-therapy-raft-an-open-label-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/faour-reperfusion-after-fibrinolytic-therapy-raft-an-open-label-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/faour-reperfusion-after-fibrinolytic-therapy-raft-an-open-label-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bergh-a-systematic-review-of-complementary-and-alternative-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bergh-a-systematic-review-of-complementary-and-alternative-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bergh-a-systematic-review-of-complementary-and-alternative-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bergh-a-systematic-review-of-complementary-and-alternative-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/duan-spontaneous-platelet-aggregation-in-blood-is-mediated-by-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/duan-spontaneous-platelet-aggregation-in-blood-is-mediated-by-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/duan-spontaneous-platelet-aggregation-in-blood-is-mediated-by-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/duan-spontaneous-platelet-aggregation-in-blood-is-mediated-by-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/landsem-complement-c3b-contributes-to-induced-platelet-aggregation-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/landsem-complement-c3b-contributes-to-induced-platelet-aggregation-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/landsem-complement-c3b-contributes-to-induced-platelet-aggregation-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/landsem-complement-c3b-contributes-to-induced-platelet-aggregation-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/devlin-analysis-of-heparin-samples-by-attenuated-total-reflectance-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/devlin-analysis-of-heparin-samples-by-attenuated-total-reflectance-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/devlin-analysis-of-heparin-samples-by-attenuated-total-reflectance-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/devlin-analysis-of-heparin-samples-by-attenuated-total-reflectance-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/feldman-impact-of-coronary-artery-disease-on-clinical-outcomes-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/feldman-impact-of-coronary-artery-disease-on-clinical-outcomes-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/feldman-impact-of-coronary-artery-disease-on-clinical-outcomes-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/feldman-impact-of-coronary-artery-disease-on-clinical-outcomes-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/galli-bivalirudin-in-acute-coronary-syndromes-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/galli-bivalirudin-in-acute-coronary-syndromes-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/galli-bivalirudin-in-acute-coronary-syndromes-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/galli-bivalirudin-in-acute-coronary-syndromes-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/martin-comparison-of-outcomes-in-patients-requiring-mechanical-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/martin-comparison-of-outcomes-in-patients-requiring-mechanical-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/martin-comparison-of-outcomes-in-patients-requiring-mechanical-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/martin-comparison-of-outcomes-in-patients-requiring-mechanical-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pexfablanco-heparin-induced-dress-syndrome-in-a-paediatric-patient-and-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pexfablanco-heparin-induced-dress-syndrome-in-a-paediatric-patient-and-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pexfablanco-heparin-induced-dress-syndrome-in-a-paediatric-patient-and-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pexfablanco-heparin-induced-dress-syndrome-in-a-paediatric-patient-and-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhao-recombinant-hirudin-suppresses-angiogenesis-of-diffuselarge-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhao-recombinant-hirudin-suppresses-angiogenesis-of-diffuselarge-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhao-recombinant-hirudin-suppresses-angiogenesis-of-diffuselarge-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhao-recombinant-hirudin-suppresses-angiogenesis-of-diffuselarge-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/termine-what-do-we-know-about-dietary-perceptions-and-beliefs-of-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/termine-what-do-we-know-about-dietary-perceptions-and-beliefs-of-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/termine-what-do-we-know-about-dietary-perceptions-and-beliefs-of-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/termine-what-do-we-know-about-dietary-perceptions-and-beliefs-of-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/alaiwah-successful-thrombolytic-therapy-formechanical-mitral-valve-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/alaiwah-successful-thrombolytic-therapy-formechanical-mitral-valve-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/alaiwah-successful-thrombolytic-therapy-formechanical-mitral-valve-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/alaiwah-successful-thrombolytic-therapy-formechanical-mitral-valve-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nadtochiy-intravenous-dabigatran-for-anticoagulation-during-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nadtochiy-intravenous-dabigatran-for-anticoagulation-during-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nadtochiy-intravenous-dabigatran-for-anticoagulation-during-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nadtochiy-intravenous-dabigatran-for-anticoagulation-during-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tran-2025-guidelines-for-direct-oral-anticoagulants-a-practical-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tran-2025-guidelines-for-direct-oral-anticoagulants-a-practical-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tran-2025-guidelines-for-direct-oral-anticoagulants-a-practical-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tran-2025-guidelines-for-direct-oral-anticoagulants-a-practical-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/teissandier-sonorheometry-parameters-during-dabigatran-reversal-with-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/teissandier-sonorheometry-parameters-during-dabigatran-reversal-with-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/teissandier-sonorheometry-parameters-during-dabigatran-reversal-with-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/teissandier-sonorheometry-parameters-during-dabigatran-reversal-with-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/von-diagnostics-and-management-of-direct-oral-anticoagulants-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/von-diagnostics-and-management-of-direct-oral-anticoagulants-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/von-diagnostics-and-management-of-direct-oral-anticoagulants-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/von-diagnostics-and-management-of-direct-oral-anticoagulants-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/savi-thrombosis-and-coagulopathy-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/savi-thrombosis-and-coagulopathy-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/savi-thrombosis-and-coagulopathy-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/savi-thrombosis-and-coagulopathy-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/teissandier-corrigendum-to-sonorheometry-parameters-during-dabigatran-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/teissandier-corrigendum-to-sonorheometry-parameters-during-dabigatran-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/teissandier-corrigendum-to-sonorheometry-parameters-during-dabigatran-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/teissandier-corrigendum-to-sonorheometry-parameters-during-dabigatran-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-idarucizumab-more-effectively-reverses-the-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-idarucizumab-more-effectively-reverses-the-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-idarucizumab-more-effectively-reverses-the-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-idarucizumab-more-effectively-reverses-the-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zxetroch-management-of-emergencies-in-direct-oral-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zxetroch-management-of-emergencies-in-direct-oral-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zxetroch-management-of-emergencies-in-direct-oral-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zxetroch-management-of-emergencies-in-direct-oral-anticoagulant-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abbot-cost-effectiveness-of-dabigatran-for-thromboembolic-events-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abbot-cost-effectiveness-of-dabigatran-for-thromboembolic-events-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abbot-cost-effectiveness-of-dabigatran-for-thromboembolic-events-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abbot-cost-effectiveness-of-dabigatran-for-thromboembolic-events-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dettore-platelet-derived-prothrombotic-microparticles-and-adverse-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dettore-platelet-derived-prothrombotic-microparticles-and-adverse-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dettore-platelet-derived-prothrombotic-microparticles-and-adverse-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dettore-platelet-derived-prothrombotic-microparticles-and-adverse-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ye-comparative-study-of-lefaxin-family-in-two-asian-leeches-and-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ye-comparative-study-of-lefaxin-family-in-two-asian-leeches-and-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ye-comparative-study-of-lefaxin-family-in-two-asian-leeches-and-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ye-comparative-study-of-lefaxin-family-in-two-asian-leeches-and-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-optimization-of-conditions-related-to-chrono-log-platelet-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-optimization-of-conditions-related-to-chrono-log-platelet-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-optimization-of-conditions-related-to-chrono-log-platelet-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-optimization-of-conditions-related-to-chrono-log-platelet-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pontesneto-latin-america-multidisciplinary-consensus-panel-on-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pontesneto-latin-america-multidisciplinary-consensus-panel-on-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pontesneto-latin-america-multidisciplinary-consensus-panel-on-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pontesneto-latin-america-multidisciplinary-consensus-panel-on-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mrvar-idarucizumab-reversal-in-subdural-hemorrhage-a-single-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mrvar-idarucizumab-reversal-in-subdural-hemorrhage-a-single-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mrvar-idarucizumab-reversal-in-subdural-hemorrhage-a-single-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mrvar-idarucizumab-reversal-in-subdural-hemorrhage-a-single-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ziyuan-the-clinical-efficacy-of-herbal-medicines-containing-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ziyuan-the-clinical-efficacy-of-herbal-medicines-containing-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ziyuan-the-clinical-efficacy-of-herbal-medicines-containing-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ziyuan-the-clinical-efficacy-of-herbal-medicines-containing-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/turner-identifying-and-prioritising-bsaci-service-standards-for-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/turner-identifying-and-prioritising-bsaci-service-standards-for-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/turner-identifying-and-prioritising-bsaci-service-standards-for-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/turner-identifying-and-prioritising-bsaci-service-standards-for-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-emergency-reversal-of-antithrombotics-in-intracerebral-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-emergency-reversal-of-antithrombotics-in-intracerebral-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-emergency-reversal-of-antithrombotics-in-intracerebral-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-emergency-reversal-of-antithrombotics-in-intracerebral-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/eaton-dabigatran-idarucizumab-pharmacokinetics-pharmacodynamics-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/eaton-dabigatran-idarucizumab-pharmacokinetics-pharmacodynamics-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/eaton-dabigatran-idarucizumab-pharmacokinetics-pharmacodynamics-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/eaton-dabigatran-idarucizumab-pharmacokinetics-pharmacodynamics-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sari-post-ablation-stroke-despite-noac-use-successful-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sari-post-ablation-stroke-despite-noac-use-successful-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sari-post-ablation-stroke-despite-noac-use-successful-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sari-post-ablation-stroke-despite-noac-use-successful-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/choudhary-balancing-bleeding-and-thrombosis-in-dental-management-of-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/choudhary-balancing-bleeding-and-thrombosis-in-dental-management-of-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/choudhary-balancing-bleeding-and-thrombosis-in-dental-management-of-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/choudhary-balancing-bleeding-and-thrombosis-in-dental-management-of-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yang-genetically-encoded-multivalent-elastin-like-polypeptide-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yang-genetically-encoded-multivalent-elastin-like-polypeptide-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yang-genetically-encoded-multivalent-elastin-like-polypeptide-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yang-genetically-encoded-multivalent-elastin-like-polypeptide-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/samhan-role-of-argatroban-infusion-in-controlling-clot-formation-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/samhan-role-of-argatroban-infusion-in-controlling-clot-formation-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/samhan-role-of-argatroban-infusion-in-controlling-clot-formation-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/samhan-role-of-argatroban-infusion-in-controlling-clot-formation-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dhakal-dabigatran-induced-gastrointestinal-bleed-treated-by-4-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dhakal-dabigatran-induced-gastrointestinal-bleed-treated-by-4-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dhakal-dabigatran-induced-gastrointestinal-bleed-treated-by-4-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dhakal-dabigatran-induced-gastrointestinal-bleed-treated-by-4-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/liu-construction-of-corynebacterium-glutamicum-for-efficient-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/liu-construction-of-corynebacterium-glutamicum-for-efficient-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/liu-construction-of-corynebacterium-glutamicum-for-efficient-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/liu-construction-of-corynebacterium-glutamicum-for-efficient-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ng-anticoagulation-stewardship-program-in-the-doac-era-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ng-anticoagulation-stewardship-program-in-the-doac-era-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ng-anticoagulation-stewardship-program-in-the-doac-era-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ng-anticoagulation-stewardship-program-in-the-doac-era-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cai-intravenous-thrombolysis-for-acute-cerebral-embolism-during-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cai-intravenous-thrombolysis-for-acute-cerebral-embolism-during-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cai-intravenous-thrombolysis-for-acute-cerebral-embolism-during-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cai-intravenous-thrombolysis-for-acute-cerebral-embolism-during-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sxeflund-safety-and-outcomes-of-dabigatran-reversal-with-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sxeflund-safety-and-outcomes-of-dabigatran-reversal-with-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sxeflund-safety-and-outcomes-of-dabigatran-reversal-with-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sxeflund-safety-and-outcomes-of-dabigatran-reversal-with-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guo-hirudin-suppresses-ovarian-cancer-cell-proliferation-and-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guo-hirudin-suppresses-ovarian-cancer-cell-proliferation-and-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guo-hirudin-suppresses-ovarian-cancer-cell-proliferation-and-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guo-hirudin-suppresses-ovarian-cancer-cell-proliferation-and-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/elmasri-anticoagulation-associated-intracerebral-haemorrhage-trends-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/elmasri-anticoagulation-associated-intracerebral-haemorrhage-trends-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/elmasri-anticoagulation-associated-intracerebral-haemorrhage-trends-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/elmasri-anticoagulation-associated-intracerebral-haemorrhage-trends-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leech-letter-incidence-and-prevalence-1973 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leech-letter-incidence-and-prevalence-1973 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leech-letter-incidence-and-prevalence-1973 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leech-letter-incidence-and-prevalence-1973 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tsuda-design-of-potent-bivalent-thrombin-inhibitors-based-on-1994 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tsuda-design-of-potent-bivalent-thrombin-inhibitors-based-on-1994 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tsuda-design-of-potent-bivalent-thrombin-inhibitors-based-on-1994 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tsuda-design-of-potent-bivalent-thrombin-inhibitors-based-on-1994 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gilhooly-salvage-of-a-microvascular-scalp-reconstruction-with-hirudo-1993 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gilhooly-salvage-of-a-microvascular-scalp-reconstruction-with-hirudo-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gilhooly-salvage-of-a-microvascular-scalp-reconstruction-with-hirudo-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gilhooly-salvage-of-a-microvascular-scalp-reconstruction-with-hirudo-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lehman-expression-purification-and-characterization-of-multigram-1993 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lehman-expression-purification-and-characterization-of-multigram-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lehman-expression-purification-and-characterization-of-multigram-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lehman-expression-purification-and-characterization-of-multigram-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mclane-a-comparison-of-the-effect-of-decorsin-and-two-disintegrins-1995 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mclane-a-comparison-of-the-effect-of-decorsin-and-two-disintegrins-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mclane-a-comparison-of-the-effect-of-decorsin-and-two-disintegrins-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mclane-a-comparison-of-the-effect-of-decorsin-and-two-disintegrins-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/funk-microvascular-replantation-of-a-traumatically-amputated-ear-1996 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/funk-microvascular-replantation-of-a-traumatically-amputated-ear-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/funk-microvascular-replantation-of-a-traumatically-amputated-ear-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/funk-microvascular-replantation-of-a-traumatically-amputated-ear-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kornowski-enhancement-of-recombinant-tissue-type-plasminogen-1996 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kornowski-enhancement-of-recombinant-tissue-type-plasminogen-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kornowski-enhancement-of-recombinant-tissue-type-plasminogen-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kornowski-enhancement-of-recombinant-tissue-type-plasminogen-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/finney-tridegin-a-new-peptidic-inhibitor-of-factor-xiiia-from-the-1997 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/finney-tridegin-a-new-peptidic-inhibitor-of-factor-xiiia-from-the-1997 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/finney-tridegin-a-new-peptidic-inhibitor-of-factor-xiiia-from-the-1997 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/finney-tridegin-a-new-peptidic-inhibitor-of-factor-xiiia-from-the-1997 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/polverino-chemical-synthesis-and-structural-characterization-of-the-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/polverino-chemical-synthesis-and-structural-characterization-of-the-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/polverino-chemical-synthesis-and-structural-characterization-of-the-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/polverino-chemical-synthesis-and-structural-characterization-of-the-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mellet-stopped-flow-fluorescence-energy-transfer-measurement-of-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mellet-stopped-flow-fluorescence-energy-transfer-measurement-of-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mellet-stopped-flow-fluorescence-energy-transfer-measurement-of-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mellet-stopped-flow-fluorescence-energy-transfer-measurement-of-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barnett-icam-1-cd18-interaction-mediates-neutrophil-cytotoxicity-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barnett-icam-1-cd18-interaction-mediates-neutrophil-cytotoxicity-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barnett-icam-1-cd18-interaction-mediates-neutrophil-cytotoxicity-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barnett-icam-1-cd18-interaction-mediates-neutrophil-cytotoxicity-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/taoka-role-of-neutrophil-elastase-in-compression-induced-spinal-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/taoka-role-of-neutrophil-elastase-in-compression-induced-spinal-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/taoka-role-of-neutrophil-elastase-in-compression-induced-spinal-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/taoka-role-of-neutrophil-elastase-in-compression-induced-spinal-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shafer-cardiovascular-chemotherapy-anticoagulants-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shafer-cardiovascular-chemotherapy-anticoagulants-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shafer-cardiovascular-chemotherapy-anticoagulants-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shafer-cardiovascular-chemotherapy-anticoagulants-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/totani-polymorphonuclear-leukocytes-induce-pdgf-release-from-il-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/totani-polymorphonuclear-leukocytes-induce-pdgf-release-from-il-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/totani-polymorphonuclear-leukocytes-induce-pdgf-release-from-il-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/totani-polymorphonuclear-leukocytes-induce-pdgf-release-from-il-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lai-elastase-in-hyperpnea-induced-guinea-pig-airway-constriction-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lai-elastase-in-hyperpnea-induced-guinea-pig-airway-constriction-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lai-elastase-in-hyperpnea-induced-guinea-pig-airway-constriction-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lai-elastase-in-hyperpnea-induced-guinea-pig-airway-constriction-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mortenson-medicinal-leeches-used-to-salvage-a-traumatic-nasal-flap-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mortenson-medicinal-leeches-used-to-salvage-a-traumatic-nasal-flap-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mortenson-medicinal-leeches-used-to-salvage-a-traumatic-nasal-flap-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mortenson-medicinal-leeches-used-to-salvage-a-traumatic-nasal-flap-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mumper-the-stabilization-and-release-of-hirudin-from-liposomes-or-2000 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mumper-the-stabilization-and-release-of-hirudin-from-liposomes-or-2000 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mumper-the-stabilization-and-release-of-hirudin-from-liposomes-or-2000 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mumper-the-stabilization-and-release-of-hirudin-from-liposomes-or-2000 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-studies-on-preparation-of-recombinant-hirudin-2-liposome-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-studies-on-preparation-of-recombinant-hirudin-2-liposome-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-studies-on-preparation-of-recombinant-hirudin-2-liposome-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-studies-on-preparation-of-recombinant-hirudin-2-liposome-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/meng-increase-of-the-pharmacological-and-pharmacokinetic-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/meng-increase-of-the-pharmacological-and-pharmacokinetic-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/meng-increase-of-the-pharmacological-and-pharmacokinetic-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/meng-increase-of-the-pharmacological-and-pharmacokinetic-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gronwald-structure-of-the-leech-protein-saratin-and-characterization-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gronwald-structure-of-the-leech-protein-saratin-and-characterization-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gronwald-structure-of-the-leech-protein-saratin-and-characterization-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gronwald-structure-of-the-leech-protein-saratin-and-characterization-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mo-a-novel-hirudin-derivative-characterized-with-anti-platelet-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mo-a-novel-hirudin-derivative-characterized-with-anti-platelet-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mo-a-novel-hirudin-derivative-characterized-with-anti-platelet-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mo-a-novel-hirudin-derivative-characterized-with-anti-platelet-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baskova-protein-lipid-particles-of-medicinal-leech-salivary-gland-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baskova-protein-lipid-particles-of-medicinal-leech-salivary-gland-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baskova-protein-lipid-particles-of-medicinal-leech-salivary-gland-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baskova-protein-lipid-particles-of-medicinal-leech-salivary-gland-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/struck-phylogenomic-analyses-unravel-annelid-evolution-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/struck-phylogenomic-analyses-unravel-annelid-evolution-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/struck-phylogenomic-analyses-unravel-annelid-evolution-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/struck-phylogenomic-analyses-unravel-annelid-evolution-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/siddall-bacterial-symbiont-and-salivary-peptide-evolution-in-the-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/siddall-bacterial-symbiont-and-salivary-peptide-evolution-in-the-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/siddall-bacterial-symbiont-and-salivary-peptide-evolution-in-the-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/siddall-bacterial-symbiont-and-salivary-peptide-evolution-in-the-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/silver-innate-and-procured-immunity-inside-the-digestive-tract-of-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/silver-innate-and-procured-immunity-inside-the-digestive-tract-of-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/silver-innate-and-procured-immunity-inside-the-digestive-tract-of-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/silver-innate-and-procured-immunity-inside-the-digestive-tract-of-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kostromina-biotechnological-production-of-recombinant-analogs-of-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kostromina-biotechnological-production-of-recombinant-analogs-of-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kostromina-biotechnological-production-of-recombinant-analogs-of-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kostromina-biotechnological-production-of-recombinant-analogs-of-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guan-analysis-of-codon-usage-patterns-in-hirudinaria-manillensis-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guan-analysis-of-codon-usage-patterns-in-hirudinaria-manillensis-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guan-analysis-of-codon-usage-patterns-in-hirudinaria-manillensis-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guan-analysis-of-codon-usage-patterns-in-hirudinaria-manillensis-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/phillips-phylogenomic-analysis-of-a-putative-missing-link-sparks-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/phillips-phylogenomic-analysis-of-a-putative-missing-link-sparks-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/phillips-phylogenomic-analysis-of-a-putative-missing-link-sparks-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/phillips-phylogenomic-analysis-of-a-putative-missing-link-sparks-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shi-proteome-and-phosphoproteome-profiling-reveals-the-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shi-proteome-and-phosphoproteome-profiling-reveals-the-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shi-proteome-and-phosphoproteome-profiling-reveals-the-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shi-proteome-and-phosphoproteome-profiling-reveals-the-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lewin-annelid-comparative-genomics-and-the-evolution-of-massive-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lewin-annelid-comparative-genomics-and-the-evolution-of-massive-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lewin-annelid-comparative-genomics-and-the-evolution-of-massive-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lewin-annelid-comparative-genomics-and-the-evolution-of-massive-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yao-chromosome-level-genome-assembly-of-the-cave-leech-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yao-chromosome-level-genome-assembly-of-the-cave-leech-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yao-chromosome-level-genome-assembly-of-the-cave-leech-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yao-chromosome-level-genome-assembly-of-the-cave-leech-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/verdes-erga-bge-reference-genome-of-the-lineid-heteronemertean-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/verdes-erga-bge-reference-genome-of-the-lineid-heteronemertean-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/verdes-erga-bge-reference-genome-of-the-lineid-heteronemertean-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/verdes-erga-bge-reference-genome-of-the-lineid-heteronemertean-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pereira-1998-leech-borne-serratia-marcescens 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pereira-1998-leech-borne-serratia-marcescens 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pereira-1998-leech-borne-serratia-marcescens 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pereira-1998-leech-borne-serratia-marcescens 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/camici-1999-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/camici-1999-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/camici-1999-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/camici-1999-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/despotis-1999-anticoagulation-and-anticoagulation-reversal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/despotis-1999-anticoagulation-and-anticoagulation-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/despotis-1999-anticoagulation-and-anticoagulation-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/despotis-1999-anticoagulation-and-anticoagulation-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/scarborough-1998-coagulation-factor-xa-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/scarborough-1998-coagulation-factor-xa-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/scarborough-1998-coagulation-factor-xa-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/scarborough-1998-coagulation-factor-xa-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/slonusakiewicz-2000-design-of-p1-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/slonusakiewicz-2000-design-of-p1-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/slonusakiewicz-2000-design-of-p1-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/slonusakiewicz-2000-design-of-p1-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/esmon-2000-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/esmon-2000-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/esmon-2000-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/esmon-2000-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/frederiksen-2000-cardiopulmonary-bypass-in-humans 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/frederiksen-2000-cardiopulmonary-bypass-in-humans 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/frederiksen-2000-cardiopulmonary-bypass-in-humans 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/frederiksen-2000-cardiopulmonary-bypass-in-humans 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/follis-2000-cardiopulmonary-bypass-in-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/follis-2000-cardiopulmonary-bypass-in-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/follis-2000-cardiopulmonary-bypass-in-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/follis-2000-cardiopulmonary-bypass-in-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pinto-2001-discovery-of-1-3 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pinto-2001-discovery-of-1-3 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pinto-2001-discovery-of-1-3 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pinto-2001-discovery-of-1-3 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gunzel-2001-apparent-intracellular-mg2-buffering 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gunzel-2001-apparent-intracellular-mg2-buffering 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gunzel-2001-apparent-intracellular-mg2-buffering 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gunzel-2001-apparent-intracellular-mg2-buffering 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rezaie-2000-heparin-binding-exosite-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rezaie-2000-heparin-binding-exosite-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rezaie-2000-heparin-binding-exosite-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rezaie-2000-heparin-binding-exosite-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/beck-2001-calcium-transients-in-subcompartments 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/beck-2001-calcium-transients-in-subcompartments 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/beck-2001-calcium-transients-in-subcompartments 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/beck-2001-calcium-transients-in-subcompartments 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/esmon-2001-protein-c-anticoagulant-pathway 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/esmon-2001-protein-c-anticoagulant-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/esmon-2001-protein-c-anticoagulant-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/esmon-2001-protein-c-anticoagulant-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hirsh-2001-new-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hirsh-2001-new-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hirsh-2001-new-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hirsh-2001-new-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/heller-2001-lower-extremity-microsurgical-reconstruction 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/heller-2001-lower-extremity-microsurgical-reconstruction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/heller-2001-lower-extremity-microsurgical-reconstruction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/heller-2001-lower-extremity-microsurgical-reconstruction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vonsegesser-2001-alternatives-to-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vonsegesser-2001-alternatives-to-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vonsegesser-2001-alternatives-to-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vonsegesser-2001-alternatives-to-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hsu-2001-heparin-coated-cardiopulmonary-bypass 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hsu-2001-heparin-coated-cardiopulmonary-bypass 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hsu-2001-heparin-coated-cardiopulmonary-bypass 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hsu-2001-heparin-coated-cardiopulmonary-bypass 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bajaj-2001-structure-and-biology-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bajaj-2001-structure-and-biology-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bajaj-2001-structure-and-biology-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bajaj-2001-structure-and-biology-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sterud-2001-the-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sterud-2001-the-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sterud-2001-the-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sterud-2001-the-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaiser-2001-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaiser-2001-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaiser-2001-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaiser-2001-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kobayashi-2005-antithrombin-abnormalities-and-perinatal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kobayashi-2005-antithrombin-abnormalities-and-perinatal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kobayashi-2005-antithrombin-abnormalities-and-perinatal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kobayashi-2005-antithrombin-abnormalities-and-perinatal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/manithody-2005-functional-mapping-of-charged 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/manithody-2005-functional-mapping-of-charged 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/manithody-2005-functional-mapping-of-charged 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/manithody-2005-functional-mapping-of-charged 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/obrien-2006-activated-protein-c-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/obrien-2006-activated-protein-c-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/obrien-2006-activated-protein-c-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/obrien-2006-activated-protein-c-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lwaleed-2006-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lwaleed-2006-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lwaleed-2006-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lwaleed-2006-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mosnier-2006-protein-c-anticoagulant-activity 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mosnier-2006-protein-c-anticoagulant-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mosnier-2006-protein-c-anticoagulant-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mosnier-2006-protein-c-anticoagulant-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mccrindle-2006-presentation-management-and-outcomes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mccrindle-2006-presentation-management-and-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mccrindle-2006-presentation-management-and-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mccrindle-2006-presentation-management-and-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rezaie-2006-determinants-of-specificity-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rezaie-2006-determinants-of-specificity-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rezaie-2006-determinants-of-specificity-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rezaie-2006-determinants-of-specificity-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lessmann-1991-development-of-serotonin-induced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lessmann-1991-development-of-serotonin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lessmann-1991-development-of-serotonin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lessmann-1991-development-of-serotonin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gittins-2006-comparison-of-alteplase-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gittins-2006-comparison-of-alteplase-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gittins-2006-comparison-of-alteplase-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gittins-2006-comparison-of-alteplase-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pryor-2006-implantable-doppler-flow-system 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pryor-2006-implantable-doppler-flow-system 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pryor-2006-implantable-doppler-flow-system 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pryor-2006-implantable-doppler-flow-system 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rose-2006-activity-dependent-suppression-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rose-2006-activity-dependent-suppression-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rose-2006-activity-dependent-suppression-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rose-2006-activity-dependent-suppression-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mosnier-2006-the-cytoprotective-protein-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mosnier-2006-the-cytoprotective-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mosnier-2006-the-cytoprotective-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mosnier-2006-the-cytoprotective-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/spiegel-2007-microvascular-flap-reconstruction-by 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/spiegel-2007-microvascular-flap-reconstruction-by 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/spiegel-2007-microvascular-flap-reconstruction-by 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/spiegel-2007-microvascular-flap-reconstruction-by 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/repez-2007-continuous-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/repez-2007-continuous-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/repez-2007-continuous-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/repez-2007-continuous-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bock-2007-exosites-in-the-substrate 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bock-2007-exosites-in-the-substrate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bock-2007-exosites-in-the-substrate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bock-2007-exosites-in-the-substrate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/weiss-1991-allergy-to-protamine 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/weiss-1991-allergy-to-protamine 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/weiss-1991-allergy-to-protamine 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/weiss-1991-allergy-to-protamine 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/crawley-2007-the-haemostatic-role-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/crawley-2007-the-haemostatic-role-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/crawley-2007-the-haemostatic-role-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/crawley-2007-the-haemostatic-role-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-2008-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-2008-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-2008-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-2008-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moran-2008-locking-solutions-for-hemodialysis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moran-2008-locking-solutions-for-hemodialysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moran-2008-locking-solutions-for-hemodialysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moran-2008-locking-solutions-for-hemodialysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qureshi-2009-membrane-dependent-interaction-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qureshi-2009-membrane-dependent-interaction-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qureshi-2009-membrane-dependent-interaction-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qureshi-2009-membrane-dependent-interaction-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/whitaker-2011-near-infrared-spectroscopy-for 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/whitaker-2011-near-infrared-spectroscopy-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/whitaker-2011-near-infrared-spectroscopy-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/whitaker-2011-near-infrared-spectroscopy-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dellavalle-2011-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dellavalle-2011-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dellavalle-2011-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dellavalle-2011-the-protein-c-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/osterud-2011-tissue-factor-tfpi-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/osterud-2011-tissue-factor-tfpi-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/osterud-2011-tissue-factor-tfpi-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/osterud-2011-tissue-factor-tfpi-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/douketis-2012-perioperative-management-of-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/douketis-2012-perioperative-management-of-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/douketis-2012-perioperative-management-of-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/douketis-2012-perioperative-management-of-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dinicolantonio-2012-dabigatran-or-warfarin-for 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dinicolantonio-2012-dabigatran-or-warfarin-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dinicolantonio-2012-dabigatran-or-warfarin-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dinicolantonio-2012-dabigatran-or-warfarin-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/griffin-2012-protein-c-anticoagulant-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/griffin-2012-protein-c-anticoagulant-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/griffin-2012-protein-c-anticoagulant-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/griffin-2012-protein-c-anticoagulant-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bertrand-2012-meta-analysis-comparing-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bertrand-2012-meta-analysis-comparing-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bertrand-2012-meta-analysis-comparing-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bertrand-2012-meta-analysis-comparing-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vadivel-2012-structural-biology-of-factor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vadivel-2012-structural-biology-of-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vadivel-2012-structural-biology-of-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vadivel-2012-structural-biology-of-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goland-2012-anticoagulation-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goland-2012-anticoagulation-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goland-2012-anticoagulation-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goland-2012-anticoagulation-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abel-2012-direct-thrombin-inhibitors-for 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abel-2012-direct-thrombin-inhibitors-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abel-2012-direct-thrombin-inhibitors-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abel-2012-direct-thrombin-inhibitors-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/giorgi-2012-rivaroxaban-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/giorgi-2012-rivaroxaban-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/giorgi-2012-rivaroxaban-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/giorgi-2012-rivaroxaban-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chae-2015-current-evidence-for-postoperative 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chae-2015-current-evidence-for-postoperative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chae-2015-current-evidence-for-postoperative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chae-2015-current-evidence-for-postoperative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lohman-2012-a-prospective-analysis-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lohman-2012-a-prospective-analysis-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lohman-2012-a-prospective-analysis-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lohman-2012-a-prospective-analysis-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yon-2013-sodium-citrate-4-versus 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yon-2013-sodium-citrate-4-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yon-2013-sodium-citrate-4-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yon-2013-sodium-citrate-4-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/finley-2013-review-article-heparin-sensitivity 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/finley-2013-review-article-heparin-sensitivity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/finley-2013-review-article-heparin-sensitivity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/finley-2013-review-article-heparin-sensitivity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schiffer-2013-central-venous-catheter-care 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schiffer-2013-central-venous-catheter-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schiffer-2013-central-venous-catheter-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schiffer-2013-central-venous-catheter-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yasaka-2013-direct-oral-thrombin-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yasaka-2013-direct-oral-thrombin-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yasaka-2013-direct-oral-thrombin-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yasaka-2013-direct-oral-thrombin-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yamada-2013-neutron-and-x-ray 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yamada-2013-neutron-and-x-ray 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yamada-2013-neutron-and-x-ray 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yamada-2013-neutron-and-x-ray 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schuijt-2013-factor-xa-activation-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schuijt-2013-factor-xa-activation-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schuijt-2013-factor-xa-activation-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schuijt-2013-factor-xa-activation-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lee-2013-treatment-of-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lee-2013-treatment-of-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lee-2013-treatment-of-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lee-2013-treatment-of-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mast-2015-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mast-2015-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mast-2015-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mast-2015-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/voineskos-2015-breast-reconstruction-following-conservative 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/voineskos-2015-breast-reconstruction-following-conservative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/voineskos-2015-breast-reconstruction-following-conservative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/voineskos-2015-breast-reconstruction-following-conservative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/buck-2015-bivalirudin-as-an-alternative 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/buck-2015-bivalirudin-as-an-alternative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/buck-2015-bivalirudin-as-an-alternative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/buck-2015-bivalirudin-as-an-alternative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chu-2016-low-dose-heparin-lock 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chu-2016-low-dose-heparin-lock 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chu-2016-low-dose-heparin-lock 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chu-2016-low-dose-heparin-lock 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rehfeldt-2016-cardiopulmonary-bypass-without-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rehfeldt-2016-cardiopulmonary-bypass-without-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rehfeldt-2016-cardiopulmonary-bypass-without-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rehfeldt-2016-cardiopulmonary-bypass-without-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barriaperez-2016-meta-analysis-of-effects 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barriaperez-2016-meta-analysis-of-effects 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barriaperez-2016-meta-analysis-of-effects 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barriaperez-2016-meta-analysis-of-effects 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chang-2016-deciphering-the-sensitivity-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chang-2016-deciphering-the-sensitivity-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chang-2016-deciphering-the-sensitivity-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chang-2016-deciphering-the-sensitivity-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/palla-2016-the-effects-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/palla-2016-the-effects-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/palla-2016-the-effects-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/palla-2016-the-effects-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sharma-2016-daboxin-p-a-major 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sharma-2016-daboxin-p-a-major 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sharma-2016-daboxin-p-a-major 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sharma-2016-daboxin-p-a-major 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carniol-2016-head-and-neck-microvascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carniol-2016-head-and-neck-microvascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carniol-2016-head-and-neck-microvascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carniol-2016-head-and-neck-microvascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/han-2016-low-dose-versus-high 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/han-2016-low-dose-versus-high 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/han-2016-low-dose-versus-high 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/han-2016-low-dose-versus-high 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/andreoli-2016-eular-recommendations-for-women 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/andreoli-2016-eular-recommendations-for-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/andreoli-2016-eular-recommendations-for-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/andreoli-2016-eular-recommendations-for-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moubayed-2016-what-are-the-optimal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moubayed-2016-what-are-the-optimal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moubayed-2016-what-are-the-optimal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moubayed-2016-what-are-the-optimal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carmo-2016-dabigatran-in-real-world 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carmo-2016-dabigatran-in-real-world 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carmo-2016-dabigatran-in-real-world 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carmo-2016-dabigatran-in-real-world 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/achilles-2017-dabigatran-enhances-platelet-reactivity 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/achilles-2017-dabigatran-enhances-platelet-reactivity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/achilles-2017-dabigatran-enhances-platelet-reactivity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/achilles-2017-dabigatran-enhances-platelet-reactivity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/franco-2016-lower-extremity-reconstruction-with 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/franco-2016-lower-extremity-reconstruction-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/franco-2016-lower-extremity-reconstruction-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/franco-2016-lower-extremity-reconstruction-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/blair-2017-dabigatran-etexilate-a-review 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/blair-2017-dabigatran-etexilate-a-review 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/blair-2017-dabigatran-etexilate-a-review 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/blair-2017-dabigatran-etexilate-a-review 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/deitmer-1987-the-regulation-of-intracellular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/deitmer-1987-the-regulation-of-intracellular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/deitmer-1987-the-regulation-of-intracellular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/deitmer-1987-the-regulation-of-intracellular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mumoli-2017-dabigatran-in-nonvalvular-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mumoli-2017-dabigatran-in-nonvalvular-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mumoli-2017-dabigatran-in-nonvalvular-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mumoli-2017-dabigatran-in-nonvalvular-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/patel-2017-free-flap-reconstruction-monitoring 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/patel-2017-free-flap-reconstruction-monitoring 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/patel-2017-free-flap-reconstruction-monitoring 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/patel-2017-free-flap-reconstruction-monitoring 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rossor-2018-anticoagulation-in-the-management 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rossor-2018-anticoagulation-in-the-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rossor-2018-anticoagulation-in-the-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rossor-2018-anticoagulation-in-the-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/khatri-2018-conservative-management-of-neonatal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/khatri-2018-conservative-management-of-neonatal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/khatri-2018-conservative-management-of-neonatal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/khatri-2018-conservative-management-of-neonatal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaariainen-2018-modern-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaariainen-2018-modern-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaariainen-2018-modern-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaariainen-2018-modern-postoperative-monitoring-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barton-2018-anticoagulation-during-ecmo-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barton-2018-anticoagulation-during-ecmo-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barton-2018-anticoagulation-during-ecmo-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barton-2018-anticoagulation-during-ecmo-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/garcia-2018-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/garcia-2018-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/garcia-2018-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/garcia-2018-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sobieraj-2018-anticoagulation-for-the-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sobieraj-2018-anticoagulation-for-the-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sobieraj-2018-anticoagulation-for-the-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sobieraj-2018-anticoagulation-for-the-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/uthman-2018-management-of-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/uthman-2018-management-of-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/uthman-2018-management-of-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/uthman-2018-management-of-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/papageorgiou-2018-disseminated-intravascular-coagulation-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/papageorgiou-2018-disseminated-intravascular-coagulation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/papageorgiou-2018-disseminated-intravascular-coagulation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/papageorgiou-2018-disseminated-intravascular-coagulation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bigdeli-2018-long-term-outcome-after 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bigdeli-2018-long-term-outcome-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bigdeli-2018-long-term-outcome-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bigdeli-2018-long-term-outcome-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/venetsanos-2018-sex-related-response-to 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/venetsanos-2018-sex-related-response-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/venetsanos-2018-sex-related-response-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/venetsanos-2018-sex-related-response-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carretta-1987-axonal-projections-of-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carretta-1987-axonal-projections-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carretta-1987-axonal-projections-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carretta-1987-axonal-projections-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aggarwal-2018-state-of-the-art 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aggarwal-2018-state-of-the-art 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aggarwal-2018-state-of-the-art 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aggarwal-2018-state-of-the-art 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carrier-2018-treatment-algorithm-in-cancer 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carrier-2018-treatment-algorithm-in-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carrier-2018-treatment-algorithm-in-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carrier-2018-treatment-algorithm-in-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bates-2018-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bates-2018-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bates-2018-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bates-2018-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/altiok-2018-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/altiok-2018-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/altiok-2018-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/altiok-2018-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yuan-2019-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yuan-2019-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yuan-2019-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yuan-2019-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pederson-2019-microsurgical-reconstruction-of-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pederson-2019-microsurgical-reconstruction-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pederson-2019-microsurgical-reconstruction-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pederson-2019-microsurgical-reconstruction-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ditaranto-2019-outcomes-following-head-neck 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ditaranto-2019-outcomes-following-head-neck 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ditaranto-2019-outcomes-following-head-neck 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ditaranto-2019-outcomes-following-head-neck 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tektonidou-2019-eular-recommendations-for-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tektonidou-2019-eular-recommendations-for-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tektonidou-2019-eular-recommendations-for-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tektonidou-2019-eular-recommendations-for-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lin-2019-free-flap-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lin-2019-free-flap-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lin-2019-free-flap-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lin-2019-free-flap-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/connor-2020-safety-and-efficacy-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/connor-2020-safety-and-efficacy-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/connor-2020-safety-and-efficacy-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/connor-2020-safety-and-efficacy-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/connell-2021-ash-isth-nhf-wfh 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/connell-2021-ash-isth-nhf-wfh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/connell-2021-ash-isth-nhf-wfh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/connell-2021-ash-isth-nhf-wfh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/blanch-2021-impact-of-an-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/blanch-2021-impact-of-an-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/blanch-2021-impact-of-an-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/blanch-2021-impact-of-an-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cui-2021-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cui-2021-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cui-2021-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cui-2021-tissue-factor-pathway-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pu-2021-locoregional-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pu-2021-locoregional-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pu-2021-locoregional-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pu-2021-locoregional-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pu-2021-free-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pu-2021-free-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pu-2021-free-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pu-2021-free-flaps-in-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-2021-mechanical-heart-valve-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-2021-mechanical-heart-valve-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-2021-mechanical-heart-valve-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-2021-mechanical-heart-valve-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/maag-2021-structure-function-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/maag-2021-structure-function-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/maag-2021-structure-function-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/maag-2021-structure-function-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tabrizi-2020-comparison-of-single-photon 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tabrizi-2020-comparison-of-single-photon 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tabrizi-2020-comparison-of-single-photon 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tabrizi-2020-comparison-of-single-photon 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/crippen-2021-outcomes-in-head-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/crippen-2021-outcomes-in-head-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/crippen-2021-outcomes-in-head-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/crippen-2021-outcomes-in-head-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cohen-2021-cancer-associated-splanchnic-vein 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cohen-2021-cancer-associated-splanchnic-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cohen-2021-cancer-associated-splanchnic-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cohen-2021-cancer-associated-splanchnic-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schoenbrunner-2021-cost-effectiveness-of-vioptix 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schoenbrunner-2021-cost-effectiveness-of-vioptix 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schoenbrunner-2021-cost-effectiveness-of-vioptix 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schoenbrunner-2021-cost-effectiveness-of-vioptix 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mady-2021-consensus-of-free-flap 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mady-2021-consensus-of-free-flap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mady-2021-consensus-of-free-flap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mady-2021-consensus-of-free-flap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huda-2021-management-of-life-threatening 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huda-2021-management-of-life-threatening 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huda-2021-management-of-life-threatening 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huda-2021-management-of-life-threatening 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stevens-2021-antithrombotic-therapy-for-vte 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stevens-2021-antithrombotic-therapy-for-vte 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stevens-2021-antithrombotic-therapy-for-vte 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stevens-2021-antithrombotic-therapy-for-vte 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ong-2021-implantable-doppler-removal-after 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ong-2021-implantable-doppler-removal-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ong-2021-implantable-doppler-removal-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ong-2021-implantable-doppler-removal-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chen-2021-sarcopenia-and-microvascular-free 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chen-2021-sarcopenia-and-microvascular-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chen-2021-sarcopenia-and-microvascular-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chen-2021-sarcopenia-and-microvascular-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhu-2021-new-internet-based-warfarin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhu-2021-new-internet-based-warfarin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhu-2021-new-internet-based-warfarin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhu-2021-new-internet-based-warfarin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reinhardt-2021-personalizing-the-decision-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reinhardt-2021-personalizing-the-decision-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reinhardt-2021-personalizing-the-decision-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reinhardt-2021-personalizing-the-decision-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/levy-2021-heparin-resistance-clinical-perspectives 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/levy-2021-heparin-resistance-clinical-perspectives 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/levy-2021-heparin-resistance-clinical-perspectives 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/levy-2021-heparin-resistance-clinical-perspectives 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dawoud-2022-does-anticoagulation-improve-outcomes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dawoud-2022-does-anticoagulation-improve-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dawoud-2022-does-anticoagulation-improve-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dawoud-2022-does-anticoagulation-improve-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lin-2022-jehovah-s-witness-head 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lin-2022-jehovah-s-witness-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lin-2022-jehovah-s-witness-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lin-2022-jehovah-s-witness-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shammas-2022-textbook-outcomes-in-diep 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shammas-2022-textbook-outcomes-in-diep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shammas-2022-textbook-outcomes-in-diep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shammas-2022-textbook-outcomes-in-diep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/makhija-2022-pregnancy-after-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/makhija-2022-pregnancy-after-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/makhija-2022-pregnancy-after-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/makhija-2022-pregnancy-after-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mittal-2023-antiphospholipid-syndrome-antiphospholipid-antibodies 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mittal-2023-antiphospholipid-syndrome-antiphospholipid-antibodies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mittal-2023-antiphospholipid-syndrome-antiphospholipid-antibodies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mittal-2023-antiphospholipid-syndrome-antiphospholipid-antibodies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/laurent-2023-diep-flap-in-breast 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/laurent-2023-diep-flap-in-breast 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/laurent-2023-diep-flap-in-breast 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/laurent-2023-diep-flap-in-breast 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vanommen-2022-neonatal-central-venous-line 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vanommen-2022-neonatal-central-venous-line 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vanommen-2022-neonatal-central-venous-line 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vanommen-2022-neonatal-central-venous-line 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/maroney-2022-platelet-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/maroney-2022-platelet-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/maroney-2022-platelet-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/maroney-2022-platelet-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-2022-umbilical-complications-following-diep 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-2022-umbilical-complications-following-diep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-2022-umbilical-complications-following-diep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-2022-umbilical-complications-following-diep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/munro-2022-reducing-donor-site-complications 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/munro-2022-reducing-donor-site-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/munro-2022-reducing-donor-site-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/munro-2022-reducing-donor-site-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bonapacepotvin-2021-canadian-trends-in-free 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bonapacepotvin-2021-canadian-trends-in-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bonapacepotvin-2021-canadian-trends-in-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bonapacepotvin-2021-canadian-trends-in-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/knight-2023-antiphospholipid-syndrome-advances-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/knight-2023-antiphospholipid-syndrome-advances-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/knight-2023-antiphospholipid-syndrome-advances-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/knight-2023-antiphospholipid-syndrome-advances-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mohammed-2023-cryo-em-structure-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mohammed-2023-cryo-em-structure-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mohammed-2023-cryo-em-structure-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mohammed-2023-cryo-em-structure-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ambati-2023-antiphospholipid-syndrome-management-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ambati-2023-antiphospholipid-syndrome-management-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ambati-2023-antiphospholipid-syndrome-management-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ambati-2023-antiphospholipid-syndrome-management-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lee-2023-updates-in-traumatic-lower 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lee-2023-updates-in-traumatic-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lee-2023-updates-in-traumatic-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lee-2023-updates-in-traumatic-lower 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/malik-2023-the-use-of-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/malik-2023-the-use-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/malik-2023-the-use-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/malik-2023-the-use-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wilson-2023-harms-reporting-in-systematic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wilson-2023-harms-reporting-in-systematic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wilson-2023-harms-reporting-in-systematic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wilson-2023-harms-reporting-in-systematic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/falanga-2023-cancer-associated-thrombosis-enhanced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/falanga-2023-cancer-associated-thrombosis-enhanced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/falanga-2023-cancer-associated-thrombosis-enhanced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/falanga-2023-cancer-associated-thrombosis-enhanced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wu-2023-prolonged-infusion-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wu-2023-prolonged-infusion-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wu-2023-prolonged-infusion-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wu-2023-prolonged-infusion-of-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/caldeira-2023-clinical-outcomes-of-anticoagulated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/caldeira-2023-clinical-outcomes-of-anticoagulated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/caldeira-2023-clinical-outcomes-of-anticoagulated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/caldeira-2023-clinical-outcomes-of-anticoagulated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rosti-2023-scip-flap-in-head 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rosti-2023-scip-flap-in-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rosti-2023-scip-flap-in-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rosti-2023-scip-flap-in-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prazetina-2023-effect-of-machine-learning 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prazetina-2023-effect-of-machine-learning 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prazetina-2023-effect-of-machine-learning 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prazetina-2023-effect-of-machine-learning 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/obrien-2023-apixaban-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/obrien-2023-apixaban-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/obrien-2023-apixaban-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/obrien-2023-apixaban-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/payne-2023-apixaban-for-prevention-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/payne-2023-apixaban-for-prevention-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/payne-2023-apixaban-for-prevention-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/payne-2023-apixaban-for-prevention-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bejjani-2024-when-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bejjani-2024-when-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bejjani-2024-when-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bejjani-2024-when-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/krijgh-2024-mental-health-is-strongly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/krijgh-2024-mental-health-is-strongly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/krijgh-2024-mental-health-is-strongly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/krijgh-2024-mental-health-is-strongly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shiranibidabadi-2024-treatment-of-cutaneous-leishmaniasis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shiranibidabadi-2024-treatment-of-cutaneous-leishmaniasis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shiranibidabadi-2024-treatment-of-cutaneous-leishmaniasis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shiranibidabadi-2024-treatment-of-cutaneous-leishmaniasis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carretta-1985-synaptic-effects-elicited-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carretta-1985-synaptic-effects-elicited-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carretta-1985-synaptic-effects-elicited-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carretta-1985-synaptic-effects-elicited-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kota-2024-outcomes-of-head-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kota-2024-outcomes-of-head-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kota-2024-outcomes-of-head-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kota-2024-outcomes-of-head-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/agarwal-2022-downregulation-of-thrombomodulin-thrombin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/agarwal-2022-downregulation-of-thrombomodulin-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/agarwal-2022-downregulation-of-thrombomodulin-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/agarwal-2022-downregulation-of-thrombomodulin-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/manning-2024-dilemmas-in-the-diagnosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/manning-2024-dilemmas-in-the-diagnosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/manning-2024-dilemmas-in-the-diagnosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/manning-2024-dilemmas-in-the-diagnosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mitta-2024-management-options-for-pediatric 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mitta-2024-management-options-for-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mitta-2024-management-options-for-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mitta-2024-management-options-for-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhou-2024-met343val-mutation-disrupts-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhou-2024-met343val-mutation-disrupts-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhou-2024-met343val-mutation-disrupts-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhou-2024-met343val-mutation-disrupts-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/parizher-2024-evaluation-and-management-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/parizher-2024-evaluation-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/parizher-2024-evaluation-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/parizher-2024-evaluation-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dubut-2024-targeting-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dubut-2024-targeting-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dubut-2024-targeting-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dubut-2024-targeting-tissue-factor-pathway 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reddy-2024-management-of-neonatal-aortic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reddy-2024-management-of-neonatal-aortic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reddy-2024-management-of-neonatal-aortic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reddy-2024-management-of-neonatal-aortic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/othman-2024-microvascular-free-flap-head 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/othman-2024-microvascular-free-flap-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/othman-2024-microvascular-free-flap-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/othman-2024-microvascular-free-flap-head 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sotopeleteiro-2024-obstetric-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sotopeleteiro-2024-obstetric-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sotopeleteiro-2024-obstetric-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sotopeleteiro-2024-obstetric-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/paredesruiz-2024-thrombotic-antiphospholipid-syndrome-from 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/paredesruiz-2024-thrombotic-antiphospholipid-syndrome-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/paredesruiz-2024-thrombotic-antiphospholipid-syndrome-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/paredesruiz-2024-thrombotic-antiphospholipid-syndrome-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rodriguezpinto-2024-catastrophic-antiphospholipid-syndrome-lessons 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rodriguezpinto-2024-catastrophic-antiphospholipid-syndrome-lessons 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rodriguezpinto-2024-catastrophic-antiphospholipid-syndrome-lessons 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rodriguezpinto-2024-catastrophic-antiphospholipid-syndrome-lessons 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-2025-sequential-free-flaps-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-2025-sequential-free-flaps-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-2025-sequential-free-flaps-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-2025-sequential-free-flaps-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/escobardomingo-2025-impact-of-closed-incision 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/escobardomingo-2025-impact-of-closed-incision 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/escobardomingo-2025-impact-of-closed-incision 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/escobardomingo-2025-impact-of-closed-incision 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tangirala-2025-anticoagulation-management-and-poor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tangirala-2025-anticoagulation-management-and-poor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tangirala-2025-anticoagulation-management-and-poor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tangirala-2025-anticoagulation-management-and-poor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/suhailds-2025-perforator-related-risk-factors 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/suhailds-2025-perforator-related-risk-factors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/suhailds-2025-perforator-related-risk-factors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/suhailds-2025-perforator-related-risk-factors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/monagle-2025-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/monagle-2025-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/monagle-2025-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/monagle-2025-american-society-of-hematology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/branch-2025-certolizumab-pegol-to-prevent 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/branch-2025-certolizumab-pegol-to-prevent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/branch-2025-certolizumab-pegol-to-prevent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/branch-2025-certolizumab-pegol-to-prevent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mousavi-2025-direct-oral-anticoagulants-versus 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mousavi-2025-direct-oral-anticoagulants-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mousavi-2025-direct-oral-anticoagulants-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mousavi-2025-direct-oral-anticoagulants-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/devito-2025-achieving-textbook-outcomes-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/devito-2025-achieving-textbook-outcomes-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/devito-2025-achieving-textbook-outcomes-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/devito-2025-achieving-textbook-outcomes-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vanthillo-2025-rebalancing-agents-in-hemophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vanthillo-2025-rebalancing-agents-in-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vanthillo-2025-rebalancing-agents-in-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vanthillo-2025-rebalancing-agents-in-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guo-2025-impact-of-postoperative-complications 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guo-2025-impact-of-postoperative-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guo-2025-impact-of-postoperative-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guo-2025-impact-of-postoperative-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/didzun-2025-comparison-of-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/didzun-2025-comparison-of-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/didzun-2025-comparison-of-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/didzun-2025-comparison-of-outcomes-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/piazza-2025-superficial-vein-thrombosis-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/piazza-2025-superficial-vein-thrombosis-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/piazza-2025-superficial-vein-thrombosis-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/piazza-2025-superficial-vein-thrombosis-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cervini-2025-monitoring-free-flaps-with 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cervini-2025-monitoring-free-flaps-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cervini-2025-monitoring-free-flaps-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cervini-2025-monitoring-free-flaps-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/riverajimenez-2025-heparin-resistance-in-cardiac 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/riverajimenez-2025-heparin-resistance-in-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/riverajimenez-2025-heparin-resistance-in-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/riverajimenez-2025-heparin-resistance-in-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/osborne-1972-the-amine-and-amino 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/osborne-1972-the-amine-and-amino 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/osborne-1972-the-amine-and-amino 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/osborne-1972-the-amine-and-amino 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/esmon-1984-protein-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/esmon-1984-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/esmon-1984-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/esmon-1984-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/osborne-1982-immunohistochemical-demonstration-of-peptides 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/osborne-1982-immunohistochemical-demonstration-of-peptides 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/osborne-1982-immunohistochemical-demonstration-of-peptides 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/osborne-1982-immunohistochemical-demonstration-of-peptides 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carretta-1981-two-bidirectional-nerve-cord 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carretta-1981-two-bidirectional-nerve-cord 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carretta-1981-two-bidirectional-nerve-cord 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carretta-1981-two-bidirectional-nerve-cord 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/irwin-1995-near-infra-red-spectroscopy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/irwin-1995-near-infra-red-spectroscopy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/irwin-1995-near-infra-red-spectroscopy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/irwin-1995-near-infra-red-spectroscopy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vijayalakshmi-1994-the-isomorphous-structures-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vijayalakshmi-1994-the-isomorphous-structures-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vijayalakshmi-1994-the-isomorphous-structures-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vijayalakshmi-1994-the-isomorphous-structures-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/decristofaro-1999-allosteric-modulation-of-bpti 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/decristofaro-1999-allosteric-modulation-of-bpti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/decristofaro-1999-allosteric-modulation-of-bpti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/decristofaro-1999-allosteric-modulation-of-bpti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huntington-2003-the-molecular-basis-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huntington-2003-the-molecular-basis-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huntington-2003-the-molecular-basis-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huntington-2003-the-molecular-basis-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/miller-2003-heparin-induced-thrombocytopenia-recognition 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/miller-2003-heparin-induced-thrombocytopenia-recognition 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/miller-2003-heparin-induced-thrombocytopenia-recognition 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/miller-2003-heparin-induced-thrombocytopenia-recognition 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-2003-management-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-2003-management-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-2003-management-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-2003-management-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/disa-2003-dextran-related-complications-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/disa-2003-dextran-related-complications-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/disa-2003-dextran-related-complications-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/disa-2003-dextran-related-complications-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/spinler-2003-overview-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/spinler-2003-overview-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/spinler-2003-overview-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/spinler-2003-overview-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greinacher-2003-treatment-options-for-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greinacher-2003-treatment-options-for-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greinacher-2003-treatment-options-for-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greinacher-2003-treatment-options-for-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carter-2004-crystal-structure-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carter-2004-crystal-structure-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carter-2004-crystal-structure-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carter-2004-crystal-structure-of-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pineda-2004-molecular-dissection-of-na 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pineda-2004-molecular-dissection-of-na 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pineda-2004-molecular-dissection-of-na 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pineda-2004-molecular-dissection-of-na 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/page-2005-determinants-of-specificity-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/page-2005-determinants-of-specificity-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/page-2005-determinants-of-specificity-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/page-2005-determinants-of-specificity-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/silva-2005-the-na-binding-channel 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/silva-2005-the-na-binding-channel 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/silva-2005-the-na-binding-channel 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/silva-2005-the-na-binding-channel 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/seybert-2006-treatment-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/seybert-2006-treatment-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/seybert-2006-treatment-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/seybert-2006-treatment-of-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/demaistre-2006-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/demaistre-2006-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/demaistre-2006-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/demaistre-2006-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dager-2007-heparin-induced-thrombocytopenia-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dager-2007-heparin-induced-thrombocytopenia-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dager-2007-heparin-induced-thrombocytopenia-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dager-2007-heparin-induced-thrombocytopenia-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ngu-2007-reduced-axon-sprouting-after 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ngu-2007-reduced-axon-sprouting-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ngu-2007-reduced-axon-sprouting-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ngu-2007-reduced-axon-sprouting-after 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huntington-2008-how-na-activates-thrombin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huntington-2008-how-na-activates-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huntington-2008-how-na-activates-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huntington-2008-how-na-activates-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qureshi-2009-mutagenesis-studies-toward-understanding 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qureshi-2009-mutagenesis-studies-toward-understanding 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qureshi-2009-mutagenesis-studies-toward-understanding 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qureshi-2009-mutagenesis-studies-toward-understanding 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dhillon-2009-argatroban-a-review-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dhillon-2009-argatroban-a-review-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dhillon-2009-argatroban-a-review-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dhillon-2009-argatroban-a-review-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/adams-2009-molecular-basis-of-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/adams-2009-molecular-basis-of-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/adams-2009-molecular-basis-of-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/adams-2009-molecular-basis-of-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/deamorim-2009-thrombin-allosteric-modulation-revisited 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/deamorim-2009-thrombin-allosteric-modulation-revisited 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/deamorim-2009-thrombin-allosteric-modulation-revisited 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/deamorim-2009-thrombin-allosteric-modulation-revisited 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nelson-2016-prevention-of-thrombosis-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nelson-2016-prevention-of-thrombosis-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nelson-2016-prevention-of-thrombosis-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nelson-2016-prevention-of-thrombosis-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/poulakos-2017-edoxaban-a-direct-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/poulakos-2017-edoxaban-a-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/poulakos-2017-edoxaban-a-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/poulakos-2017-edoxaban-a-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/radulescu-2017-anticoagulation-therapy-in-children 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/radulescu-2017-anticoagulation-therapy-in-children 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/radulescu-2017-anticoagulation-therapy-in-children 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/radulescu-2017-anticoagulation-therapy-in-children 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greinacher-2017-autoimmune-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greinacher-2017-autoimmune-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greinacher-2017-autoimmune-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greinacher-2017-autoimmune-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/francomoreno-2017-direct-oral-anticoagulants-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/francomoreno-2017-direct-oral-anticoagulants-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/francomoreno-2017-direct-oral-anticoagulants-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/francomoreno-2017-direct-oral-anticoagulants-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xiao-2018-probing-light-chain-mutation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xiao-2018-probing-light-chain-mutation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xiao-2018-probing-light-chain-mutation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xiao-2018-probing-light-chain-mutation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abdelaziz-2018-novel-heparin-mimetics-reveal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abdelaziz-2018-novel-heparin-mimetics-reveal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abdelaziz-2018-novel-heparin-mimetics-reveal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abdelaziz-2018-novel-heparin-mimetics-reveal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abdillah-2018-heparin-induced-thrombocytopenia-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abdillah-2018-heparin-induced-thrombocytopenia-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abdillah-2018-heparin-induced-thrombocytopenia-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abdillah-2018-heparin-induced-thrombocytopenia-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/netley-2018-bivalirudin-anticoagulation-dosing-protocol 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/netley-2018-bivalirudin-anticoagulation-dosing-protocol 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/netley-2018-bivalirudin-anticoagulation-dosing-protocol 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/netley-2018-bivalirudin-anticoagulation-dosing-protocol 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xiao-2019-na-binding-modes-involved 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xiao-2019-na-binding-modes-involved 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xiao-2019-na-binding-modes-involved 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xiao-2019-na-binding-modes-involved 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/joseph-2019-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/joseph-2019-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/joseph-2019-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/joseph-2019-diagnosis-and-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/key-2019-venous-thromboembolism-prophylaxis-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/key-2019-venous-thromboembolism-prophylaxis-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/key-2019-venous-thromboembolism-prophylaxis-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/key-2019-venous-thromboembolism-prophylaxis-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/filipan-2020-the-effects-of-dextran 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/filipan-2020-the-effects-of-dextran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/filipan-2020-the-effects-of-dextran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/filipan-2020-the-effects-of-dextran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaseer-2020-heparin-vs-bivalirudin-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaseer-2020-heparin-vs-bivalirudin-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaseer-2020-heparin-vs-bivalirudin-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaseer-2020-heparin-vs-bivalirudin-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bauersachs-2020-cancer-associated-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bauersachs-2020-cancer-associated-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bauersachs-2020-cancer-associated-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bauersachs-2020-cancer-associated-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hannevik-2020-thrombosis-and-bleedings-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hannevik-2020-thrombosis-and-bleedings-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hannevik-2020-thrombosis-and-bleedings-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hannevik-2020-thrombosis-and-bleedings-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chopard-2020-diagnosis-and-treatment-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chopard-2020-diagnosis-and-treatment-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chopard-2020-diagnosis-and-treatment-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chopard-2020-diagnosis-and-treatment-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hvas-2021-heparin-induced-thrombocytopenia-pathophysiology 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hvas-2021-heparin-induced-thrombocytopenia-pathophysiology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hvas-2021-heparin-induced-thrombocytopenia-pathophysiology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hvas-2021-heparin-induced-thrombocytopenia-pathophysiology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/giuliano-2021-extracorporeal-membrane-oxygenation-complications 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/giuliano-2021-extracorporeal-membrane-oxygenation-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/giuliano-2021-extracorporeal-membrane-oxygenation-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/giuliano-2021-extracorporeal-membrane-oxygenation-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sadowski-2024-the-efficacy-and-safety 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sadowski-2024-the-efficacy-and-safety 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sadowski-2024-the-efficacy-and-safety 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sadowski-2024-the-efficacy-and-safety 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/migliorini-2024-antithrombotic-prophylaxis-following-total 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/migliorini-2024-antithrombotic-prophylaxis-following-total 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/migliorini-2024-antithrombotic-prophylaxis-following-total 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/migliorini-2024-antithrombotic-prophylaxis-following-total 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/credille-2024-bleeding-complications-between-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/credille-2024-bleeding-complications-between-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/credille-2024-bleeding-complications-between-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/credille-2024-bleeding-complications-between-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thapa-2024-direct-oral-anticoagulants-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thapa-2024-direct-oral-anticoagulants-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thapa-2024-direct-oral-anticoagulants-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thapa-2024-direct-oral-anticoagulants-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vajter-2025-anticoagulation-management-during-ecmo 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vajter-2025-anticoagulation-management-during-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vajter-2025-anticoagulation-management-during-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vajter-2025-anticoagulation-management-during-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/odorico-2025-efficacy-and-morbidity-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/odorico-2025-efficacy-and-morbidity-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/odorico-2025-efficacy-and-morbidity-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/odorico-2025-efficacy-and-morbidity-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tittl-2025-venous-thromboembolism-therapy-with 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tittl-2025-venous-thromboembolism-therapy-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tittl-2025-venous-thromboembolism-therapy-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tittl-2025-venous-thromboembolism-therapy-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hu-2025-effectiveness-and-safety-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hu-2025-effectiveness-and-safety-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hu-2025-effectiveness-and-safety-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hu-2025-effectiveness-and-safety-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yamin-2025-revisiting-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yamin-2025-revisiting-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yamin-2025-revisiting-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yamin-2025-revisiting-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rohrich-2025-preoperative-deep-and-superficial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rohrich-2025-preoperative-deep-and-superficial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rohrich-2025-preoperative-deep-and-superficial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rohrich-2025-preoperative-deep-and-superficial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/luebke-1995-in-situ-hybridization-reveals 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/luebke-1995-in-situ-hybridization-reveals 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/luebke-1995-in-situ-hybridization-reveals 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/luebke-1995-in-situ-hybridization-reveals 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dicera-1995-the-na-binding-site 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dicera-1995-the-na-binding-site 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dicera-1995-the-na-binding-site 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dicera-1995-the-na-binding-site 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yajima-1993-vascular-complications-of-vascularized 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yajima-1993-vascular-complications-of-vascularized 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yajima-1993-vascular-complications-of-vascularized 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yajima-1993-vascular-complications-of-vascularized 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dibella-1996-the-role-of-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dibella-1996-the-role-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dibella-1996-the-role-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dibella-1996-the-role-of-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dang-1997-rational-engineering-of-activity 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dang-1997-rational-engineering-of-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dang-1997-rational-engineering-of-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dang-1997-rational-engineering-of-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guinto-1997-critical-role-of-w60d 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guinto-1997-critical-role-of-w60d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guinto-1997-critical-role-of-w60d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guinto-1997-critical-role-of-w60d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dicera-1997-molecular-mechanisms-of-thrombin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dicera-1997-molecular-mechanisms-of-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dicera-1997-molecular-mechanisms-of-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dicera-1997-molecular-mechanisms-of-thrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hall-1997-strategies-for-development-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hall-1997-strategies-for-development-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hall-1997-strategies-for-development-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hall-1997-strategies-for-development-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lai-1997-kinetic-pathway-for-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lai-1997-kinetic-pathway-for-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lai-1997-kinetic-pathway-for-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lai-1997-kinetic-pathway-for-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-1997-heparin-induced-thrombocytopenia-pathogenesis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-1997-heparin-induced-thrombocytopenia-pathogenesis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-1997-heparin-induced-thrombocytopenia-pathogenesis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-1997-heparin-induced-thrombocytopenia-pathogenesis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rabinowitz-1996-salivary-lipid-profiles-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rabinowitz-1996-salivary-lipid-profiles-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rabinowitz-1996-salivary-lipid-profiles-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rabinowitz-1996-salivary-lipid-profiles-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gunzel-1996-sodium-magnesium-antiport-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gunzel-1996-sodium-magnesium-antiport-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gunzel-1996-sodium-magnesium-antiport-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gunzel-1996-sodium-magnesium-antiport-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wilson-1996-an-increase-in-activity 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wilson-1996-an-increase-in-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wilson-1996-an-increase-in-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wilson-1996-an-increase-in-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/muller-2003-activation-of-ampa-kainate 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/muller-2003-activation-of-ampa-kainate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/muller-2003-activation-of-ampa-kainate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/muller-2003-activation-of-ampa-kainate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carretta-1987-afferent-sensillar-inputs-to 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carretta-1987-afferent-sensillar-inputs-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carretta-1987-afferent-sensillar-inputs-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carretta-1987-afferent-sensillar-inputs-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dorner-1990-glutaminergic-responses-of-neuropile 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dorner-1990-glutaminergic-responses-of-neuropile 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dorner-1990-glutaminergic-responses-of-neuropile 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dorner-1990-glutaminergic-responses-of-neuropile 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/groome-1995-ingestive-sensory-inputs-excite 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/groome-1995-ingestive-sensory-inputs-excite 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/groome-1995-ingestive-sensory-inputs-excite 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/groome-1995-ingestive-sensory-inputs-excite 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leake-1995-central-and-peripheral-5 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leake-1995-central-and-peripheral-5 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leake-1995-central-and-peripheral-5 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leake-1995-central-and-peripheral-5 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greinacher-1999-lepirudin-recombinant-hirudin-for-parenteral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greinacher-1999-lepirudin-recombinant-hirudin-for-parenteral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greinacher-1999-lepirudin-recombinant-hirudin-for-parenteral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greinacher-1999-lepirudin-recombinant-hirudin-for-parenteral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greinacher-2000-heparin-induced-thrombocytopenia-with-thromboembolic-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greinacher-2000-heparin-induced-thrombocytopenia-with-thromboembolic-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greinacher-2000-heparin-induced-thrombocytopenia-with-thromboembolic-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greinacher-2000-heparin-induced-thrombocytopenia-with-thromboembolic-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/farner-2001-a-comparison-of-danaparoid-and-lepirudin-in-heparin-induce 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/farner-2001-a-comparison-of-danaparoid-and-lepirudin-in-heparin-induce 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/farner-2001-a-comparison-of-danaparoid-and-lepirudin-in-heparin-induce 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/farner-2001-a-comparison-of-danaparoid-and-lepirudin-in-heparin-induce 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/avgerinos-2001-production-and-clinical-development-of-a-hansenula-poly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/avgerinos-2001-production-and-clinical-development-of-a-hansenula-poly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/avgerinos-2001-production-and-clinical-development-of-a-hansenula-poly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/avgerinos-2001-production-and-clinical-development-of-a-hansenula-poly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/senior-2001-microvascular-simulator-a-device-for-micro-anastomosis-tra 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/senior-2001-microvascular-simulator-a-device-for-micro-anastomosis-tra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/senior-2001-microvascular-simulator-a-device-for-micro-anastomosis-tra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/senior-2001-microvascular-simulator-a-device-for-micro-anastomosis-tra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leyh-2002-anticoagulation-for-prosthetic-heart-valves-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leyh-2002-anticoagulation-for-prosthetic-heart-valves-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leyh-2002-anticoagulation-for-prosthetic-heart-valves-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leyh-2002-anticoagulation-for-prosthetic-heart-valves-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tanahashi-2002-treatment-of-acute-ischemic-stroke-recent-progress 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tanahashi-2002-treatment-of-acute-ischemic-stroke-recent-progress 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tanahashi-2002-treatment-of-acute-ischemic-stroke-recent-progress 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tanahashi-2002-treatment-of-acute-ischemic-stroke-recent-progress 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chong-2003-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chong-2003-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chong-2003-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chong-2003-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cochran-2003-use-of-lepirudin-during-percutaneous-vascular-interventio 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cochran-2003-use-of-lepirudin-during-percutaneous-vascular-interventio 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cochran-2003-use-of-lepirudin-during-percutaneous-vascular-interventio 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cochran-2003-use-of-lepirudin-during-percutaneous-vascular-interventio 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/heuts-2004-lmwh-for-perioperative-anticoagulation-in-patients-on-chron 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/heuts-2004-lmwh-for-perioperative-anticoagulation-in-patients-on-chron 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/heuts-2004-lmwh-for-perioperative-anticoagulation-in-patients-on-chron 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/heuts-2004-lmwh-for-perioperative-anticoagulation-in-patients-on-chron 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lamonte-2004-argatroban-anticoagulation-in-patients-with-acute-ischemi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lamonte-2004-argatroban-anticoagulation-in-patients-with-acute-ischemi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lamonte-2004-argatroban-anticoagulation-in-patients-with-acute-ischemi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lamonte-2004-argatroban-anticoagulation-in-patients-with-acute-ischemi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/french-1992-mesenchyme-of-embryonic-reproductive-ducts-directs-process 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/french-1992-mesenchyme-of-embryonic-reproductive-ducts-directs-process 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/french-1992-mesenchyme-of-embryonic-reproductive-ducts-directs-process 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/french-1992-mesenchyme-of-embryonic-reproductive-ducts-directs-process 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lubenow-2004-lepirudin-for-prophylaxis-of-thrombosis-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lubenow-2004-lepirudin-for-prophylaxis-of-thrombosis-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lubenow-2004-lepirudin-for-prophylaxis-of-thrombosis-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lubenow-2004-lepirudin-for-prophylaxis-of-thrombosis-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greinacher-2004-the-use-of-direct-thrombin-inhibitors-in-cardiovascula 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greinacher-2004-the-use-of-direct-thrombin-inhibitors-in-cardiovascula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greinacher-2004-the-use-of-direct-thrombin-inhibitors-in-cardiovascula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greinacher-2004-the-use-of-direct-thrombin-inhibitors-in-cardiovascula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-2004-heparin-induced-thrombocytopenia-recognition-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-2004-heparin-induced-thrombocytopenia-recognition-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-2004-heparin-induced-thrombocytopenia-recognition-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-2004-heparin-induced-thrombocytopenia-recognition-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/petersen-2005-ximelagatran-a-promising-new-drug-in-thromboembolic-diso 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/petersen-2005-ximelagatran-a-promising-new-drug-in-thromboembolic-diso 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/petersen-2005-ximelagatran-a-promising-new-drug-in-thromboembolic-diso 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/petersen-2005-ximelagatran-a-promising-new-drug-in-thromboembolic-diso 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/many-2005-low-molecular-weight-heparins-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/many-2005-low-molecular-weight-heparins-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/many-2005-low-molecular-weight-heparins-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/many-2005-low-molecular-weight-heparins-during-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-2005-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-2005-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-2005-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-2005-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wolzt-2005-pharmacokinetics-and-pharmacodynamics-of-ximelagatran 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wolzt-2005-pharmacokinetics-and-pharmacodynamics-of-ximelagatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wolzt-2005-pharmacokinetics-and-pharmacodynamics-of-ximelagatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wolzt-2005-pharmacokinetics-and-pharmacodynamics-of-ximelagatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jaffer-2005-low-molecular-weight-heparins-as-periprocedural-anticoagul 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jaffer-2005-low-molecular-weight-heparins-as-periprocedural-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jaffer-2005-low-molecular-weight-heparins-as-periprocedural-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jaffer-2005-low-molecular-weight-heparins-as-periprocedural-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mcintosh-2004-developing-an-algorithm-for-treating-heparin-induced-thr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mcintosh-2004-developing-an-algorithm-for-treating-heparin-induced-thr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mcintosh-2004-developing-an-algorithm-for-treating-heparin-induced-thr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mcintosh-2004-developing-an-algorithm-for-treating-heparin-induced-thr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lubenow-2005-lepirudin-in-patients-with-heparin-induced-thrombocytopen 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lubenow-2005-lepirudin-in-patients-with-heparin-induced-thrombocytopen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lubenow-2005-lepirudin-in-patients-with-heparin-induced-thrombocytopen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lubenow-2005-lepirudin-in-patients-with-heparin-induced-thrombocytopen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/matthai-2006-treatment-of-heparin-induced-thrombocytopenia-in-cardiova 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/matthai-2006-treatment-of-heparin-induced-thrombocytopenia-in-cardiova 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/matthai-2006-treatment-of-heparin-induced-thrombocytopenia-in-cardiova 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/matthai-2006-treatment-of-heparin-induced-thrombocytopenia-in-cardiova 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/crisp-2006-beyond-the-central-pattern-generator-amine-modulation-of-de 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/crisp-2006-beyond-the-central-pattern-generator-amine-modulation-of-de 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/crisp-2006-beyond-the-central-pattern-generator-amine-modulation-of-de 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/crisp-2006-beyond-the-central-pattern-generator-amine-modulation-of-de 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gocht-2007-postactivation-inhibition-of-spontaneously-active-neurosecr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gocht-2007-postactivation-inhibition-of-spontaneously-active-neurosecr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gocht-2007-postactivation-inhibition-of-spontaneously-active-neurosecr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gocht-2007-postactivation-inhibition-of-spontaneously-active-neurosecr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cruz-gonz-lez-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cruz-gonz-lez-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cruz-gonz-lez-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cruz-gonz-lez-2007-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/douketis-2008-perioperative-management-of-warfarin-therapy-to-bridge-o 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/douketis-2008-perioperative-management-of-warfarin-therapy-to-bridge-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/douketis-2008-perioperative-management-of-warfarin-therapy-to-bridge-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/douketis-2008-perioperative-management-of-warfarin-therapy-to-bridge-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/boggio-2008-argatroban-use-in-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/boggio-2008-argatroban-use-in-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/boggio-2008-argatroban-use-in-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/boggio-2008-argatroban-use-in-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gupta-2008-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gupta-2008-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gupta-2008-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gupta-2008-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/krahn-2009-anticoagulation-of-patients-on-chronic-warfarin-undergoing 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/krahn-2009-anticoagulation-of-patients-on-chronic-warfarin-undergoing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/krahn-2009-anticoagulation-of-patients-on-chronic-warfarin-undergoing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/krahn-2009-anticoagulation-of-patients-on-chronic-warfarin-undergoing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/faltas-2009-update-on-perioperative-bridging-in-patients-on-chronic-or 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/faltas-2009-update-on-perioperative-bridging-in-patients-on-chronic-or 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/faltas-2009-update-on-perioperative-bridging-in-patients-on-chronic-or 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/faltas-2009-update-on-perioperative-bridging-in-patients-on-chronic-or 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/palaniswamy-2011-periprocedural-bridging-anticoagulation-current-persp 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/palaniswamy-2011-periprocedural-bridging-anticoagulation-current-persp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/palaniswamy-2011-periprocedural-bridging-anticoagulation-current-persp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/palaniswamy-2011-periprocedural-bridging-anticoagulation-current-persp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pisters-2010-a-novel-user-friendly-score-has-bled-to-assess-1-year-ris 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pisters-2010-a-novel-user-friendly-score-has-bled-to-assess-1-year-ris 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pisters-2010-a-novel-user-friendly-score-has-bled-to-assess-1-year-ris 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pisters-2010-a-novel-user-friendly-score-has-bled-to-assess-1-year-ris 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lockery-1991-two-forms-of-sensitization-of-the-local-bending-reflex-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lockery-1991-two-forms-of-sensitization-of-the-local-bending-reflex-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lockery-1991-two-forms-of-sensitization-of-the-local-bending-reflex-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lockery-1991-two-forms-of-sensitization-of-the-local-bending-reflex-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/szokol-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/szokol-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/szokol-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/szokol-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thiele-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thiele-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thiele-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thiele-2010-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chan-2010-case-report-superior-gluteal-artery-perforator-flap-breast-r 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chan-2010-case-report-superior-gluteal-artery-perforator-flap-breast-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chan-2010-case-report-superior-gluteal-artery-perforator-flap-breast-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chan-2010-case-report-superior-gluteal-artery-perforator-flap-breast-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jeske-2010-pharmacology-of-argatroban 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jeske-2010-pharmacology-of-argatroban 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jeske-2010-pharmacology-of-argatroban 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jeske-2010-pharmacology-of-argatroban 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lip-2011-comparative-validation-of-a-novel-risk-score-for-predicting-b 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lip-2011-comparative-validation-of-a-novel-risk-score-for-predicting-b 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lip-2011-comparative-validation-of-a-novel-risk-score-for-predicting-b 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lip-2011-comparative-validation-of-a-novel-risk-score-for-predicting-b 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mohammed-2010-perioperative-bridging-anticoagulation-therapy-in-at-ris 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mohammed-2010-perioperative-bridging-anticoagulation-therapy-in-at-ris 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mohammed-2010-perioperative-bridging-anticoagulation-therapy-in-at-ris 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mohammed-2010-perioperative-bridging-anticoagulation-therapy-in-at-ris 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaatz-2011-update-in-bridging-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaatz-2011-update-in-bridging-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaatz-2011-update-in-bridging-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaatz-2011-update-in-bridging-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jones-2011-successful-salvage-of-venous-thrombosis-of-a-free-flap-by-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jones-2011-successful-salvage-of-venous-thrombosis-of-a-free-flap-by-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jones-2011-successful-salvage-of-venous-thrombosis-of-a-free-flap-by-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jones-2011-successful-salvage-of-venous-thrombosis-of-a-free-flap-by-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/meriaux-2011-multiple-changes-in-peptide-and-lipid-expression-associat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/meriaux-2011-multiple-changes-in-peptide-and-lipid-expression-associat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/meriaux-2011-multiple-changes-in-peptide-and-lipid-expression-associat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/meriaux-2011-multiple-changes-in-peptide-and-lipid-expression-associat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fries-2011-coagulation-monitoring-using-rotem-pro 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fries-2011-coagulation-monitoring-using-rotem-pro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fries-2011-coagulation-monitoring-using-rotem-pro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fries-2011-coagulation-monitoring-using-rotem-pro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/price-2011-a-randomized-evaluation-of-simulation-training-on-performan 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/price-2011-a-randomized-evaluation-of-simulation-training-on-performan 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/price-2011-a-randomized-evaluation-of-simulation-training-on-performan 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/price-2011-a-randomized-evaluation-of-simulation-training-on-performan 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/banerjee-2012-net-clinical-benefit-of-new-oral-anticoagulants-dabigatr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/banerjee-2012-net-clinical-benefit-of-new-oral-anticoagulants-dabigatr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/banerjee-2012-net-clinical-benefit-of-new-oral-anticoagulants-dabigatr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/banerjee-2012-net-clinical-benefit-of-new-oral-anticoagulants-dabigatr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/friberg-2012-evaluation-of-risk-stratification-schemes-for-ischaemic-s 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/friberg-2012-evaluation-of-risk-stratification-schemes-for-ischaemic-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/friberg-2012-evaluation-of-risk-stratification-schemes-for-ischaemic-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/friberg-2012-evaluation-of-risk-stratification-schemes-for-ischaemic-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/linkins-2012-treatment-and-prevention-of-heparin-induced-thrombocytope 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/linkins-2012-treatment-and-prevention-of-heparin-induced-thrombocytope 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/linkins-2012-treatment-and-prevention-of-heparin-induced-thrombocytope 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/linkins-2012-treatment-and-prevention-of-heparin-induced-thrombocytope 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bates-2012-vte-thrombophilia-antithrombotic-therapy-and-pregnancy-anti 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bates-2012-vte-thrombophilia-antithrombotic-therapy-and-pregnancy-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bates-2012-vte-thrombophilia-antithrombotic-therapy-and-pregnancy-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bates-2012-vte-thrombophilia-antithrombotic-therapy-and-pregnancy-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gharbaran-2012-segmental-and-regional-differences-in-neuronal-expressi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gharbaran-2012-segmental-and-regional-differences-in-neuronal-expressi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gharbaran-2012-segmental-and-regional-differences-in-neuronal-expressi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gharbaran-2012-segmental-and-regional-differences-in-neuronal-expressi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/di-2012-versatility-of-the-anterolateral-thigh-free-flap-the-four-seas 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/di-2012-versatility-of-the-anterolateral-thigh-free-flap-the-four-seas 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/di-2012-versatility-of-the-anterolateral-thigh-free-flap-the-four-seas 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/di-2012-versatility-of-the-anterolateral-thigh-free-flap-the-four-seas 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hassan-2008-the-pharmacotherapy-of-heparin-induced-thrombocytopenia-hi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hassan-2008-the-pharmacotherapy-of-heparin-induced-thrombocytopenia-hi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hassan-2008-the-pharmacotherapy-of-heparin-induced-thrombocytopenia-hi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hassan-2008-the-pharmacotherapy-of-heparin-induced-thrombocytopenia-hi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nin-2013-a-randomized-controlled-trial-of-dabigatran-versus-warfarin-f 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nin-2013-a-randomized-controlled-trial-of-dabigatran-versus-warfarin-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nin-2013-a-randomized-controlled-trial-of-dabigatran-versus-warfarin-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nin-2013-a-randomized-controlled-trial-of-dabigatran-versus-warfarin-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lip-2013-stroke-and-bleeding-risk-assessment-in-atrial-fibrillation-wh 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lip-2013-stroke-and-bleeding-risk-assessment-in-atrial-fibrillation-wh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lip-2013-stroke-and-bleeding-risk-assessment-in-atrial-fibrillation-wh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lip-2013-stroke-and-bleeding-risk-assessment-in-atrial-fibrillation-wh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guo-2013-bleeding-risk-assessment-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guo-2013-bleeding-risk-assessment-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guo-2013-bleeding-risk-assessment-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guo-2013-bleeding-risk-assessment-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sergie-2013-current-periprocedural-anticoagulation-in-transcatheter-ao 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sergie-2013-current-periprocedural-anticoagulation-in-transcatheter-ao 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sergie-2013-current-periprocedural-anticoagulation-in-transcatheter-ao 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sergie-2013-current-periprocedural-anticoagulation-in-transcatheter-ao 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/steiner-2013-recommendations-for-the-emergency-management-of-complicat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/steiner-2013-recommendations-for-the-emergency-management-of-complicat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/steiner-2013-recommendations-for-the-emergency-management-of-complicat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/steiner-2013-recommendations-for-the-emergency-management-of-complicat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/unknown-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/unknown-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/unknown-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/unknown-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tang-2013-free-deep-inferior-epigastric-artery-perforator-flap-for-rec 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tang-2013-free-deep-inferior-epigastric-artery-perforator-flap-for-rec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tang-2013-free-deep-inferior-epigastric-artery-perforator-flap-for-rec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tang-2013-free-deep-inferior-epigastric-artery-perforator-flap-for-rec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/han-2013-anticoagulation-management-of-patients-with-long-term-warfari 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/han-2013-anticoagulation-management-of-patients-with-long-term-warfari 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/han-2013-anticoagulation-management-of-patients-with-long-term-warfari 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/han-2013-anticoagulation-management-of-patients-with-long-term-warfari 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yap-2014-a-single-centre-experience-of-the-efficacy-and-safety-of-dabi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yap-2014-a-single-centre-experience-of-the-efficacy-and-safety-of-dabi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yap-2014-a-single-centre-experience-of-the-efficacy-and-safety-of-dabi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yap-2014-a-single-centre-experience-of-the-efficacy-and-safety-of-dabi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chen-2014-an-old-controversy-revisited-one-versus-two-venous-anastomos 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chen-2014-an-old-controversy-revisited-one-versus-two-venous-anastomos 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chen-2014-an-old-controversy-revisited-one-versus-two-venous-anastomos 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chen-2014-an-old-controversy-revisited-one-versus-two-venous-anastomos 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cheng-2014-non-vitamin-k-antagonist-oral-anticoagulants-in-cardiovascu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cheng-2014-non-vitamin-k-antagonist-oral-anticoagulants-in-cardiovascu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cheng-2014-non-vitamin-k-antagonist-oral-anticoagulants-in-cardiovascu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cheng-2014-non-vitamin-k-antagonist-oral-anticoagulants-in-cardiovascu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/turpie-2014-rivaroxaban-as-an-oral-anticoagulant-for-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/turpie-2014-rivaroxaban-as-an-oral-anticoagulant-for-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/turpie-2014-rivaroxaban-as-an-oral-anticoagulant-for-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/turpie-2014-rivaroxaban-as-an-oral-anticoagulant-for-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kayalar-2014-clinical-applications-of-free-arterialized-venous-flaps 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kayalar-2014-clinical-applications-of-free-arterialized-venous-flaps 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kayalar-2014-clinical-applications-of-free-arterialized-venous-flaps 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kayalar-2014-clinical-applications-of-free-arterialized-venous-flaps 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/browne-2014-end-stage-renal-disease-with-atrial-fibrillation-uncharted 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/browne-2014-end-stage-renal-disease-with-atrial-fibrillation-uncharted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/browne-2014-end-stage-renal-disease-with-atrial-fibrillation-uncharted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/browne-2014-end-stage-renal-disease-with-atrial-fibrillation-uncharted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/berger-2014-a-standardized-bleeding-risk-score-aligns-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/berger-2014-a-standardized-bleeding-risk-score-aligns-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/berger-2014-a-standardized-bleeding-risk-score-aligns-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/berger-2014-a-standardized-bleeding-risk-score-aligns-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yeung-2015-use-of-viscoelastic-haemostatic-assay-in-emergency-and-elec 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yeung-2015-use-of-viscoelastic-haemostatic-assay-in-emergency-and-elec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yeung-2015-use-of-viscoelastic-haemostatic-assay-in-emergency-and-elec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yeung-2015-use-of-viscoelastic-haemostatic-assay-in-emergency-and-elec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dzeshka-2014-stroke-and-bleeding-risk-in-atrial-fibrillation-navigatin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dzeshka-2014-stroke-and-bleeding-risk-in-atrial-fibrillation-navigatin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dzeshka-2014-stroke-and-bleeding-risk-in-atrial-fibrillation-navigatin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dzeshka-2014-stroke-and-bleeding-risk-in-atrial-fibrillation-navigatin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/olesen-2015-non-vitamin-k-antagonist-oral-anticoagulation-agents-in-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/olesen-2015-non-vitamin-k-antagonist-oral-anticoagulation-agents-in-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/olesen-2015-non-vitamin-k-antagonist-oral-anticoagulation-agents-in-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/olesen-2015-non-vitamin-k-antagonist-oral-anticoagulation-agents-in-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/verdecchia-2015-safety-of-dabigatran-in-an-elderly-population-single-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/verdecchia-2015-safety-of-dabigatran-in-an-elderly-population-single-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/verdecchia-2015-safety-of-dabigatran-in-an-elderly-population-single-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/verdecchia-2015-safety-of-dabigatran-in-an-elderly-population-single-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sangani-2014-bivalirudin-and-transcatheter-aortic-valve-replacement-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sangani-2014-bivalirudin-and-transcatheter-aortic-valve-replacement-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sangani-2014-bivalirudin-and-transcatheter-aortic-valve-replacement-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sangani-2014-bivalirudin-and-transcatheter-aortic-valve-replacement-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/douketis-2015-perioperative-bridging-anticoagulation-during-dabigatran 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/douketis-2015-perioperative-bridging-anticoagulation-during-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/douketis-2015-perioperative-bridging-anticoagulation-during-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/douketis-2015-perioperative-bridging-anticoagulation-during-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/scott-2015-transfemoral-transcatheter-aortic-valve-replacement-in-a-pa 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/scott-2015-transfemoral-transcatheter-aortic-valve-replacement-in-a-pa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/scott-2015-transfemoral-transcatheter-aortic-valve-replacement-in-a-pa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/scott-2015-transfemoral-transcatheter-aortic-valve-replacement-in-a-pa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/harder-2014-pharmacokinetic-and-pharmacodynamic-evaluation-of-rivaroxa 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/harder-2014-pharmacokinetic-and-pharmacodynamic-evaluation-of-rivaroxa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/harder-2014-pharmacokinetic-and-pharmacodynamic-evaluation-of-rivaroxa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/harder-2014-pharmacokinetic-and-pharmacodynamic-evaluation-of-rivaroxa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mullier-2015-non-vka-oral-anticoagulants-an-update-for-the-clinical-bi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mullier-2015-non-vka-oral-anticoagulants-an-update-for-the-clinical-bi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mullier-2015-non-vka-oral-anticoagulants-an-update-for-the-clinical-bi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mullier-2015-non-vka-oral-anticoagulants-an-update-for-the-clinical-bi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ko-2015-effectiveness-of-a-microvascular-surgery-training-curriculum-f 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ko-2015-effectiveness-of-a-microvascular-surgery-training-curriculum-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ko-2015-effectiveness-of-a-microvascular-surgery-training-curriculum-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ko-2015-effectiveness-of-a-microvascular-surgery-training-curriculum-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ment-2015-direct-oral-anticoagulants-key-considerations-for-use-to-pre 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ment-2015-direct-oral-anticoagulants-key-considerations-for-use-to-pre 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ment-2015-direct-oral-anticoagulants-key-considerations-for-use-to-pre 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ment-2015-direct-oral-anticoagulants-key-considerations-for-use-to-pre 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/douketis-2015-perioperative-bridging-anticoagulation-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/douketis-2015-perioperative-bridging-anticoagulation-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/douketis-2015-perioperative-bridging-anticoagulation-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/douketis-2015-perioperative-bridging-anticoagulation-in-patients-with 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greinacher-2015-clinical-practice-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greinacher-2015-clinical-practice-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greinacher-2015-clinical-practice-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greinacher-2015-clinical-practice-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lange-2015-bivalirudin-vs-heparin-in-patients-who-undergo-transcathete 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lange-2015-bivalirudin-vs-heparin-in-patients-who-undergo-transcathete 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lange-2015-bivalirudin-vs-heparin-in-patients-who-undergo-transcathete 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lange-2015-bivalirudin-vs-heparin-in-patients-who-undergo-transcathete 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhu-2015-the-has-bled-score-for-predicting-major-bleeding-risk-in-anti 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhu-2015-the-has-bled-score-for-predicting-major-bleeding-risk-in-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhu-2015-the-has-bled-score-for-predicting-major-bleeding-risk-in-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhu-2015-the-has-bled-score-for-predicting-major-bleeding-risk-in-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dangas-2015-bivalirudin-versus-heparin-anticoagulation-in-transcathete 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dangas-2015-bivalirudin-versus-heparin-anticoagulation-in-transcathete 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dangas-2015-bivalirudin-versus-heparin-anticoagulation-in-transcathete 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dangas-2015-bivalirudin-versus-heparin-anticoagulation-in-transcathete 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/russo-2015-efficacy-and-safety-of-dabigatran-in-a-real-life-population 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/russo-2015-efficacy-and-safety-of-dabigatran-in-a-real-life-population 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/russo-2015-efficacy-and-safety-of-dabigatran-in-a-real-life-population 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/russo-2015-efficacy-and-safety-of-dabigatran-in-a-real-life-population 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/d-cousus-2015-treatment-of-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/d-cousus-2015-treatment-of-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/d-cousus-2015-treatment-of-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/d-cousus-2015-treatment-of-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaminsky-2017-the-vastus-lateralis-free-flap-for-lower-extremity-gusti 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaminsky-2017-the-vastus-lateralis-free-flap-for-lower-extremity-gusti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaminsky-2017-the-vastus-lateralis-free-flap-for-lower-extremity-gusti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaminsky-2017-the-vastus-lateralis-free-flap-for-lower-extremity-gusti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shapiro-2016-critical-review-and-update-on-the-treatment-of-acute-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shapiro-2016-critical-review-and-update-on-the-treatment-of-acute-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shapiro-2016-critical-review-and-update-on-the-treatment-of-acute-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shapiro-2016-critical-review-and-update-on-the-treatment-of-acute-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barbanti-2016-antithrombotic-therapy-following-transcatheter-aortic-va 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barbanti-2016-antithrombotic-therapy-following-transcatheter-aortic-va 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barbanti-2016-antithrombotic-therapy-following-transcatheter-aortic-va 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barbanti-2016-antithrombotic-therapy-following-transcatheter-aortic-va 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thomas-2015-thromboelastometry-versus-free-oscillation-rheometry-and-e 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thomas-2015-thromboelastometry-versus-free-oscillation-rheometry-and-e 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thomas-2015-thromboelastometry-versus-free-oscillation-rheometry-and-e 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thomas-2015-thromboelastometry-versus-free-oscillation-rheometry-and-e 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/van-2015-using-direct-oral-anticoagulants-doacs-in-cancer-and-other-hi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/van-2015-using-direct-oral-anticoagulants-doacs-in-cancer-and-other-hi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/van-2015-using-direct-oral-anticoagulants-doacs-in-cancer-and-other-hi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/van-2015-using-direct-oral-anticoagulants-doacs-in-cancer-and-other-hi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mastoris-2016-bivalirudin-or-heparin-treatment-during-transcatheter-va 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mastoris-2016-bivalirudin-or-heparin-treatment-during-transcatheter-va 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mastoris-2016-bivalirudin-or-heparin-treatment-during-transcatheter-va 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mastoris-2016-bivalirudin-or-heparin-treatment-during-transcatheter-va 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ghanem-2016-anastomosis-lapse-index-ali-a-validated-end-product-assess 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ghanem-2016-anastomosis-lapse-index-ali-a-validated-end-product-assess 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ghanem-2016-anastomosis-lapse-index-ali-a-validated-end-product-assess 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ghanem-2016-anastomosis-lapse-index-ali-a-validated-end-product-assess 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/patel-2016-oral-anticoagulation-in-patients-with-end-stage-renal-disea 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/patel-2016-oral-anticoagulation-in-patients-with-end-stage-renal-disea 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/patel-2016-oral-anticoagulation-in-patients-with-end-stage-renal-disea 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/patel-2016-oral-anticoagulation-in-patients-with-end-stage-renal-disea 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ghadimi-2016-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-re 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ghadimi-2016-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-re 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ghadimi-2016-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-re 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ghadimi-2016-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-re 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pearson-2016-desmopressin-in-vitro-effects-on-platelet-function-monito 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pearson-2016-desmopressin-in-vitro-effects-on-platelet-function-monito 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pearson-2016-desmopressin-in-vitro-effects-on-platelet-function-monito 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pearson-2016-desmopressin-in-vitro-effects-on-platelet-function-monito 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/panikker-2016-outcomes-and-costs-of-left-atrial-appendage-closure-from 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/panikker-2016-outcomes-and-costs-of-left-atrial-appendage-closure-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/panikker-2016-outcomes-and-costs-of-left-atrial-appendage-closure-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/panikker-2016-outcomes-and-costs-of-left-atrial-appendage-closure-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hu-2016-reversing-anticoagulant-effects-of-novel-oral-anticoagulants-r 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hu-2016-reversing-anticoagulant-effects-of-novel-oral-anticoagulants-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hu-2016-reversing-anticoagulant-effects-of-novel-oral-anticoagulants-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hu-2016-reversing-anticoagulant-effects-of-novel-oral-anticoagulants-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yavuz-2016-a-real-world-data-of-dabigatran-etexilate-multicenter-regis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yavuz-2016-a-real-world-data-of-dabigatran-etexilate-multicenter-regis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yavuz-2016-a-real-world-data-of-dabigatran-etexilate-multicenter-regis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yavuz-2016-a-real-world-data-of-dabigatran-etexilate-multicenter-regis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/uprichard-2016-management-of-rivaroxaban-in-relation-to-bodyweight-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/uprichard-2016-management-of-rivaroxaban-in-relation-to-bodyweight-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/uprichard-2016-management-of-rivaroxaban-in-relation-to-bodyweight-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/uprichard-2016-management-of-rivaroxaban-in-relation-to-bodyweight-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nazha-2016-the-bridge-trial-what-the-hospitalist-should-know 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nazha-2016-the-bridge-trial-what-the-hospitalist-should-know 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nazha-2016-the-bridge-trial-what-the-hospitalist-should-know 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nazha-2016-the-bridge-trial-what-the-hospitalist-should-know 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/smythe-2016-reversal-agents-for-use-with-direct-and-indirect-anticoagu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/smythe-2016-reversal-agents-for-use-with-direct-and-indirect-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/smythe-2016-reversal-agents-for-use-with-direct-and-indirect-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/smythe-2016-reversal-agents-for-use-with-direct-and-indirect-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/asgar-2017-sex-based-differences-in-outcomes-with-bivalirudin-or-unfra 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/asgar-2017-sex-based-differences-in-outcomes-with-bivalirudin-or-unfra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/asgar-2017-sex-based-differences-in-outcomes-with-bivalirudin-or-unfra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/asgar-2017-sex-based-differences-in-outcomes-with-bivalirudin-or-unfra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vanassche-2016-reversal-of-dabigatran-by-idarucizumab-when-and-how 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vanassche-2016-reversal-of-dabigatran-by-idarucizumab-when-and-how 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vanassche-2016-reversal-of-dabigatran-by-idarucizumab-when-and-how 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vanassche-2016-reversal-of-dabigatran-by-idarucizumab-when-and-how 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yorkgitis-2016-non-vitamin-k-antagonist-oral-anticoagulant-reversal-ho 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yorkgitis-2016-non-vitamin-k-antagonist-oral-anticoagulant-reversal-ho 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yorkgitis-2016-non-vitamin-k-antagonist-oral-anticoagulant-reversal-ho 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yorkgitis-2016-non-vitamin-k-antagonist-oral-anticoagulant-reversal-ho 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reardon-2016-idarucizumab-for-dabigatran-reversal-guideline 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reardon-2016-idarucizumab-for-dabigatran-reversal-guideline 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reardon-2016-idarucizumab-for-dabigatran-reversal-guideline 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reardon-2016-idarucizumab-for-dabigatran-reversal-guideline 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/van-2016-cerebral-embolism-during-transcatheter-aortic-valve-replaceme 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/van-2016-cerebral-embolism-during-transcatheter-aortic-valve-replaceme 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/van-2016-cerebral-embolism-during-transcatheter-aortic-valve-replaceme 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/van-2016-cerebral-embolism-during-transcatheter-aortic-valve-replaceme 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hussain-2017-reversal-of-newer-direct-oral-anticoagulant-drugs-doacs 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hussain-2017-reversal-of-newer-direct-oral-anticoagulant-drugs-doacs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hussain-2017-reversal-of-newer-direct-oral-anticoagulant-drugs-doacs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hussain-2017-reversal-of-newer-direct-oral-anticoagulant-drugs-doacs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/minhas-2016-renal-function-in-atrial-fibrillation-patients-switched-fr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/minhas-2016-renal-function-in-atrial-fibrillation-patients-switched-fr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/minhas-2016-renal-function-in-atrial-fibrillation-patients-switched-fr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/minhas-2016-renal-function-in-atrial-fibrillation-patients-switched-fr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/salter-2016-heparin-induced-thrombocytopenia-a-comprehensive-clinical 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/salter-2016-heparin-induced-thrombocytopenia-a-comprehensive-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/salter-2016-heparin-induced-thrombocytopenia-a-comprehensive-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/salter-2016-heparin-induced-thrombocytopenia-a-comprehensive-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/boey-2016-drug-treatment-of-venous-thromboembolism-in-the-elderly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/boey-2016-drug-treatment-of-venous-thromboembolism-in-the-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/boey-2016-drug-treatment-of-venous-thromboembolism-in-the-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/boey-2016-drug-treatment-of-venous-thromboembolism-in-the-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wight-2016-perioperative-bridging-anticoagulation-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wight-2016-perioperative-bridging-anticoagulation-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wight-2016-perioperative-bridging-anticoagulation-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wight-2016-perioperative-bridging-anticoagulation-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ayoub-2016-perioperative-heparin-bridging-in-atrial-fibrillation-patie 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ayoub-2016-perioperative-heparin-bridging-in-atrial-fibrillation-patie 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ayoub-2016-perioperative-heparin-bridging-in-atrial-fibrillation-patie 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ayoub-2016-perioperative-heparin-bridging-in-atrial-fibrillation-patie 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2016-effect-of-microvascular-anastomosis-technique-on-end-product 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2016-effect-of-microvascular-anastomosis-technique-on-end-product 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2016-effect-of-microvascular-anastomosis-technique-on-end-product 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2016-effect-of-microvascular-anastomosis-technique-on-end-product 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barra-2016-evaluation-of-dose-reduced-direct-oral-anticoagulant-therap 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barra-2016-evaluation-of-dose-reduced-direct-oral-anticoagulant-therap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barra-2016-evaluation-of-dose-reduced-direct-oral-anticoagulant-therap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barra-2016-evaluation-of-dose-reduced-direct-oral-anticoagulant-therap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bertoletti-2017-direct-oral-anticoagulants-current-indications-and-unm 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bertoletti-2017-direct-oral-anticoagulants-current-indications-and-unm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bertoletti-2017-direct-oral-anticoagulants-current-indications-and-unm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bertoletti-2017-direct-oral-anticoagulants-current-indications-and-unm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-2016-management-of-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-2016-management-of-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-2016-management-of-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-2016-management-of-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/syed-2016-idarucizumab-a-review-as-a-reversal-agent-for-dabigatran 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/syed-2016-idarucizumab-a-review-as-a-reversal-agent-for-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/syed-2016-idarucizumab-a-review-as-a-reversal-agent-for-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/syed-2016-idarucizumab-a-review-as-a-reversal-agent-for-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ansell-2016-ciraparantag-safely-and-completely-reverses-the-anticoagul 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ansell-2016-ciraparantag-safely-and-completely-reverses-the-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ansell-2016-ciraparantag-safely-and-completely-reverses-the-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ansell-2016-ciraparantag-safely-and-completely-reverses-the-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/koster-2016-bivalirudin-anticoagulation-for-minimal-invasive-transapic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/koster-2016-bivalirudin-anticoagulation-for-minimal-invasive-transapic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/koster-2016-bivalirudin-anticoagulation-for-minimal-invasive-transapic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/koster-2016-bivalirudin-anticoagulation-for-minimal-invasive-transapic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/esteve-pastor-2016-is-the-orbit-bleeding-risk-score-superior-to-the-ha 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/esteve-pastor-2016-is-the-orbit-bleeding-risk-score-superior-to-the-ha 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/esteve-pastor-2016-is-the-orbit-bleeding-risk-score-superior-to-the-ha 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/esteve-pastor-2016-is-the-orbit-bleeding-risk-score-superior-to-the-ha 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ba-aran-2016-suboptimal-use-of-non-vitamin-k-antagonist-oral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ba-aran-2016-suboptimal-use-of-non-vitamin-k-antagonist-oral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ba-aran-2016-suboptimal-use-of-non-vitamin-k-antagonist-oral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ba-aran-2016-suboptimal-use-of-non-vitamin-k-antagonist-oral-anticoagu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/genovesi-2016-oral-anticoagulation-in-end-stage-renal-disease-is-it-ti 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/genovesi-2016-oral-anticoagulation-in-end-stage-renal-disease-is-it-ti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/genovesi-2016-oral-anticoagulation-in-end-stage-renal-disease-is-it-ti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/genovesi-2016-oral-anticoagulation-in-end-stage-renal-disease-is-it-ti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/samuelson-2017-measurement-and-reversal-of-the-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/samuelson-2017-measurement-and-reversal-of-the-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/samuelson-2017-measurement-and-reversal-of-the-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/samuelson-2017-measurement-and-reversal-of-the-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi-27697436 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi-27697436 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi-27697436 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pollack-2016-evidence-supporting-idarucizumab-for-the-reversal-of-dabi-27697436 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jandali-2018-the-free-medial-sural-artery-perforator-flap-versatile-op 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jandali-2018-the-free-medial-sural-artery-perforator-flap-versatile-op 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jandali-2018-the-free-medial-sural-artery-perforator-flap-versatile-op 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jandali-2018-the-free-medial-sural-artery-perforator-flap-versatile-op 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/buckley-2017-direct-oral-anticoagulants-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/buckley-2017-direct-oral-anticoagulants-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/buckley-2017-direct-oral-anticoagulants-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/buckley-2017-direct-oral-anticoagulants-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greer-2016-low-molecular-weight-heparin-for-pregnancy-complications 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greer-2016-low-molecular-weight-heparin-for-pregnancy-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greer-2016-low-molecular-weight-heparin-for-pregnancy-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greer-2016-low-molecular-weight-heparin-for-pregnancy-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ansell-2017-single-dose-ciraparantag-safely-and-completely-reverses-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ansell-2017-single-dose-ciraparantag-safely-and-completely-reverses-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ansell-2017-single-dose-ciraparantag-safely-and-completely-reverses-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ansell-2017-single-dose-ciraparantag-safely-and-completely-reverses-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/riley-2017-role-of-agents-for-reversing-the-effects-of-target-specific 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/riley-2017-role-of-agents-for-reversing-the-effects-of-target-specific 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/riley-2017-role-of-agents-for-reversing-the-effects-of-target-specific 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/riley-2017-role-of-agents-for-reversing-the-effects-of-target-specific 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xian-2016-acute-management-of-stroke-patients-taking-non-vitamin-k-ant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xian-2016-acute-management-of-stroke-patients-taking-non-vitamin-k-ant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xian-2016-acute-management-of-stroke-patients-taking-non-vitamin-k-ant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xian-2016-acute-management-of-stroke-patients-taking-non-vitamin-k-ant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/k-nigsbr-gge-2016-thromboembolic-events-bleeding-and-drug-discontinuat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/k-nigsbr-gge-2016-thromboembolic-events-bleeding-and-drug-discontinuat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/k-nigsbr-gge-2016-thromboembolic-events-bleeding-and-drug-discontinuat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/k-nigsbr-gge-2016-thromboembolic-events-bleeding-and-drug-discontinuat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/haddad-2017-low-molecular-weight-heparin-for-the-prevention-of-placent 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/haddad-2017-low-molecular-weight-heparin-for-the-prevention-of-placent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/haddad-2017-low-molecular-weight-heparin-for-the-prevention-of-placent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/haddad-2017-low-molecular-weight-heparin-for-the-prevention-of-placent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/doherty-2017-2017-acc-expert-consensus-decision-pathway-for-periproced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/doherty-2017-2017-acc-expert-consensus-decision-pathway-for-periproced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/doherty-2017-2017-acc-expert-consensus-decision-pathway-for-periproced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/doherty-2017-2017-acc-expert-consensus-decision-pathway-for-periproced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/acosta-urquidi-1989-serotonin-differentially-modulates-two-k-currents 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/acosta-urquidi-1989-serotonin-differentially-modulates-two-k-currents 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/acosta-urquidi-1989-serotonin-differentially-modulates-two-k-currents 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/acosta-urquidi-1989-serotonin-differentially-modulates-two-k-currents 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gottlieb-2017-idarucizumab-for-the-reversal-of-dabigatran 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gottlieb-2017-idarucizumab-for-the-reversal-of-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gottlieb-2017-idarucizumab-for-the-reversal-of-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gottlieb-2017-idarucizumab-for-the-reversal-of-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/apfelberg-1989-high-and-low-technology-solutions-for-massive-cavernous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/apfelberg-1989-high-and-low-technology-solutions-for-massive-cavernous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/apfelberg-1989-high-and-low-technology-solutions-for-massive-cavernous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/apfelberg-1989-high-and-low-technology-solutions-for-massive-cavernous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/froio-2017-anticoagulation-in-acute-ischemic-stroke-a-systematic-searc 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/froio-2017-anticoagulation-in-acute-ischemic-stroke-a-systematic-searc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/froio-2017-anticoagulation-in-acute-ischemic-stroke-a-systematic-searc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/froio-2017-anticoagulation-in-acute-ischemic-stroke-a-systematic-searc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pelliccia-2016-real-world-data-on-novel-oral-anticoagulants-the-added 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pelliccia-2016-real-world-data-on-novel-oral-anticoagulants-the-added 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pelliccia-2016-real-world-data-on-novel-oral-anticoagulants-the-added 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pelliccia-2016-real-world-data-on-novel-oral-anticoagulants-the-added 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/taune-2017-whole-blood-coagulation-assays-rotem-and-t-tas-to-monitor-d 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/taune-2017-whole-blood-coagulation-assays-rotem-and-t-tas-to-monitor-d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/taune-2017-whole-blood-coagulation-assays-rotem-and-t-tas-to-monitor-d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/taune-2017-whole-blood-coagulation-assays-rotem-and-t-tas-to-monitor-d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/o-malley-2017-adjuvant-antithrombotic-therapy-in-tavr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/o-malley-2017-adjuvant-antithrombotic-therapy-in-tavr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/o-malley-2017-adjuvant-antithrombotic-therapy-in-tavr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/o-malley-2017-adjuvant-antithrombotic-therapy-in-tavr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schoeff-2017-microvascular-anastomosis-simulation-using-a-chicken-thig 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schoeff-2017-microvascular-anastomosis-simulation-using-a-chicken-thig 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schoeff-2017-microvascular-anastomosis-simulation-using-a-chicken-thig 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schoeff-2017-microvascular-anastomosis-simulation-using-a-chicken-thig 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/willett-2017-use-of-direct-oral-anticoagulants-for-the-prevention-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/willett-2017-use-of-direct-oral-anticoagulants-for-the-prevention-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/willett-2017-use-of-direct-oral-anticoagulants-for-the-prevention-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/willett-2017-use-of-direct-oral-anticoagulants-for-the-prevention-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/willis-2017-development-and-evaluation-of-a-simulation-model-for-micro 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/willis-2017-development-and-evaluation-of-a-simulation-model-for-micro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/willis-2017-development-and-evaluation-of-a-simulation-model-for-micro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/willis-2017-development-and-evaluation-of-a-simulation-model-for-micro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hengstenberg-2017-impact-of-pre-existing-or-new-onset-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hengstenberg-2017-impact-of-pre-existing-or-new-onset-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hengstenberg-2017-impact-of-pre-existing-or-new-onset-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hengstenberg-2017-impact-of-pre-existing-or-new-onset-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fanikos-2017-renal-function-considerations-for-stroke-prevention-in-at 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fanikos-2017-renal-function-considerations-for-stroke-prevention-in-at 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fanikos-2017-renal-function-considerations-for-stroke-prevention-in-at 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fanikos-2017-renal-function-considerations-for-stroke-prevention-in-at 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chunduri-2017-antithrombotic-therapy-in-end-stage-renal-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chunduri-2017-antithrombotic-therapy-in-end-stage-renal-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chunduri-2017-antithrombotic-therapy-in-end-stage-renal-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chunduri-2017-antithrombotic-therapy-in-end-stage-renal-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moore-2017-influences-of-obesity-and-bariatric-surgery-on-the-clinical 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moore-2017-influences-of-obesity-and-bariatric-surgery-on-the-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moore-2017-influences-of-obesity-and-bariatric-surgery-on-the-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moore-2017-influences-of-obesity-and-bariatric-surgery-on-the-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/turpie-2017-nonvitamin-k-antagonist-oral-anticoagulant-use-in-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/turpie-2017-nonvitamin-k-antagonist-oral-anticoagulant-use-in-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/turpie-2017-nonvitamin-k-antagonist-oral-anticoagulant-use-in-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/turpie-2017-nonvitamin-k-antagonist-oral-anticoagulant-use-in-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sideris-2019-biomarkers-associated-with-bleeding-risk-in-the-setting-o 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sideris-2019-biomarkers-associated-with-bleeding-risk-in-the-setting-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sideris-2019-biomarkers-associated-with-bleeding-risk-in-the-setting-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sideris-2019-biomarkers-associated-with-bleeding-risk-in-the-setting-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pafitanis-2017-the-chicken-thigh-adductor-profundus-free-muscle-flap-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pafitanis-2017-the-chicken-thigh-adductor-profundus-free-muscle-flap-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pafitanis-2017-the-chicken-thigh-adductor-profundus-free-muscle-flap-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pafitanis-2017-the-chicken-thigh-adductor-profundus-free-muscle-flap-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hernandez-2017-thromboelastrography-teg-is-still-relevant-in-the-21st 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hernandez-2017-thromboelastrography-teg-is-still-relevant-in-the-21st 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hernandez-2017-thromboelastrography-teg-is-still-relevant-in-the-21st 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hernandez-2017-thromboelastrography-teg-is-still-relevant-in-the-21st 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/irizarry-alvarado-2017-perioperative-management-of-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/irizarry-alvarado-2017-perioperative-management-of-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/irizarry-alvarado-2017-perioperative-management-of-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/irizarry-alvarado-2017-perioperative-management-of-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pafitanis-2017-putting-the-heart-into-microvascular-training-the-micro 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pafitanis-2017-putting-the-heart-into-microvascular-training-the-micro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pafitanis-2017-putting-the-heart-into-microvascular-training-the-micro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pafitanis-2017-putting-the-heart-into-microvascular-training-the-micro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hellenbart-2017-evaluation-of-bleeding-in-patients-receiving-direct-or 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hellenbart-2017-evaluation-of-bleeding-in-patients-receiving-direct-or 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hellenbart-2017-evaluation-of-bleeding-in-patients-receiving-direct-or 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hellenbart-2017-evaluation-of-bleeding-in-patients-receiving-direct-or 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dzeshka-2017-direct-oral-anticoagulant-reversal-how-when-and-issues-fa 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dzeshka-2017-direct-oral-anticoagulant-reversal-how-when-and-issues-fa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dzeshka-2017-direct-oral-anticoagulant-reversal-how-when-and-issues-fa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dzeshka-2017-direct-oral-anticoagulant-reversal-how-when-and-issues-fa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kvint-2017-neurosurgical-applications-of-viscoelastic-hemostatic-assay 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kvint-2017-neurosurgical-applications-of-viscoelastic-hemostatic-assay 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kvint-2017-neurosurgical-applications-of-viscoelastic-hemostatic-assay 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kvint-2017-neurosurgical-applications-of-viscoelastic-hemostatic-assay 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ruiz-2018-inappropriate-doses-of-direct-oral-anticoagulants-in-real-wo 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ruiz-2018-inappropriate-doses-of-direct-oral-anticoagulants-in-real-wo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ruiz-2018-inappropriate-doses-of-direct-oral-anticoagulants-in-real-wo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ruiz-2018-inappropriate-doses-of-direct-oral-anticoagulants-in-real-wo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sirico-2019-low-molecular-weight-heparin-use-during-pregnancy-and-risk 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sirico-2019-low-molecular-weight-heparin-use-during-pregnancy-and-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sirico-2019-low-molecular-weight-heparin-use-during-pregnancy-and-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sirico-2019-low-molecular-weight-heparin-use-during-pregnancy-and-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lu-2017-the-safety-of-low-molecular-weight-heparin-during-and-after-pr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lu-2017-the-safety-of-low-molecular-weight-heparin-during-and-after-pr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lu-2017-the-safety-of-low-molecular-weight-heparin-during-and-after-pr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lu-2017-the-safety-of-low-molecular-weight-heparin-during-and-after-pr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/darras-2018-anteroposterior-axis-patterning-by-early-canonical-wnt-sig 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/darras-2018-anteroposterior-axis-patterning-by-early-canonical-wnt-sig 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/darras-2018-anteroposterior-axis-patterning-by-early-canonical-wnt-sig 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/darras-2018-anteroposterior-axis-patterning-by-early-canonical-wnt-sig 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/levy-2018-reversal-agents-for-non-vitamin-k-antagonist-oral-anticoagul 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/levy-2018-reversal-agents-for-non-vitamin-k-antagonist-oral-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/levy-2018-reversal-agents-for-non-vitamin-k-antagonist-oral-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/levy-2018-reversal-agents-for-non-vitamin-k-antagonist-oral-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stewart-2018-management-of-perioperative-anticoagulation-for-device-im 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stewart-2018-management-of-perioperative-anticoagulation-for-device-im 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stewart-2018-management-of-perioperative-anticoagulation-for-device-im 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stewart-2018-management-of-perioperative-anticoagulation-for-device-im 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bartlett-2018-algorithmic-approach-for-intraoperative-salvage-of-venou 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bartlett-2018-algorithmic-approach-for-intraoperative-salvage-of-venou 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bartlett-2018-algorithmic-approach-for-intraoperative-salvage-of-venou 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bartlett-2018-algorithmic-approach-for-intraoperative-salvage-of-venou 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ali-2018-basic-microvascular-anastomosis-simulation-hub-microsurgery-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ali-2018-basic-microvascular-anastomosis-simulation-hub-microsurgery-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ali-2018-basic-microvascular-anastomosis-simulation-hub-microsurgery-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ali-2018-basic-microvascular-anastomosis-simulation-hub-microsurgery-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/malas-2018-impact-of-visualization-on-simulation-training-for-vascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/malas-2018-impact-of-visualization-on-simulation-training-for-vascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/malas-2018-impact-of-visualization-on-simulation-training-for-vascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/malas-2018-impact-of-visualization-on-simulation-training-for-vascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/watanabe-2018-atrial-fibrillation-in-patients-with-end-stage-kidney-di 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/watanabe-2018-atrial-fibrillation-in-patients-with-end-stage-kidney-di 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/watanabe-2018-atrial-fibrillation-in-patients-with-end-stage-kidney-di 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/watanabe-2018-atrial-fibrillation-in-patients-with-end-stage-kidney-di 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huisman-2018-two-year-follow-up-of-patients-treated-with-dabigatran-fo 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huisman-2018-two-year-follow-up-of-patients-treated-with-dabigatran-fo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huisman-2018-two-year-follow-up-of-patients-treated-with-dabigatran-fo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huisman-2018-two-year-follow-up-of-patients-treated-with-dabigatran-fo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mokhtari-2019-microvascular-anastomosis-proposition-of-a-learning-curv 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mokhtari-2019-microvascular-anastomosis-proposition-of-a-learning-curv 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mokhtari-2019-microvascular-anastomosis-proposition-of-a-learning-curv 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mokhtari-2019-microvascular-anastomosis-proposition-of-a-learning-curv 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nilsson-2018-warfarin-monitoring-with-viscoelastic-haemostatic-assays 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nilsson-2018-warfarin-monitoring-with-viscoelastic-haemostatic-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nilsson-2018-warfarin-monitoring-with-viscoelastic-haemostatic-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nilsson-2018-warfarin-monitoring-with-viscoelastic-haemostatic-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prochaska-2018-sustained-atrial-fibrillation-increases-the-risk-of-ant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prochaska-2018-sustained-atrial-fibrillation-increases-the-risk-of-ant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prochaska-2018-sustained-atrial-fibrillation-increases-the-risk-of-ant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prochaska-2018-sustained-atrial-fibrillation-increases-the-risk-of-ant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/siontis-2018-outcomes-associated-with-apixaban-use-in-patients-with-en 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/siontis-2018-outcomes-associated-with-apixaban-use-in-patients-with-en 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/siontis-2018-outcomes-associated-with-apixaban-use-in-patients-with-en 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/siontis-2018-outcomes-associated-with-apixaban-use-in-patients-with-en 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chen-2018-argatroban-plus-aspirin-versus-aspirin-in-acute-ischemic-str 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chen-2018-argatroban-plus-aspirin-versus-aspirin-in-acute-ischemic-str 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chen-2018-argatroban-plus-aspirin-versus-aspirin-in-acute-ischemic-str 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chen-2018-argatroban-plus-aspirin-versus-aspirin-in-acute-ischemic-str 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dabi-2018-reversal-strategies-for-intracranial-hemorrhage-related-to-d 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dabi-2018-reversal-strategies-for-intracranial-hemorrhage-related-to-d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dabi-2018-reversal-strategies-for-intracranial-hemorrhage-related-to-d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dabi-2018-reversal-strategies-for-intracranial-hemorrhage-related-to-d 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barnes-2019-periprocedural-bridging-anticoagulation-measuring-the-impa 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barnes-2019-periprocedural-bridging-anticoagulation-measuring-the-impa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barnes-2019-periprocedural-bridging-anticoagulation-measuring-the-impa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barnes-2019-periprocedural-bridging-anticoagulation-measuring-the-impa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/paravattil-2018-approaches-to-direct-oral-anticoagulant-selection-in-p 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/paravattil-2018-approaches-to-direct-oral-anticoagulant-selection-in-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/paravattil-2018-approaches-to-direct-oral-anticoagulant-selection-in-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/paravattil-2018-approaches-to-direct-oral-anticoagulant-selection-in-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chou-2018-pdumbase-a-transcriptome-database-and-research-tool-for-plat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chou-2018-pdumbase-a-transcriptome-database-and-research-tool-for-plat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chou-2018-pdumbase-a-transcriptome-database-and-research-tool-for-plat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chou-2018-pdumbase-a-transcriptome-database-and-research-tool-for-plat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prince-2018-heparin-induced-thrombocytopaenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prince-2018-heparin-induced-thrombocytopaenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prince-2018-heparin-induced-thrombocytopaenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prince-2018-heparin-induced-thrombocytopaenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lip-2018-antithrombotic-therapy-for-atrial-fibrillation-chest-guidelin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lip-2018-antithrombotic-therapy-for-atrial-fibrillation-chest-guidelin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lip-2018-antithrombotic-therapy-for-atrial-fibrillation-chest-guidelin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lip-2018-antithrombotic-therapy-for-atrial-fibrillation-chest-guidelin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mccaughan-2018-anticoagulation-at-the-extremes-of-body-weight-choices 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mccaughan-2018-anticoagulation-at-the-extremes-of-body-weight-choices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mccaughan-2018-anticoagulation-at-the-extremes-of-body-weight-choices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mccaughan-2018-anticoagulation-at-the-extremes-of-body-weight-choices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/padrini-2019-clinical-pharmacokinetics-and-pharmacodynamics-of-direct 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/padrini-2019-clinical-pharmacokinetics-and-pharmacodynamics-of-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/padrini-2019-clinical-pharmacokinetics-and-pharmacodynamics-of-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/padrini-2019-clinical-pharmacokinetics-and-pharmacodynamics-of-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sheikh-taha-2019-idarucizumab-for-reversal-of-dabigatran-single-center 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sheikh-taha-2019-idarucizumab-for-reversal-of-dabigatran-single-center 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sheikh-taha-2019-idarucizumab-for-reversal-of-dabigatran-single-center 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sheikh-taha-2019-idarucizumab-for-reversal-of-dabigatran-single-center 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/skeith-2018-low-molecular-weight-heparin-for-the-prevention-and-treatm 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/skeith-2018-low-molecular-weight-heparin-for-the-prevention-and-treatm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/skeith-2018-low-molecular-weight-heparin-for-the-prevention-and-treatm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/skeith-2018-low-molecular-weight-heparin-for-the-prevention-and-treatm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/brodfuehrer-1986-initiation-of-swimming-activity-by-trigger-neurons-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/brodfuehrer-1986-initiation-of-swimming-activity-by-trigger-neurons-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/brodfuehrer-1986-initiation-of-swimming-activity-by-trigger-neurons-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/brodfuehrer-1986-initiation-of-swimming-activity-by-trigger-neurons-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/taune-2018-rapid-determination-of-anticoagulating-effects-of-dabigatra 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/taune-2018-rapid-determination-of-anticoagulating-effects-of-dabigatra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/taune-2018-rapid-determination-of-anticoagulating-effects-of-dabigatra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/taune-2018-rapid-determination-of-anticoagulating-effects-of-dabigatra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hu-2018-oral-anticoagulation-in-patients-with-end-stage-kidney-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hu-2018-oral-anticoagulation-in-patients-with-end-stage-kidney-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hu-2018-oral-anticoagulation-in-patients-with-end-stage-kidney-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hu-2018-oral-anticoagulation-in-patients-with-end-stage-kidney-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vinding-2019-the-importance-of-time-in-therapeutic-range-in-switching 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vinding-2019-the-importance-of-time-in-therapeutic-range-in-switching 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vinding-2019-the-importance-of-time-in-therapeutic-range-in-switching 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vinding-2019-the-importance-of-time-in-therapeutic-range-in-switching 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lafuente-lafuente-2019-treatment-with-oral-anticoagulants-in-older-pat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lafuente-lafuente-2019-treatment-with-oral-anticoagulants-in-older-pat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lafuente-lafuente-2019-treatment-with-oral-anticoagulants-in-older-pat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lafuente-lafuente-2019-treatment-with-oral-anticoagulants-in-older-pat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/koretsune-2019-characteristics-of-japanese-patients-with-nonvalvular-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/koretsune-2019-characteristics-of-japanese-patients-with-nonvalvular-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/koretsune-2019-characteristics-of-japanese-patients-with-nonvalvular-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/koretsune-2019-characteristics-of-japanese-patients-with-nonvalvular-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lee-2019-label-adherence-for-non-vitamin-k-antagonist-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lee-2019-label-adherence-for-non-vitamin-k-antagonist-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lee-2019-label-adherence-for-non-vitamin-k-antagonist-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lee-2019-label-adherence-for-non-vitamin-k-antagonist-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/powell-2019-andexanet-alfa-a-novel-factor-xa-inhibitor-reversal-agent 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/powell-2019-andexanet-alfa-a-novel-factor-xa-inhibitor-reversal-agent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/powell-2019-andexanet-alfa-a-novel-factor-xa-inhibitor-reversal-agent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/powell-2019-andexanet-alfa-a-novel-factor-xa-inhibitor-reversal-agent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cuker-2019-reversal-of-direct-oral-anticoagulants-guidance-from-the-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cuker-2019-reversal-of-direct-oral-anticoagulants-guidance-from-the-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cuker-2019-reversal-of-direct-oral-anticoagulants-guidance-from-the-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cuker-2019-reversal-of-direct-oral-anticoagulants-guidance-from-the-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/favresse-2019-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitors 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/favresse-2019-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/favresse-2019-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/favresse-2019-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2020-a-prospective-survey-of-the-persistence-of-warfarin-or-noac-i 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2020-a-prospective-survey-of-the-persistence-of-warfarin-or-noac-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2020-a-prospective-survey-of-the-persistence-of-warfarin-or-noac-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2020-a-prospective-survey-of-the-persistence-of-warfarin-or-noac-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lu-2019-dabigatran-reversal-by-idarucizumab-in-the-setting-of-intracra 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lu-2019-dabigatran-reversal-by-idarucizumab-in-the-setting-of-intracra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lu-2019-dabigatran-reversal-by-idarucizumab-in-the-setting-of-intracra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lu-2019-dabigatran-reversal-by-idarucizumab-in-the-setting-of-intracra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/freixo-2019-has-bled-score-predicts-the-risk-of-major-bleeding-in-chro 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/freixo-2019-has-bled-score-predicts-the-risk-of-major-bleeding-in-chro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/freixo-2019-has-bled-score-predicts-the-risk-of-major-bleeding-in-chro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/freixo-2019-has-bled-score-predicts-the-risk-of-major-bleeding-in-chro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hamadi-2019-bariatric-venous-thromboembolism-prophylaxis-an-update-on 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hamadi-2019-bariatric-venous-thromboembolism-prophylaxis-an-update-on 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hamadi-2019-bariatric-venous-thromboembolism-prophylaxis-an-update-on 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hamadi-2019-bariatric-venous-thromboembolism-prophylaxis-an-update-on 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zaman-2019-oral-anticoagulants-in-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zaman-2019-oral-anticoagulants-in-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zaman-2019-oral-anticoagulants-in-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zaman-2019-oral-anticoagulants-in-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/inoue-2020-has-bled-score-as-a-predictor-of-bleeding-complications-fro 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/inoue-2020-has-bled-score-as-a-predictor-of-bleeding-complications-fro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/inoue-2020-has-bled-score-as-a-predictor-of-bleeding-complications-fro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/inoue-2020-has-bled-score-as-a-predictor-of-bleeding-complications-fro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2019-indirect-comparison-of-novel-oral-anticoagulants-among-asia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2019-indirect-comparison-of-novel-oral-anticoagulants-among-asia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2019-indirect-comparison-of-novel-oral-anticoagulants-among-asia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2019-indirect-comparison-of-novel-oral-anticoagulants-among-asia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sethia-2019-free-flap-salvage-from-venous-thrombosis-by-creation-of-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sethia-2019-free-flap-salvage-from-venous-thrombosis-by-creation-of-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sethia-2019-free-flap-salvage-from-venous-thrombosis-by-creation-of-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sethia-2019-free-flap-salvage-from-venous-thrombosis-by-creation-of-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bellin-2019-new-oral-anti-coagulants-versus-vitamin-k-antagonists-in-h 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bellin-2019-new-oral-anti-coagulants-versus-vitamin-k-antagonists-in-h 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bellin-2019-new-oral-anti-coagulants-versus-vitamin-k-antagonists-in-h 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bellin-2019-new-oral-anti-coagulants-versus-vitamin-k-antagonists-in-h 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/k-nigsbr-gge-2019-atrial-fibrillation-in-patients-with-end-stage-renal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/k-nigsbr-gge-2019-atrial-fibrillation-in-patients-with-end-stage-renal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/k-nigsbr-gge-2019-atrial-fibrillation-in-patients-with-end-stage-renal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/k-nigsbr-gge-2019-atrial-fibrillation-in-patients-with-end-stage-renal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abdulrehman-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abdulrehman-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abdulrehman-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abdulrehman-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xipell-2020-percutaneous-left-atrial-appendage-closure-a-safe-alternat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xipell-2020-percutaneous-left-atrial-appendage-closure-a-safe-alternat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xipell-2020-percutaneous-left-atrial-appendage-closure-a-safe-alternat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xipell-2020-percutaneous-left-atrial-appendage-closure-a-safe-alternat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ribeiro-2019-comparative-transcriptomics-in-syllidae-annelida-indicate 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ribeiro-2019-comparative-transcriptomics-in-syllidae-annelida-indicate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ribeiro-2019-comparative-transcriptomics-in-syllidae-annelida-indicate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ribeiro-2019-comparative-transcriptomics-in-syllidae-annelida-indicate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carpenter-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitor-asso 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carpenter-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitor-asso 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carpenter-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitor-asso 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carpenter-2019-andexanet-alfa-for-reversal-of-factor-xa-inhibitor-asso 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jansson-2020-direct-comparisons-of-effectiveness-and-safety-of-treatme 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jansson-2020-direct-comparisons-of-effectiveness-and-safety-of-treatme 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jansson-2020-direct-comparisons-of-effectiveness-and-safety-of-treatme 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jansson-2020-direct-comparisons-of-effectiveness-and-safety-of-treatme 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/van-2020-stroke-prophylaxis-in-patients-with-atrial-fibrillation-and-e 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/van-2020-stroke-prophylaxis-in-patients-with-atrial-fibrillation-and-e 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/van-2020-stroke-prophylaxis-in-patients-with-atrial-fibrillation-and-e 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/van-2020-stroke-prophylaxis-in-patients-with-atrial-fibrillation-and-e 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/inigoj-2020-risk-of-major-bleeding-in-elderly-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/inigoj-2020-risk-of-major-bleeding-in-elderly-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/inigoj-2020-risk-of-major-bleeding-in-elderly-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/inigoj-2020-risk-of-major-bleeding-in-elderly-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/randhawa-2020-association-between-use-of-warfarin-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/randhawa-2020-association-between-use-of-warfarin-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/randhawa-2020-association-between-use-of-warfarin-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/randhawa-2020-association-between-use-of-warfarin-for-atrial-fibrillat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aderibigbe-2020-latex-glove-conduit-as-improvised-blood-vessel-model-f 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aderibigbe-2020-latex-glove-conduit-as-improvised-blood-vessel-model-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aderibigbe-2020-latex-glove-conduit-as-improvised-blood-vessel-model-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aderibigbe-2020-latex-glove-conduit-as-improvised-blood-vessel-model-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tromeur-2020-diagnostic-and-therapeutic-management-of-venous-thromboem 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tromeur-2020-diagnostic-and-therapeutic-management-of-venous-thromboem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tromeur-2020-diagnostic-and-therapeutic-management-of-venous-thromboem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tromeur-2020-diagnostic-and-therapeutic-management-of-venous-thromboem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/covert-2020-direct-acting-oral-anticoagulant-use-at-extremes-of-body-w 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/covert-2020-direct-acting-oral-anticoagulant-use-at-extremes-of-body-w 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/covert-2020-direct-acting-oral-anticoagulant-use-at-extremes-of-body-w 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/covert-2020-direct-acting-oral-anticoagulant-use-at-extremes-of-body-w 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barnes-2020-periprocedural-bridging-anticoagulation-in-patients-with-v 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barnes-2020-periprocedural-bridging-anticoagulation-in-patients-with-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barnes-2020-periprocedural-bridging-anticoagulation-in-patients-with-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barnes-2020-periprocedural-bridging-anticoagulation-in-patients-with-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sebaaly-2020-direct-oral-anticoagulants-in-obesity-an-updated-literatu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sebaaly-2020-direct-oral-anticoagulants-in-obesity-an-updated-literatu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sebaaly-2020-direct-oral-anticoagulants-in-obesity-an-updated-literatu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sebaaly-2020-direct-oral-anticoagulants-in-obesity-an-updated-literatu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yang-2020-randomized-trial-of-argatroban-plus-recombinant-tissue-type 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yang-2020-randomized-trial-of-argatroban-plus-recombinant-tissue-type 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yang-2020-randomized-trial-of-argatroban-plus-recombinant-tissue-type 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yang-2020-randomized-trial-of-argatroban-plus-recombinant-tissue-type 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bavalia-2020-treatment-of-venous-thromboembolism-in-special-population 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bavalia-2020-treatment-of-venous-thromboembolism-in-special-population 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bavalia-2020-treatment-of-venous-thromboembolism-in-special-population 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bavalia-2020-treatment-of-venous-thromboembolism-in-special-population 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mcbane-2020-end-stage-renal-disease-nonvalvular-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mcbane-2020-end-stage-renal-disease-nonvalvular-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mcbane-2020-end-stage-renal-disease-nonvalvular-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mcbane-2020-end-stage-renal-disease-nonvalvular-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shaw-2020-periprocedural-management-of-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shaw-2020-periprocedural-management-of-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shaw-2020-periprocedural-management-of-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shaw-2020-periprocedural-management-of-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kapila-2020-characteristics-and-outcomes-of-primary-interposition-vasc 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kapila-2020-characteristics-and-outcomes-of-primary-interposition-vasc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kapila-2020-characteristics-and-outcomes-of-primary-interposition-vasc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kapila-2020-characteristics-and-outcomes-of-primary-interposition-vasc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zeng-2020-comparison-of-has-bled-with-other-risk-models-for-predicting 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zeng-2020-comparison-of-has-bled-with-other-risk-models-for-predicting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zeng-2020-comparison-of-has-bled-with-other-risk-models-for-predicting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zeng-2020-comparison-of-has-bled-with-other-risk-models-for-predicting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/liu-2020-argatroban-increased-the-basal-vein-drainage-and-improved-out 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/liu-2020-argatroban-increased-the-basal-vein-drainage-and-improved-out 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/liu-2020-argatroban-increased-the-basal-vein-drainage-and-improved-out 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/liu-2020-argatroban-increased-the-basal-vein-drainage-and-improved-out 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gallardo-2020-novel-simulation-model-with-pulsatile-flow-system-for-mi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gallardo-2020-novel-simulation-model-with-pulsatile-flow-system-for-mi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gallardo-2020-novel-simulation-model-with-pulsatile-flow-system-for-mi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gallardo-2020-novel-simulation-model-with-pulsatile-flow-system-for-mi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lingamaneni-2020-heparin-induced-thrombocytopenia-in-covid-19 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lingamaneni-2020-heparin-induced-thrombocytopenia-in-covid-19 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lingamaneni-2020-heparin-induced-thrombocytopenia-in-covid-19 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lingamaneni-2020-heparin-induced-thrombocytopenia-in-covid-19 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wu-2020-rivaroxaban-treatment-for-young-patients-with-pulmonary-emboli 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wu-2020-rivaroxaban-treatment-for-young-patients-with-pulmonary-emboli 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wu-2020-rivaroxaban-treatment-for-young-patients-with-pulmonary-emboli 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wu-2020-rivaroxaban-treatment-for-young-patients-with-pulmonary-emboli 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sweeny-2020-factors-impacting-successful-salvage-of-the-failing-free-f 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sweeny-2020-factors-impacting-successful-salvage-of-the-failing-free-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sweeny-2020-factors-impacting-successful-salvage-of-the-failing-free-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sweeny-2020-factors-impacting-successful-salvage-of-the-failing-free-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/havrdov-2021-relationship-of-edoxaban-plasma-concentration-and-blood-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/havrdov-2021-relationship-of-edoxaban-plasma-concentration-and-blood-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/havrdov-2021-relationship-of-edoxaban-plasma-concentration-and-blood-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/havrdov-2021-relationship-of-edoxaban-plasma-concentration-and-blood-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/siddiqui-2021-efficacy-and-safety-of-perioperative-bridging-anticoagul 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/siddiqui-2021-efficacy-and-safety-of-perioperative-bridging-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/siddiqui-2021-efficacy-and-safety-of-perioperative-bridging-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/siddiqui-2021-efficacy-and-safety-of-perioperative-bridging-anticoagul 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tsantes-2020-covid-19-infection-related-coagulopathy-and-viscoelastic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tsantes-2020-covid-19-infection-related-coagulopathy-and-viscoelastic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tsantes-2020-covid-19-infection-related-coagulopathy-and-viscoelastic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tsantes-2020-covid-19-infection-related-coagulopathy-and-viscoelastic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/levy-2021-andexanet-alfa-use-in-cardiac-surgical-patients-a-xa-inhibit 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/levy-2021-andexanet-alfa-use-in-cardiac-surgical-patients-a-xa-inhibit 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/levy-2021-andexanet-alfa-use-in-cardiac-surgical-patients-a-xa-inhibit 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/levy-2021-andexanet-alfa-use-in-cardiac-surgical-patients-a-xa-inhibit 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sayce-2020-viscoelastic-monitoring-in-trauma-resuscitation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sayce-2020-viscoelastic-monitoring-in-trauma-resuscitation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sayce-2020-viscoelastic-monitoring-in-trauma-resuscitation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sayce-2020-viscoelastic-monitoring-in-trauma-resuscitation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stojanovic-2020-does-has-bled-risk-score-underestimate-the-risk-of-ble 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stojanovic-2020-does-has-bled-risk-score-underestimate-the-risk-of-ble 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stojanovic-2020-does-has-bled-risk-score-underestimate-the-risk-of-ble 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stojanovic-2020-does-has-bled-risk-score-underestimate-the-risk-of-ble 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/harano-2021-dabigatran-reversal-with-idarucizumab-prior-to-lung-transp 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/harano-2021-dabigatran-reversal-with-idarucizumab-prior-to-lung-transp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/harano-2021-dabigatran-reversal-with-idarucizumab-prior-to-lung-transp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/harano-2021-dabigatran-reversal-with-idarucizumab-prior-to-lung-transp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bixby-2021-use-of-direct-acting-oral-anticoagulants-in-solid-organ-tra 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bixby-2021-use-of-direct-acting-oral-anticoagulants-in-solid-organ-tra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bixby-2021-use-of-direct-acting-oral-anticoagulants-in-solid-organ-tra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bixby-2021-use-of-direct-acting-oral-anticoagulants-in-solid-organ-tra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dubner-2020-effectiveness-and-safety-of-dabigatran-in-latin-american-p 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dubner-2020-effectiveness-and-safety-of-dabigatran-in-latin-american-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dubner-2020-effectiveness-and-safety-of-dabigatran-in-latin-american-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dubner-2020-effectiveness-and-safety-of-dabigatran-in-latin-american-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ansell-2021-ciraparantag-an-anticoagulant-reversal-drug-mechanism-of-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ansell-2021-ciraparantag-an-anticoagulant-reversal-drug-mechanism-of-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ansell-2021-ciraparantag-an-anticoagulant-reversal-drug-mechanism-of-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ansell-2021-ciraparantag-an-anticoagulant-reversal-drug-mechanism-of-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/halperin-2021-anticoagulation-for-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/halperin-2021-anticoagulation-for-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/halperin-2021-anticoagulation-for-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/halperin-2021-anticoagulation-for-patients-with-atrial-fibrillation-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/berg-2021-biomarkers-for-risk-assessment-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/berg-2021-biomarkers-for-risk-assessment-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/berg-2021-biomarkers-for-risk-assessment-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/berg-2021-biomarkers-for-risk-assessment-in-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wadsworth-2021-a-review-of-indications-and-comorbidities-in-which-warf 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wadsworth-2021-a-review-of-indications-and-comorbidities-in-which-warf 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wadsworth-2021-a-review-of-indications-and-comorbidities-in-which-warf 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wadsworth-2021-a-review-of-indications-and-comorbidities-in-which-warf 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/g-rlinger-2021-the-role-of-rotational-thromboelastometry-during-the-co 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/g-rlinger-2021-the-role-of-rotational-thromboelastometry-during-the-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/g-rlinger-2021-the-role-of-rotational-thromboelastometry-during-the-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/g-rlinger-2021-the-role-of-rotational-thromboelastometry-during-the-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/giani-2021-thromboelastometry-thromboelastography-and-conventional-tes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/giani-2021-thromboelastometry-thromboelastography-and-conventional-tes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/giani-2021-thromboelastometry-thromboelastography-and-conventional-tes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/giani-2021-thromboelastometry-thromboelastography-and-conventional-tes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jackevicius-2021-bleeding-risk-of-direct-oral-anticoagulants-in-patien 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jackevicius-2021-bleeding-risk-of-direct-oral-anticoagulants-in-patien 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jackevicius-2021-bleeding-risk-of-direct-oral-anticoagulants-in-patien 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jackevicius-2021-bleeding-risk-of-direct-oral-anticoagulants-in-patien 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hull-2021-resolution-of-warfarin-induced-alopecia-with-conversion-to-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hull-2021-resolution-of-warfarin-induced-alopecia-with-conversion-to-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hull-2021-resolution-of-warfarin-induced-alopecia-with-conversion-to-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hull-2021-resolution-of-warfarin-induced-alopecia-with-conversion-to-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/de-2021-safety-and-efficacy-of-vitamin-k-antagonists-versus-rivaroxaba 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/de-2021-safety-and-efficacy-of-vitamin-k-antagonists-versus-rivaroxaba 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/de-2021-safety-and-efficacy-of-vitamin-k-antagonists-versus-rivaroxaba 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/de-2021-safety-and-efficacy-of-vitamin-k-antagonists-versus-rivaroxaba 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/su-2021-oral-anticoagulant-agents-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/su-2021-oral-anticoagulant-agents-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/su-2021-oral-anticoagulant-agents-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/su-2021-oral-anticoagulant-agents-in-patients-with-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fisser-2021-argatroban-versus-heparin-in-patients-without-heparin-indu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fisser-2021-argatroban-versus-heparin-in-patients-without-heparin-indu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fisser-2021-argatroban-versus-heparin-in-patients-without-heparin-indu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fisser-2021-argatroban-versus-heparin-in-patients-without-heparin-indu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/azar-2021-antithrombotic-treatment-pattern-in-newly-diagnosed-atrial-f 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/azar-2021-antithrombotic-treatment-pattern-in-newly-diagnosed-atrial-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/azar-2021-antithrombotic-treatment-pattern-in-newly-diagnosed-atrial-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/azar-2021-antithrombotic-treatment-pattern-in-newly-diagnosed-atrial-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nederpelt-2021-andexanet-alfa-or-prothrombin-complex-concentrate-for-f 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nederpelt-2021-andexanet-alfa-or-prothrombin-complex-concentrate-for-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nederpelt-2021-andexanet-alfa-or-prothrombin-complex-concentrate-for-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nederpelt-2021-andexanet-alfa-or-prothrombin-complex-concentrate-for-f 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wagner-2019-perioperative-management-of-anticoagulant-therapy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wagner-2019-perioperative-management-of-anticoagulant-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wagner-2019-perioperative-management-of-anticoagulant-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wagner-2019-perioperative-management-of-anticoagulant-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hess-2021-use-of-oral-anticoagulants-in-patients-with-valvular-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hess-2021-use-of-oral-anticoagulants-in-patients-with-valvular-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hess-2021-use-of-oral-anticoagulants-in-patients-with-valvular-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hess-2021-use-of-oral-anticoagulants-in-patients-with-valvular-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kjaergaard-2021-anti-xa-monitoring-of-low-molecular-weight-heparin-dur 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kjaergaard-2021-anti-xa-monitoring-of-low-molecular-weight-heparin-dur 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kjaergaard-2021-anti-xa-monitoring-of-low-molecular-weight-heparin-dur 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kjaergaard-2021-anti-xa-monitoring-of-low-molecular-weight-heparin-dur 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/frol-2021-intravenous-thrombolysis-after-dabigatran-reversal-by-idaruc 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/frol-2021-intravenous-thrombolysis-after-dabigatran-reversal-by-idaruc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/frol-2021-intravenous-thrombolysis-after-dabigatran-reversal-by-idaruc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/frol-2021-intravenous-thrombolysis-after-dabigatran-reversal-by-idaruc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mokhtari-2021-learning-microvascular-anastomosis-analysis-of-practice 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mokhtari-2021-learning-microvascular-anastomosis-analysis-of-practice 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mokhtari-2021-learning-microvascular-anastomosis-analysis-of-practice 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mokhtari-2021-learning-microvascular-anastomosis-analysis-of-practice 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/quintero-2021-negative-pressure-wound-therapy-as-a-salvage-procedure-i 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/quintero-2021-negative-pressure-wound-therapy-as-a-salvage-procedure-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/quintero-2021-negative-pressure-wound-therapy-as-a-salvage-procedure-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/quintero-2021-negative-pressure-wound-therapy-as-a-salvage-procedure-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ansell-2022-ciraparantag-reverses-the-anticoagulant-activity-of-apixab 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ansell-2022-ciraparantag-reverses-the-anticoagulant-activity-of-apixab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ansell-2022-ciraparantag-reverses-the-anticoagulant-activity-of-apixab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ansell-2022-ciraparantag-reverses-the-anticoagulant-activity-of-apixab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/camoin-jau-2022-heparin-induced-thrombocytopenia-update 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/camoin-jau-2022-heparin-induced-thrombocytopenia-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/camoin-jau-2022-heparin-induced-thrombocytopenia-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/camoin-jau-2022-heparin-induced-thrombocytopenia-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/proietti-2022-comparison-of-has-bled-and-orbit-bleeding-risk-scores-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/proietti-2022-comparison-of-has-bled-and-orbit-bleeding-risk-scores-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/proietti-2022-comparison-of-has-bled-and-orbit-bleeding-risk-scores-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/proietti-2022-comparison-of-has-bled-and-orbit-bleeding-risk-scores-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/patel-2021-andexanet-alfa-for-factor-xa-inhibitor-associated-intracere 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/patel-2021-andexanet-alfa-for-factor-xa-inhibitor-associated-intracere 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/patel-2021-andexanet-alfa-for-factor-xa-inhibitor-associated-intracere 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/patel-2021-andexanet-alfa-for-factor-xa-inhibitor-associated-intracere 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/murai-2021-investigation-of-objectivity-in-scoring-and-evaluating-micr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/murai-2021-investigation-of-objectivity-in-scoring-and-evaluating-micr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/murai-2021-investigation-of-objectivity-in-scoring-and-evaluating-micr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/murai-2021-investigation-of-objectivity-in-scoring-and-evaluating-micr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chan-2022-ciraparantag-as-a-potential-universal-anticoagulant-reversal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chan-2022-ciraparantag-as-a-potential-universal-anticoagulant-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chan-2022-ciraparantag-as-a-potential-universal-anticoagulant-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chan-2022-ciraparantag-as-a-potential-universal-anticoagulant-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/keepanasseril-2021-alternatives-to-low-molecular-weight-heparin-for-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/keepanasseril-2021-alternatives-to-low-molecular-weight-heparin-for-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/keepanasseril-2021-alternatives-to-low-molecular-weight-heparin-for-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/keepanasseril-2021-alternatives-to-low-molecular-weight-heparin-for-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leonte-2019-atrial-fibrillation-end-stage-renal-disease-and-hemorrhagi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leonte-2019-atrial-fibrillation-end-stage-renal-disease-and-hemorrhagi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leonte-2019-atrial-fibrillation-end-stage-renal-disease-and-hemorrhagi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leonte-2019-atrial-fibrillation-end-stage-renal-disease-and-hemorrhagi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guy-2022-laboratory-methods-for-monitoring-argatroban-in-heparin-induc 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guy-2022-laboratory-methods-for-monitoring-argatroban-in-heparin-induc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guy-2022-laboratory-methods-for-monitoring-argatroban-in-heparin-induc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guy-2022-laboratory-methods-for-monitoring-argatroban-in-heparin-induc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kobayashi-2022-using-blood-glucose-and-lactate-levels-for-early-detect 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kobayashi-2022-using-blood-glucose-and-lactate-levels-for-early-detect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kobayashi-2022-using-blood-glucose-and-lactate-levels-for-early-detect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kobayashi-2022-using-blood-glucose-and-lactate-levels-for-early-detect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abuan-2019-andexanet-alfa-a-recombinant-modified-human-factor-xa-prote 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abuan-2019-andexanet-alfa-a-recombinant-modified-human-factor-xa-prote 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abuan-2019-andexanet-alfa-a-recombinant-modified-human-factor-xa-prote 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abuan-2019-andexanet-alfa-a-recombinant-modified-human-factor-xa-prote 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/frol-2021-dabigatran-reversal-with-idarucizumab-and-in-hospital-mortal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/frol-2021-dabigatran-reversal-with-idarucizumab-and-in-hospital-mortal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/frol-2021-dabigatran-reversal-with-idarucizumab-and-in-hospital-mortal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/frol-2021-dabigatran-reversal-with-idarucizumab-and-in-hospital-mortal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/martinez-2021-it-cuts-both-ways-an-annelid-model-system-for-the-study 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/martinez-2021-it-cuts-both-ways-an-annelid-model-system-for-the-study 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/martinez-2021-it-cuts-both-ways-an-annelid-model-system-for-the-study 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/martinez-2021-it-cuts-both-ways-an-annelid-model-system-for-the-study 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lu-2022-characterization-of-the-complete-mitochondrial-genome-of-haema 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lu-2022-characterization-of-the-complete-mitochondrial-genome-of-haema 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lu-2022-characterization-of-the-complete-mitochondrial-genome-of-haema 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lu-2022-characterization-of-the-complete-mitochondrial-genome-of-haema 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lv-2022-efficacy-and-safety-of-argatroban-in-treatment-of-acute-ischem 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lv-2022-efficacy-and-safety-of-argatroban-in-treatment-of-acute-ischem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lv-2022-efficacy-and-safety-of-argatroban-in-treatment-of-acute-ischem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lv-2022-efficacy-and-safety-of-argatroban-in-treatment-of-acute-ischem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tuleja-2022-cost-effectiveness-analysis-of-alternative-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tuleja-2022-cost-effectiveness-analysis-of-alternative-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tuleja-2022-cost-effectiveness-analysis-of-alternative-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tuleja-2022-cost-effectiveness-analysis-of-alternative-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/harkness-2022-observed-apixaban-anti-xa-levels-in-obese-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/harkness-2022-observed-apixaban-anti-xa-levels-in-obese-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/harkness-2022-observed-apixaban-anti-xa-levels-in-obese-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/harkness-2022-observed-apixaban-anti-xa-levels-in-obese-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huisman-2022-dabigatran-versus-vitamin-k-antagonists-for-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huisman-2022-dabigatran-versus-vitamin-k-antagonists-for-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huisman-2022-dabigatran-versus-vitamin-k-antagonists-for-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huisman-2022-dabigatran-versus-vitamin-k-antagonists-for-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ellabban-2022-virtual-planning-of-the-anterolateral-thigh-free-flap-fo 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ellabban-2022-virtual-planning-of-the-anterolateral-thigh-free-flap-fo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ellabban-2022-virtual-planning-of-the-anterolateral-thigh-free-flap-fo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ellabban-2022-virtual-planning-of-the-anterolateral-thigh-free-flap-fo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/paul-2022-importance-of-clitellar-tissue-in-the-regeneration-ability-o 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/paul-2022-importance-of-clitellar-tissue-in-the-regeneration-ability-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/paul-2022-importance-of-clitellar-tissue-in-the-regeneration-ability-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/paul-2022-importance-of-clitellar-tissue-in-the-regeneration-ability-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/regling-2022-viscoelastic-testing-in-pediatric-mechanical-circulatory 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/regling-2022-viscoelastic-testing-in-pediatric-mechanical-circulatory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/regling-2022-viscoelastic-testing-in-pediatric-mechanical-circulatory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/regling-2022-viscoelastic-testing-in-pediatric-mechanical-circulatory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chen-2022-low-molecular-weight-heparin-and-pregnancy-outcomes-in-women 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chen-2022-low-molecular-weight-heparin-and-pregnancy-outcomes-in-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chen-2022-low-molecular-weight-heparin-and-pregnancy-outcomes-in-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chen-2022-low-molecular-weight-heparin-and-pregnancy-outcomes-in-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/di-2022-atrial-fibrillation-and-anticoagulant-treatment-in-end-stage-r 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/di-2022-atrial-fibrillation-and-anticoagulant-treatment-in-end-stage-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/di-2022-atrial-fibrillation-and-anticoagulant-treatment-in-end-stage-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/di-2022-atrial-fibrillation-and-anticoagulant-treatment-in-end-stage-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2022-safety-and-preliminary-efficacy-of-argatroban-plus-dual-antipl 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2022-safety-and-preliminary-efficacy-of-argatroban-plus-dual-antipl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2022-safety-and-preliminary-efficacy-of-argatroban-plus-dual-antipl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2022-safety-and-preliminary-efficacy-of-argatroban-plus-dual-antipl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rauch-2022-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-in-intr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rauch-2022-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-in-intr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rauch-2022-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-in-intr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rauch-2022-andexanet-alfa-for-reversal-of-factor-xa-inhibitors-in-intr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zucal-2022-an-innovative-simulation-model-for-microvascular-training 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zucal-2022-an-innovative-simulation-model-for-microvascular-training 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zucal-2022-an-innovative-simulation-model-for-microvascular-training 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zucal-2022-an-innovative-simulation-model-for-microvascular-training 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/esteve-pastor-2022-a-comparison-of-front-line-oral-anticoagulants-for 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/esteve-pastor-2022-a-comparison-of-front-line-oral-anticoagulants-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/esteve-pastor-2022-a-comparison-of-front-line-oral-anticoagulants-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/esteve-pastor-2022-a-comparison-of-front-line-oral-anticoagulants-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/belykh-2023-seven-bypasses-simulation-set-description-and-validity-ass 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/belykh-2023-seven-bypasses-simulation-set-description-and-validity-ass 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/belykh-2023-seven-bypasses-simulation-set-description-and-validity-ass 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/belykh-2023-seven-bypasses-simulation-set-description-and-validity-ass 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leentjens-2022-a-short-review-of-ciraparantag-in-perspective-of-the-cu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leentjens-2022-a-short-review-of-ciraparantag-in-perspective-of-the-cu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leentjens-2022-a-short-review-of-ciraparantag-in-perspective-of-the-cu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leentjens-2022-a-short-review-of-ciraparantag-in-perspective-of-the-cu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/perino-2022-atrial-fibrillation-bleeding-risk-and-prediction-while-tre 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/perino-2022-atrial-fibrillation-bleeding-risk-and-prediction-while-tre 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/perino-2022-atrial-fibrillation-bleeding-risk-and-prediction-while-tre 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/perino-2022-atrial-fibrillation-bleeding-risk-and-prediction-while-tre 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/douketis-2022-executive-summary-perioperative-management-of-antithromb 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/douketis-2022-executive-summary-perioperative-management-of-antithromb 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/douketis-2022-executive-summary-perioperative-management-of-antithromb 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/douketis-2022-executive-summary-perioperative-management-of-antithromb 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/douketis-2022-perioperative-management-of-antithrombotic-therapy-an-am 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/douketis-2022-perioperative-management-of-antithrombotic-therapy-an-am 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/douketis-2022-perioperative-management-of-antithrombotic-therapy-an-am 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/douketis-2022-perioperative-management-of-antithrombotic-therapy-an-am 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/milling-2022-microtools-a-systematic-review-of-validated-assessment-to 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/milling-2022-microtools-a-systematic-review-of-validated-assessment-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/milling-2022-microtools-a-systematic-review-of-validated-assessment-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/milling-2022-microtools-a-systematic-review-of-validated-assessment-to 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/glass-2022-thin-and-superthin-free-flaps-an-innovative-approach-to-ped 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/glass-2022-thin-and-superthin-free-flaps-an-innovative-approach-to-ped 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/glass-2022-thin-and-superthin-free-flaps-an-innovative-approach-to-ped 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/glass-2022-thin-and-superthin-free-flaps-an-innovative-approach-to-ped 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/le-n-garc-a-2022-women-s-values-and-preferences-on-low-molecular-weigh 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/le-n-garc-a-2022-women-s-values-and-preferences-on-low-molecular-weigh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/le-n-garc-a-2022-women-s-values-and-preferences-on-low-molecular-weigh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/le-n-garc-a-2022-women-s-values-and-preferences-on-low-molecular-weigh 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/erstad-2023-dilemmas-related-to-direct-acting-oral-anticoagulant-admin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/erstad-2023-dilemmas-related-to-direct-acting-oral-anticoagulant-admin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/erstad-2023-dilemmas-related-to-direct-acting-oral-anticoagulant-admin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/erstad-2023-dilemmas-related-to-direct-acting-oral-anticoagulant-admin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mitrovic-2023-protocols-for-perioperative-management-of-direct-oral-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mitrovic-2023-protocols-for-perioperative-management-of-direct-oral-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mitrovic-2023-protocols-for-perioperative-management-of-direct-oral-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mitrovic-2023-protocols-for-perioperative-management-of-direct-oral-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/esteve-pastor-2022-predicting-performance-of-the-has-bled-and-orbit-bl 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/esteve-pastor-2022-predicting-performance-of-the-has-bled-and-orbit-bl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/esteve-pastor-2022-predicting-performance-of-the-has-bled-and-orbit-bl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/esteve-pastor-2022-predicting-performance-of-the-has-bled-and-orbit-bl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/raposeiras-roub-n-2023-bleeding-and-embolic-risk-in-patients-with-atri 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/raposeiras-roub-n-2023-bleeding-and-embolic-risk-in-patients-with-atri 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/raposeiras-roub-n-2023-bleeding-and-embolic-risk-in-patients-with-atri 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/raposeiras-roub-n-2023-bleeding-and-embolic-risk-in-patients-with-atri 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hart-2022-management-of-antithrombin-deficiency-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hart-2022-management-of-antithrombin-deficiency-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hart-2022-management-of-antithrombin-deficiency-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hart-2022-management-of-antithrombin-deficiency-in-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/manikumari-2022-simulation-of-reconstructive-microsurgery-in-soft-emba 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/manikumari-2022-simulation-of-reconstructive-microsurgery-in-soft-emba 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/manikumari-2022-simulation-of-reconstructive-microsurgery-in-soft-emba 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/manikumari-2022-simulation-of-reconstructive-microsurgery-in-soft-emba 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pokorney-2022-apixaban-for-patients-with-atrial-fibrillation-on-hemodi 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pokorney-2022-apixaban-for-patients-with-atrial-fibrillation-on-hemodi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pokorney-2022-apixaban-for-patients-with-atrial-fibrillation-on-hemodi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pokorney-2022-apixaban-for-patients-with-atrial-fibrillation-on-hemodi 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reinecke-2023-a-randomized-controlled-trial-comparing-apixaban-with-th 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reinecke-2023-a-randomized-controlled-trial-comparing-apixaban-with-th 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reinecke-2023-a-randomized-controlled-trial-comparing-apixaban-with-th 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reinecke-2023-a-randomized-controlled-trial-comparing-apixaban-with-th 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shah-2023-perioperative-management-of-vitamin-k-antagonists-and-direct 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shah-2023-perioperative-management-of-vitamin-k-antagonists-and-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shah-2023-perioperative-management-of-vitamin-k-antagonists-and-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shah-2023-perioperative-management-of-vitamin-k-antagonists-and-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/burton-2023-the-tale-of-the-unlucky-13-errors-in-the-journey-towards-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/burton-2023-the-tale-of-the-unlucky-13-errors-in-the-journey-towards-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/burton-2023-the-tale-of-the-unlucky-13-errors-in-the-journey-towards-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/burton-2023-the-tale-of-the-unlucky-13-errors-in-the-journey-towards-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nwanosike-2023-challenges-and-possible-solutions-to-direct-acting-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nwanosike-2023-challenges-and-possible-solutions-to-direct-acting-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nwanosike-2023-challenges-and-possible-solutions-to-direct-acting-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nwanosike-2023-challenges-and-possible-solutions-to-direct-acting-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wee-2023-management-of-venous-thromboembolism-in-morbidly-obese-patien 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wee-2023-management-of-venous-thromboembolism-in-morbidly-obese-patien 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wee-2023-management-of-venous-thromboembolism-in-morbidly-obese-patien 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wee-2023-management-of-venous-thromboembolism-in-morbidly-obese-patien 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fink-2023-left-atrial-appendage-closure-in-end-stage-renal-disease-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fink-2023-left-atrial-appendage-closure-in-end-stage-renal-disease-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fink-2023-left-atrial-appendage-closure-in-end-stage-renal-disease-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fink-2023-left-atrial-appendage-closure-in-end-stage-renal-disease-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/frol-2023-standard-operating-procedure-for-idarucizumab-reversal-of-da 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/frol-2023-standard-operating-procedure-for-idarucizumab-reversal-of-da 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/frol-2023-standard-operating-procedure-for-idarucizumab-reversal-of-da 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/frol-2023-standard-operating-procedure-for-idarucizumab-reversal-of-da 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pu-2023-reoperative-microsurgical-free-flap-surgery-lessons-learned 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pu-2023-reoperative-microsurgical-free-flap-surgery-lessons-learned 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pu-2023-reoperative-microsurgical-free-flap-surgery-lessons-learned 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pu-2023-reoperative-microsurgical-free-flap-surgery-lessons-learned 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chen-2023-effect-of-argatroban-plus-intravenous-alteplase-vs-intraveno 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chen-2023-effect-of-argatroban-plus-intravenous-alteplase-vs-intraveno 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chen-2023-effect-of-argatroban-plus-intravenous-alteplase-vs-intraveno 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chen-2023-effect-of-argatroban-plus-intravenous-alteplase-vs-intraveno 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhao-2023-pharmacokinetics-and-dosing-regimens-of-direct-oral-anticoag 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhao-2023-pharmacokinetics-and-dosing-regimens-of-direct-oral-anticoag 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhao-2023-pharmacokinetics-and-dosing-regimens-of-direct-oral-anticoag 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhao-2023-pharmacokinetics-and-dosing-regimens-of-direct-oral-anticoag 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/d-orio-2022-outcomes-of-a-long-terms-microvascular-training-for-reside 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/d-orio-2022-outcomes-of-a-long-terms-microvascular-training-for-reside 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/d-orio-2022-outcomes-of-a-long-terms-microvascular-training-for-reside 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/d-orio-2022-outcomes-of-a-long-terms-microvascular-training-for-reside 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/manzoni-2023-viscoelastic-coagulation-testing-in-neonatal-intensive-ca 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/manzoni-2023-viscoelastic-coagulation-testing-in-neonatal-intensive-ca 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/manzoni-2023-viscoelastic-coagulation-testing-in-neonatal-intensive-ca 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/manzoni-2023-viscoelastic-coagulation-testing-in-neonatal-intensive-ca 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/milling-2023-final-study-report-of-andexanet-alfa-for-major-bleeding-w 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/milling-2023-final-study-report-of-andexanet-alfa-for-major-bleeding-w 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/milling-2023-final-study-report-of-andexanet-alfa-for-major-bleeding-w 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/milling-2023-final-study-report-of-andexanet-alfa-for-major-bleeding-w 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rosovsky-2023-direct-oral-anticoagulants-in-obese-patients-with-venous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rosovsky-2023-direct-oral-anticoagulants-in-obese-patients-with-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rosovsky-2023-direct-oral-anticoagulants-in-obese-patients-with-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rosovsky-2023-direct-oral-anticoagulants-in-obese-patients-with-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rosenberg-2023-low-dose-low-molecular-weight-heparin-for-thromboprophy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rosenberg-2023-low-dose-low-molecular-weight-heparin-for-thromboprophy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rosenberg-2023-low-dose-low-molecular-weight-heparin-for-thromboprophy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rosenberg-2023-low-dose-low-molecular-weight-heparin-for-thromboprophy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nwanosike-2023-a-real-world-exploration-into-clinical-outcomes-of-dire 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nwanosike-2023-a-real-world-exploration-into-clinical-outcomes-of-dire 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nwanosike-2023-a-real-world-exploration-into-clinical-outcomes-of-dire 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nwanosike-2023-a-real-world-exploration-into-clinical-outcomes-of-dire 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaylor-2023-pharmacist-practice-patterns-regarding-direct-oral-anticoa 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaylor-2023-pharmacist-practice-patterns-regarding-direct-oral-anticoa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaylor-2023-pharmacist-practice-patterns-regarding-direct-oral-anticoa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaylor-2023-pharmacist-practice-patterns-regarding-direct-oral-anticoa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/omond-2024-why-study-sleep-in-flatworms 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/omond-2024-why-study-sleep-in-flatworms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/omond-2024-why-study-sleep-in-flatworms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/omond-2024-why-study-sleep-in-flatworms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/seiler-2023-a-case-of-argatroban-refractory-heparin-induced-thrombocyt 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/seiler-2023-a-case-of-argatroban-refractory-heparin-induced-thrombocyt 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/seiler-2023-a-case-of-argatroban-refractory-heparin-induced-thrombocyt 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/seiler-2023-a-case-of-argatroban-refractory-heparin-induced-thrombocyt 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chichareon-2023-comparative-validation-of-has-bled-garfield-af-and-orb 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chichareon-2023-comparative-validation-of-has-bled-garfield-af-and-orb 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chichareon-2023-comparative-validation-of-has-bled-garfield-af-and-orb 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chichareon-2023-comparative-validation-of-has-bled-garfield-af-and-orb 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/g-mez-outes-2023-when-and-how-to-use-reversal-agents-for-direct-oral-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/g-mez-outes-2023-when-and-how-to-use-reversal-agents-for-direct-oral-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/g-mez-outes-2023-when-and-how-to-use-reversal-agents-for-direct-oral-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/g-mez-outes-2023-when-and-how-to-use-reversal-agents-for-direct-oral-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2023-oral-direct-thrombin-inhibitors-or-oral-factor-xa-inhibitors-v 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2023-oral-direct-thrombin-inhibitors-or-oral-factor-xa-inhibitors-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2023-oral-direct-thrombin-inhibitors-or-oral-factor-xa-inhibitors-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2023-oral-direct-thrombin-inhibitors-or-oral-factor-xa-inhibitors-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yin-2023-meta-analysis-of-the-efficacy-of-low-molecular-weight-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yin-2023-meta-analysis-of-the-efficacy-of-low-molecular-weight-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yin-2023-meta-analysis-of-the-efficacy-of-low-molecular-weight-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yin-2023-meta-analysis-of-the-efficacy-of-low-molecular-weight-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xu-2023-efficacy-and-prognosis-of-adjuvant-argatroban-treatment-in-acu 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xu-2023-efficacy-and-prognosis-of-adjuvant-argatroban-treatment-in-acu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xu-2023-efficacy-and-prognosis-of-adjuvant-argatroban-treatment-in-acu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xu-2023-efficacy-and-prognosis-of-adjuvant-argatroban-treatment-in-acu 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nusbaum-1986-swim-initiation-in-the-leech-by-serotonin-containing-inte 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nusbaum-1986-swim-initiation-in-the-leech-by-serotonin-containing-inte 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nusbaum-1986-swim-initiation-in-the-leech-by-serotonin-containing-inte 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nusbaum-1986-swim-initiation-in-the-leech-by-serotonin-containing-inte 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hamadi-2023-heparin-induced-thrombocytopenia-in-chronic-hemodialysis-p 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hamadi-2023-heparin-induced-thrombocytopenia-in-chronic-hemodialysis-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hamadi-2023-heparin-induced-thrombocytopenia-in-chronic-hemodialysis-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hamadi-2023-heparin-induced-thrombocytopenia-in-chronic-hemodialysis-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/van-2023-idarucizumab-for-dabigatran-reversal-a-systematic-review-and 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/van-2023-idarucizumab-for-dabigatran-reversal-a-systematic-review-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/van-2023-idarucizumab-for-dabigatran-reversal-a-systematic-review-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/van-2023-idarucizumab-for-dabigatran-reversal-a-systematic-review-and 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2023-selective-application-of-blood-glucose-monitoring-after-free 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2023-selective-application-of-blood-glucose-monitoring-after-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2023-selective-application-of-blood-glucose-monitoring-after-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2023-selective-application-of-blood-glucose-monitoring-after-free 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/joy-2024-impact-of-high-fidelity-microvascular-surgery-simulation-on-r 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/joy-2024-impact-of-high-fidelity-microvascular-surgery-simulation-on-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/joy-2024-impact-of-high-fidelity-microvascular-surgery-simulation-on-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/joy-2024-impact-of-high-fidelity-microvascular-surgery-simulation-on-r 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sikes-2023-anti-factor-xa-level-monitoring-for-enoxaparin-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sikes-2023-anti-factor-xa-level-monitoring-for-enoxaparin-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sikes-2023-anti-factor-xa-level-monitoring-for-enoxaparin-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sikes-2023-anti-factor-xa-level-monitoring-for-enoxaparin-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/elad-2023-effectiveness-and-safety-of-direct-oral-anticoagulants-for-s 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/elad-2023-effectiveness-and-safety-of-direct-oral-anticoagulants-for-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/elad-2023-effectiveness-and-safety-of-direct-oral-anticoagulants-for-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/elad-2023-effectiveness-and-safety-of-direct-oral-anticoagulants-for-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rosenfeld-2023-weighing-in-on-direct-oral-anticoagulant-dosing-in-pati 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rosenfeld-2023-weighing-in-on-direct-oral-anticoagulant-dosing-in-pati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rosenfeld-2023-weighing-in-on-direct-oral-anticoagulant-dosing-in-pati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rosenfeld-2023-weighing-in-on-direct-oral-anticoagulant-dosing-in-pati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/liu-2023-real-world-time-trends-in-antithrombotic-treatment-for-newly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/liu-2023-real-world-time-trends-in-antithrombotic-treatment-for-newly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/liu-2023-real-world-time-trends-in-antithrombotic-treatment-for-newly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/liu-2023-real-world-time-trends-in-antithrombotic-treatment-for-newly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fleurette-2023-training-in-microvascular-anastomosis-a-randomized-comp 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fleurette-2023-training-in-microvascular-anastomosis-a-randomized-comp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fleurette-2023-training-in-microvascular-anastomosis-a-randomized-comp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fleurette-2023-training-in-microvascular-anastomosis-a-randomized-comp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lin-2024-cardiovascular-and-renal-outcomes-in-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lin-2024-cardiovascular-and-renal-outcomes-in-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lin-2024-cardiovascular-and-renal-outcomes-in-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lin-2024-cardiovascular-and-renal-outcomes-in-patients-with-atrial-fib 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aggarwal-2023-development-and-validation-of-the-doac-score-a-novel-ble 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aggarwal-2023-development-and-validation-of-the-doac-score-a-novel-ble 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aggarwal-2023-development-and-validation-of-the-doac-score-a-novel-ble 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aggarwal-2023-development-and-validation-of-the-doac-score-a-novel-ble 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/toyoda-2024-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-act 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/toyoda-2024-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-act 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/toyoda-2024-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-act 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/toyoda-2024-andexanet-alfa-for-the-reversal-of-factor-xa-inhibitor-act 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kyriakoulis-2024-efficacy-and-safety-of-direct-oral-anticoagulants-vs 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kyriakoulis-2024-efficacy-and-safety-of-direct-oral-anticoagulants-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kyriakoulis-2024-efficacy-and-safety-of-direct-oral-anticoagulants-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kyriakoulis-2024-efficacy-and-safety-of-direct-oral-anticoagulants-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ceccato-2023-two-stage-pulsatile-human-placenta-model-for-microvascula 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ceccato-2023-two-stage-pulsatile-human-placenta-model-for-microvascula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ceccato-2023-two-stage-pulsatile-human-placenta-model-for-microvascula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ceccato-2023-two-stage-pulsatile-human-placenta-model-for-microvascula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nemola-2023-baseline-characteristics-and-3-year-outcome-of-nonvalvular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nemola-2023-baseline-characteristics-and-3-year-outcome-of-nonvalvular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nemola-2023-baseline-characteristics-and-3-year-outcome-of-nonvalvular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nemola-2023-baseline-characteristics-and-3-year-outcome-of-nonvalvular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/faisaluddin-2023-safety-and-efficacy-of-direct-oral-anticoagulants-ver 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/faisaluddin-2023-safety-and-efficacy-of-direct-oral-anticoagulants-ver 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/faisaluddin-2023-safety-and-efficacy-of-direct-oral-anticoagulants-ver 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/faisaluddin-2023-safety-and-efficacy-of-direct-oral-anticoagulants-ver 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guenoun-2023-characteristics-of-patients-with-atrial-fibrillation-trea 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guenoun-2023-characteristics-of-patients-with-atrial-fibrillation-trea 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guenoun-2023-characteristics-of-patients-with-atrial-fibrillation-trea 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guenoun-2023-characteristics-of-patients-with-atrial-fibrillation-trea 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abi-2023-long-term-outcomes-of-bariatric-surgery-in-patients-on-chroni 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abi-2023-long-term-outcomes-of-bariatric-surgery-in-patients-on-chroni 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abi-2023-long-term-outcomes-of-bariatric-surgery-in-patients-on-chroni 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abi-2023-long-term-outcomes-of-bariatric-surgery-in-patients-on-chroni 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hattaway-2023-direct-oral-anticoagulants-for-the-treatment-of-venous-t 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hattaway-2023-direct-oral-anticoagulants-for-the-treatment-of-venous-t 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hattaway-2023-direct-oral-anticoagulants-for-the-treatment-of-venous-t 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hattaway-2023-direct-oral-anticoagulants-for-the-treatment-of-venous-t 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hindley-2023-pharmacokinetics-and-pharmacodynamics-of-direct-oral-anti 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hindley-2023-pharmacokinetics-and-pharmacodynamics-of-direct-oral-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hindley-2023-pharmacokinetics-and-pharmacodynamics-of-direct-oral-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hindley-2023-pharmacokinetics-and-pharmacodynamics-of-direct-oral-anti 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tanaka-2024-andexanet-alfa-or-prothrombin-complex-concentrate-for-acut 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tanaka-2024-andexanet-alfa-or-prothrombin-complex-concentrate-for-acut 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tanaka-2024-andexanet-alfa-or-prothrombin-complex-concentrate-for-acut 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tanaka-2024-andexanet-alfa-or-prothrombin-complex-concentrate-for-acut 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moore-2024-efficacy-and-safety-of-apixaban-compared-to-warfarin-for-no 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moore-2024-efficacy-and-safety-of-apixaban-compared-to-warfarin-for-no 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moore-2024-efficacy-and-safety-of-apixaban-compared-to-warfarin-for-no 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moore-2024-efficacy-and-safety-of-apixaban-compared-to-warfarin-for-no 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/al-salihi-2024-efficacy-and-safety-of-argatroban-in-the-management-of 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/al-salihi-2024-efficacy-and-safety-of-argatroban-in-the-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/al-salihi-2024-efficacy-and-safety-of-argatroban-in-the-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/al-salihi-2024-efficacy-and-safety-of-argatroban-in-the-management-of 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2024-argatroban-in-patients-with-acute-ischemic-stroke-with-earl 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2024-argatroban-in-patients-with-acute-ischemic-stroke-with-earl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2024-argatroban-in-patients-with-acute-ischemic-stroke-with-earl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2024-argatroban-in-patients-with-acute-ischemic-stroke-with-earl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chen-2024-low-molecular-weight-heparin-for-the-prevention-of-preeclamp 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chen-2024-low-molecular-weight-heparin-for-the-prevention-of-preeclamp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chen-2024-low-molecular-weight-heparin-for-the-prevention-of-preeclamp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chen-2024-low-molecular-weight-heparin-for-the-prevention-of-preeclamp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/beznoshchenco-2023-procoagulant-status-and-fibrinolytic-activity-in-co 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/beznoshchenco-2023-procoagulant-status-and-fibrinolytic-activity-in-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/beznoshchenco-2023-procoagulant-status-and-fibrinolytic-activity-in-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/beznoshchenco-2023-procoagulant-status-and-fibrinolytic-activity-in-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chlorogiannis-2024-argatroban-as-an-add-on-to-rtpa-in-acute-ischemic-s 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chlorogiannis-2024-argatroban-as-an-add-on-to-rtpa-in-acute-ischemic-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chlorogiannis-2024-argatroban-as-an-add-on-to-rtpa-in-acute-ischemic-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chlorogiannis-2024-argatroban-as-an-add-on-to-rtpa-in-acute-ischemic-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/escal-2024-latest-advances-in-the-reversal-strategies-for-direct-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/escal-2024-latest-advances-in-the-reversal-strategies-for-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/escal-2024-latest-advances-in-the-reversal-strategies-for-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/escal-2024-latest-advances-in-the-reversal-strategies-for-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cheng-2024-efficacy-and-safety-of-argatroban-in-patients-with-acute-is 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cheng-2024-efficacy-and-safety-of-argatroban-in-patients-with-acute-is 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cheng-2024-efficacy-and-safety-of-argatroban-in-patients-with-acute-is 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cheng-2024-efficacy-and-safety-of-argatroban-in-patients-with-acute-is 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/unknown-2024-andexanet-alfa-for-reversal-of-direct-factor-xa-inhibitor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/unknown-2024-andexanet-alfa-for-reversal-of-direct-factor-xa-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/unknown-2024-andexanet-alfa-for-reversal-of-direct-factor-xa-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/unknown-2024-andexanet-alfa-for-reversal-of-direct-factor-xa-inhibitor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/johnston-2024-evaluation-of-the-safety-of-uninterrupted-warfarin-antic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/johnston-2024-evaluation-of-the-safety-of-uninterrupted-warfarin-antic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/johnston-2024-evaluation-of-the-safety-of-uninterrupted-warfarin-antic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/johnston-2024-evaluation-of-the-safety-of-uninterrupted-warfarin-antic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fasanya-2024-use-of-andexanet-alfa-for-factor-xa-inhibitor-reversal-in 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fasanya-2024-use-of-andexanet-alfa-for-factor-xa-inhibitor-reversal-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fasanya-2024-use-of-andexanet-alfa-for-factor-xa-inhibitor-reversal-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fasanya-2024-use-of-andexanet-alfa-for-factor-xa-inhibitor-reversal-in 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kao-2024-anticoagulation-for-patients-with-concomitant-atrial-fibrilla 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kao-2024-anticoagulation-for-patients-with-concomitant-atrial-fibrilla 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kao-2024-anticoagulation-for-patients-with-concomitant-atrial-fibrilla 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kao-2024-anticoagulation-for-patients-with-concomitant-atrial-fibrilla 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gendron-2024-is-there-a-role-for-the-laboratory-monitoring-in-the-mana 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gendron-2024-is-there-a-role-for-the-laboratory-monitoring-in-the-mana 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gendron-2024-is-there-a-role-for-the-laboratory-monitoring-in-the-mana 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gendron-2024-is-there-a-role-for-the-laboratory-monitoring-in-the-mana 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ota-2024-clinical-outcomes-of-perforator-based-propeller-flaps-versus 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ota-2024-clinical-outcomes-of-perforator-based-propeller-flaps-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ota-2024-clinical-outcomes-of-perforator-based-propeller-flaps-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ota-2024-clinical-outcomes-of-perforator-based-propeller-flaps-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/connolly-2024-andexanet-for-factor-xa-inhibitor-associated-acute-intra 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/connolly-2024-andexanet-for-factor-xa-inhibitor-associated-acute-intra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/connolly-2024-andexanet-for-factor-xa-inhibitor-associated-acute-intra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/connolly-2024-andexanet-for-factor-xa-inhibitor-associated-acute-intra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sulli-2024-in-search-of-optimal-practice-a-retrospective-comparative-s 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sulli-2024-in-search-of-optimal-practice-a-retrospective-comparative-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sulli-2024-in-search-of-optimal-practice-a-retrospective-comparative-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sulli-2024-in-search-of-optimal-practice-a-retrospective-comparative-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cui-2024-baseline-neurological-deficit-and-argatroban-plus-alteplase-i 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cui-2024-baseline-neurological-deficit-and-argatroban-plus-alteplase-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cui-2024-baseline-neurological-deficit-and-argatroban-plus-alteplase-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cui-2024-baseline-neurological-deficit-and-argatroban-plus-alteplase-i 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ferreira-2024-andexanet-alfa-versus-four-factor-prothrombin-complex-co 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ferreira-2024-andexanet-alfa-versus-four-factor-prothrombin-complex-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ferreira-2024-andexanet-alfa-versus-four-factor-prothrombin-complex-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ferreira-2024-andexanet-alfa-versus-four-factor-prothrombin-complex-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/scarrone-2024-low-molecular-weight-heparin-in-the-prevention-of-unexpl 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/scarrone-2024-low-molecular-weight-heparin-in-the-prevention-of-unexpl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/scarrone-2024-low-molecular-weight-heparin-in-the-prevention-of-unexpl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/scarrone-2024-low-molecular-weight-heparin-in-the-prevention-of-unexpl 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/alturki-2024-meta-analysis-evaluating-apixaban-in-patients-with-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/alturki-2024-meta-analysis-evaluating-apixaban-in-patients-with-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/alturki-2024-meta-analysis-evaluating-apixaban-in-patients-with-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/alturki-2024-meta-analysis-evaluating-apixaban-in-patients-with-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mutemi-2024-a-genome-resource-for-the-marine-annelid-platynereis-dumer 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mutemi-2024-a-genome-resource-for-the-marine-annelid-platynereis-dumer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mutemi-2024-a-genome-resource-for-the-marine-annelid-platynereis-dumer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mutemi-2024-a-genome-resource-for-the-marine-annelid-platynereis-dumer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/levy-2024-reversal-of-direct-oral-anticoagulants-guidance-from-the-ssc 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/levy-2024-reversal-of-direct-oral-anticoagulants-guidance-from-the-ssc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/levy-2024-reversal-of-direct-oral-anticoagulants-guidance-from-the-ssc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/levy-2024-reversal-of-direct-oral-anticoagulants-guidance-from-the-ssc 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/soler-espejo-2024-navigating-the-bleeding-risk-dilemma-in-patients-wit 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/soler-espejo-2024-navigating-the-bleeding-risk-dilemma-in-patients-wit 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/soler-espejo-2024-navigating-the-bleeding-risk-dilemma-in-patients-wit 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/soler-espejo-2024-navigating-the-bleeding-risk-dilemma-in-patients-wit 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/arellano-2024-outcomes-of-muscle-versus-fasciocutaneous-free-flap-reco 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/arellano-2024-outcomes-of-muscle-versus-fasciocutaneous-free-flap-reco 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/arellano-2024-outcomes-of-muscle-versus-fasciocutaneous-free-flap-reco 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/arellano-2024-outcomes-of-muscle-versus-fasciocutaneous-free-flap-reco 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/douketis-2024-perioperative-management-of-patients-taking-direct-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/douketis-2024-perioperative-management-of-patients-taking-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/douketis-2024-perioperative-management-of-patients-taking-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/douketis-2024-perioperative-management-of-patients-taking-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xiong-2024-factor-xa-inhibitors-versus-vitamin-k-antagonists-in-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xiong-2024-factor-xa-inhibitors-versus-vitamin-k-antagonists-in-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xiong-2024-factor-xa-inhibitors-versus-vitamin-k-antagonists-in-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xiong-2024-factor-xa-inhibitors-versus-vitamin-k-antagonists-in-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moore-2024-reprint-of-efficacy-and-safety-of-apixaban-compared-to-warf 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moore-2024-reprint-of-efficacy-and-safety-of-apixaban-compared-to-warf 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moore-2024-reprint-of-efficacy-and-safety-of-apixaban-compared-to-warf 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moore-2024-reprint-of-efficacy-and-safety-of-apixaban-compared-to-warf 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baskova-1985-destabilase-an-enzyme-of-medicinal-leech-salivary-gland-s 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baskova-1985-destabilase-an-enzyme-of-medicinal-leech-salivary-gland-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baskova-1985-destabilase-an-enzyme-of-medicinal-leech-salivary-gland-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baskova-1985-destabilase-an-enzyme-of-medicinal-leech-salivary-gland-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/adeoye-2024-adjunctive-intravenous-argatroban-or-eptifibatide-for-isch 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/adeoye-2024-adjunctive-intravenous-argatroban-or-eptifibatide-for-isch 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/adeoye-2024-adjunctive-intravenous-argatroban-or-eptifibatide-for-isch 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/adeoye-2024-adjunctive-intravenous-argatroban-or-eptifibatide-for-isch 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sarhan-2025-efficacy-and-safety-of-andexanet-alfa-versus-four-factor-p 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sarhan-2025-efficacy-and-safety-of-andexanet-alfa-versus-four-factor-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sarhan-2025-efficacy-and-safety-of-andexanet-alfa-versus-four-factor-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sarhan-2025-efficacy-and-safety-of-andexanet-alfa-versus-four-factor-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/amoey-2024-predictors-and-outcomes-of-inappropriate-dosing-of-direct-o 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/amoey-2024-predictors-and-outcomes-of-inappropriate-dosing-of-direct-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/amoey-2024-predictors-and-outcomes-of-inappropriate-dosing-of-direct-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/amoey-2024-predictors-and-outcomes-of-inappropriate-dosing-of-direct-o 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/colombo-2024-intensive-2-days-training-on-perfused-human-placenta-for 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/colombo-2024-intensive-2-days-training-on-perfused-human-placenta-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/colombo-2024-intensive-2-days-training-on-perfused-human-placenta-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/colombo-2024-intensive-2-days-training-on-perfused-human-placenta-for 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mittal-2024-warfarin-and-heparin-monitoring-in-antiphospholipid-syndro 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mittal-2024-warfarin-and-heparin-monitoring-in-antiphospholipid-syndro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mittal-2024-warfarin-and-heparin-monitoring-in-antiphospholipid-syndro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mittal-2024-warfarin-and-heparin-monitoring-in-antiphospholipid-syndro 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2024-heparin-induced-thrombocytopenia-during-anticoagulation-the 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2024-heparin-induced-thrombocytopenia-during-anticoagulation-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2024-heparin-induced-thrombocytopenia-during-anticoagulation-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2024-heparin-induced-thrombocytopenia-during-anticoagulation-the 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vullien-2025-the-rich-evolutionary-history-of-the-reactive-oxygen-spec 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vullien-2025-the-rich-evolutionary-history-of-the-reactive-oxygen-spec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vullien-2025-the-rich-evolutionary-history-of-the-reactive-oxygen-spec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vullien-2025-the-rich-evolutionary-history-of-the-reactive-oxygen-spec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bhatnagar-2025-the-impact-of-lovenox-prophylaxis-and-other-anticoagula 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bhatnagar-2025-the-impact-of-lovenox-prophylaxis-and-other-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bhatnagar-2025-the-impact-of-lovenox-prophylaxis-and-other-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bhatnagar-2025-the-impact-of-lovenox-prophylaxis-and-other-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chaudhary-2025-machine-learning-predicts-bleeding-risk-in-atrial-fibri 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chaudhary-2025-machine-learning-predicts-bleeding-risk-in-atrial-fibri 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chaudhary-2025-machine-learning-predicts-bleeding-risk-in-atrial-fibri 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chaudhary-2025-machine-learning-predicts-bleeding-risk-in-atrial-fibri 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vazquez-2025-who-are-we-bridging-description-of-warfarin-patients-rece 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vazquez-2025-who-are-we-bridging-description-of-warfarin-patients-rece 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vazquez-2025-who-are-we-bridging-description-of-warfarin-patients-rece 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vazquez-2025-who-are-we-bridging-description-of-warfarin-patients-rece 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iwawaki-2025-discontinuation-of-oral-anticoagulation-after-successful 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iwawaki-2025-discontinuation-of-oral-anticoagulation-after-successful 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iwawaki-2025-discontinuation-of-oral-anticoagulation-after-successful 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iwawaki-2025-discontinuation-of-oral-anticoagulation-after-successful 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tsuchida-2025-rapidly-progressive-disseminated-intravascular-coagulati 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tsuchida-2025-rapidly-progressive-disseminated-intravascular-coagulati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tsuchida-2025-rapidly-progressive-disseminated-intravascular-coagulati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tsuchida-2025-rapidly-progressive-disseminated-intravascular-coagulati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/panos-2025-reversal-of-factor-xa-inhibitor-related-intracranial-hemorr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/panos-2025-reversal-of-factor-xa-inhibitor-related-intracranial-hemorr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/panos-2025-reversal-of-factor-xa-inhibitor-related-intracranial-hemorr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/panos-2025-reversal-of-factor-xa-inhibitor-related-intracranial-hemorr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/murthy-2025-outcomes-following-minimally-invasive-surgery-for-intracer 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/murthy-2025-outcomes-following-minimally-invasive-surgery-for-intracer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/murthy-2025-outcomes-following-minimally-invasive-surgery-for-intracer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/murthy-2025-outcomes-following-minimally-invasive-surgery-for-intracer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xie-2025-argatroban-in-patients-with-acute-ischemic-stroke-with-early 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xie-2025-argatroban-in-patients-with-acute-ischemic-stroke-with-early 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xie-2025-argatroban-in-patients-with-acute-ischemic-stroke-with-early 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xie-2025-argatroban-in-patients-with-acute-ischemic-stroke-with-early 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/luojus-2025-reduced-dose-direct-oral-anticoagulants-and-time-in-therap 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/luojus-2025-reduced-dose-direct-oral-anticoagulants-and-time-in-therap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/luojus-2025-reduced-dose-direct-oral-anticoagulants-and-time-in-therap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/luojus-2025-reduced-dose-direct-oral-anticoagulants-and-time-in-therap 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/miceli-2025-challenges-and-opportunities-of-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/miceli-2025-challenges-and-opportunities-of-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/miceli-2025-challenges-and-opportunities-of-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/miceli-2025-challenges-and-opportunities-of-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shi-2025-feasibility-and-practicality-of-a-novel-teaching-aid-for-micr 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shi-2025-feasibility-and-practicality-of-a-novel-teaching-aid-for-micr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shi-2025-feasibility-and-practicality-of-a-novel-teaching-aid-for-micr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shi-2025-feasibility-and-practicality-of-a-novel-teaching-aid-for-micr 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carbajo-2025-efficient-small-molecule-reversal-agents-for-anticoagulan 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carbajo-2025-efficient-small-molecule-reversal-agents-for-anticoagulan 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carbajo-2025-efficient-small-molecule-reversal-agents-for-anticoagulan 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carbajo-2025-efficient-small-molecule-reversal-agents-for-anticoagulan 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ahmed-2025-exploring-the-efficacy-and-safety-of-argatroban-as-an-adjun 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ahmed-2025-exploring-the-efficacy-and-safety-of-argatroban-as-an-adjun 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ahmed-2025-exploring-the-efficacy-and-safety-of-argatroban-as-an-adjun 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ahmed-2025-exploring-the-efficacy-and-safety-of-argatroban-as-an-adjun 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/parveen-2025-role-of-low-molecular-weight-heparin-in-unexplained-recur 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/parveen-2025-role-of-low-molecular-weight-heparin-in-unexplained-recur 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/parveen-2025-role-of-low-molecular-weight-heparin-in-unexplained-recur 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/parveen-2025-role-of-low-molecular-weight-heparin-in-unexplained-recur 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qureshi-2025-the-role-of-direct-oral-anticoagulants-doacs-in-cancer-as 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qureshi-2025-the-role-of-direct-oral-anticoagulants-doacs-in-cancer-as 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qureshi-2025-the-role-of-direct-oral-anticoagulants-doacs-in-cancer-as 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qureshi-2025-the-role-of-direct-oral-anticoagulants-doacs-in-cancer-as 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lerman-2025-machine-learning-application-for-bleeding-risk-prediction 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lerman-2025-machine-learning-application-for-bleeding-risk-prediction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lerman-2025-machine-learning-application-for-bleeding-risk-prediction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lerman-2025-machine-learning-application-for-bleeding-risk-prediction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kow-2025-bleeding-risk-assessment-tools-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kow-2025-bleeding-risk-assessment-tools-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kow-2025-bleeding-risk-assessment-tools-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kow-2025-bleeding-risk-assessment-tools-in-patients-with-atrial-fibril 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/alghamdi-2025-evaluation-of-gaps-in-direct-oral-anticoagulants-doacs-m 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/alghamdi-2025-evaluation-of-gaps-in-direct-oral-anticoagulants-doacs-m 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/alghamdi-2025-evaluation-of-gaps-in-direct-oral-anticoagulants-doacs-m 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/alghamdi-2025-evaluation-of-gaps-in-direct-oral-anticoagulants-doacs-m 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cui-2025-efficacy-of-argatroban-plus-alteplase-according-to-time-from 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cui-2025-efficacy-of-argatroban-plus-alteplase-according-to-time-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cui-2025-efficacy-of-argatroban-plus-alteplase-according-to-time-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cui-2025-efficacy-of-argatroban-plus-alteplase-according-to-time-from 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mutemi-2025-a-genome-resource-for-the-marine-annelid-platynereis-spp 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mutemi-2025-a-genome-resource-for-the-marine-annelid-platynereis-spp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mutemi-2025-a-genome-resource-for-the-marine-annelid-platynereis-spp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mutemi-2025-a-genome-resource-for-the-marine-annelid-platynereis-spp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/soler-espejo-2026-a-comparative-analysis-of-has-bled-orbit-doac-and-af 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/soler-espejo-2026-a-comparative-analysis-of-has-bled-orbit-doac-and-af 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/soler-espejo-2026-a-comparative-analysis-of-has-bled-orbit-doac-and-af 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/soler-espejo-2026-a-comparative-analysis-of-has-bled-orbit-doac-and-af 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tripathi-2025-perioperative-anticoagulation-management-revisiting-brid 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tripathi-2025-perioperative-anticoagulation-management-revisiting-brid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tripathi-2025-perioperative-anticoagulation-management-revisiting-brid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tripathi-2025-perioperative-anticoagulation-management-revisiting-brid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2026-clinical-case-handling-and-experience-sharing-for-venous-co 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2026-clinical-case-handling-and-experience-sharing-for-venous-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2026-clinical-case-handling-and-experience-sharing-for-venous-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2026-clinical-case-handling-and-experience-sharing-for-venous-co 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vater-2025-microvascular-alt-flap-reconstruction-for-distal-forearm-an 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vater-2025-microvascular-alt-flap-reconstruction-for-distal-forearm-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vater-2025-microvascular-alt-flap-reconstruction-for-distal-forearm-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vater-2025-microvascular-alt-flap-reconstruction-for-distal-forearm-an 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tsiklin-2025-optimization-of-the-non-living-animal-models-for-simulati 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tsiklin-2025-optimization-of-the-non-living-animal-models-for-simulati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tsiklin-2025-optimization-of-the-non-living-animal-models-for-simulati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tsiklin-2025-optimization-of-the-non-living-animal-models-for-simulati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lyra-2025-extended-treatment-with-reduced-dose-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lyra-2025-extended-treatment-with-reduced-dose-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lyra-2025-extended-treatment-with-reduced-dose-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lyra-2025-extended-treatment-with-reduced-dose-direct-oral-anticoagula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cremer-2026-macroid-formation-in-salmacina-stellaebayensis-n-sp-from-m 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cremer-2026-macroid-formation-in-salmacina-stellaebayensis-n-sp-from-m 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cremer-2026-macroid-formation-in-salmacina-stellaebayensis-n-sp-from-m 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cremer-2026-macroid-formation-in-salmacina-stellaebayensis-n-sp-from-m 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/makhoul-2026-free-flap-reconstruction-of-xylazine-associated-wounds-a 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/makhoul-2026-free-flap-reconstruction-of-xylazine-associated-wounds-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/makhoul-2026-free-flap-reconstruction-of-xylazine-associated-wounds-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/makhoul-2026-free-flap-reconstruction-of-xylazine-associated-wounds-a 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/platova-2026-transcriptomic-analysis-of-three-annelid-species-looking 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/platova-2026-transcriptomic-analysis-of-three-annelid-species-looking 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/platova-2026-transcriptomic-analysis-of-three-annelid-species-looking 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/platova-2026-transcriptomic-analysis-of-three-annelid-species-looking 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/landmesser-2026-left-atrial-appendage-closure-or-medical-therapy-in-at 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/landmesser-2026-left-atrial-appendage-closure-or-medical-therapy-in-at 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/landmesser-2026-left-atrial-appendage-closure-or-medical-therapy-in-at 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/landmesser-2026-left-atrial-appendage-closure-or-medical-therapy-in-at 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/negargar-2025-comprehensive-coagulation-management-in-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/negargar-2025-comprehensive-coagulation-management-in-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/negargar-2025-comprehensive-coagulation-management-in-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/negargar-2025-comprehensive-coagulation-management-in-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sandeep-2026-pitfalls-during-mandible-reconstruction-with-free-fibula 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sandeep-2026-pitfalls-during-mandible-reconstruction-with-free-fibula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sandeep-2026-pitfalls-during-mandible-reconstruction-with-free-fibula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sandeep-2026-pitfalls-during-mandible-reconstruction-with-free-fibula 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/matarazzo-2026-propeller-flaps-in-extremity-sarcoma-reconstruction-a-s 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/matarazzo-2026-propeller-flaps-in-extremity-sarcoma-reconstruction-a-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/matarazzo-2026-propeller-flaps-in-extremity-sarcoma-reconstruction-a-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/matarazzo-2026-propeller-flaps-in-extremity-sarcoma-reconstruction-a-s 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rude-1969-chemical-and-ultrastructural-identification-of-5-hydroxytryp 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rude-1969-chemical-and-ultrastructural-identification-of-5-hydroxytryp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rude-1969-chemical-and-ultrastructural-identification-of-5-hydroxytryp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rude-1969-chemical-and-ultrastructural-identification-of-5-hydroxytryp 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/belardetti-1984-serotonin-and-retzius-cell-depress-the-hyperpolarizati 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/belardetti-1984-serotonin-and-retzius-cell-depress-the-hyperpolarizati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/belardetti-1984-serotonin-and-retzius-cell-depress-the-hyperpolarizati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/belardetti-1984-serotonin-and-retzius-cell-depress-the-hyperpolarizati 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ching-1993-selection-of-transmitter-responses-at-sites-of-neurite-cont 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ching-1993-selection-of-transmitter-responses-at-sites-of-neurite-cont 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ching-1993-selection-of-transmitter-responses-at-sites-of-neurite-cont 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ching-1993-selection-of-transmitter-responses-at-sites-of-neurite-cont 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bayascas-1997-planarian-hox-genes-novel-patterns-of-expression-during 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bayascas-1997-planarian-hox-genes-novel-patterns-of-expression-during 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bayascas-1997-planarian-hox-genes-novel-patterns-of-expression-during 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bayascas-1997-planarian-hox-genes-novel-patterns-of-expression-during 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/utley-1998-the-failing-flap-in-facial-plastic-and-reconstructive-surge 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/utley-1998-the-failing-flap-in-facial-plastic-and-reconstructive-surge 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/utley-1998-the-failing-flap-in-facial-plastic-and-reconstructive-surge 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/utley-1998-the-failing-flap-in-facial-plastic-and-reconstructive-surge 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/unknown-1998-lepirudin-for-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/unknown-1998-lepirudin-for-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/unknown-1998-lepirudin-for-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/unknown-1998-lepirudin-for-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/greinacher-1999-recombinant-hirudin-lepirudin-provides-safe-and-effect 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/greinacher-1999-recombinant-hirudin-lepirudin-provides-safe-and-effect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/greinacher-1999-recombinant-hirudin-lepirudin-provides-safe-and-effect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/greinacher-1999-recombinant-hirudin-lepirudin-provides-safe-and-effect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lutsey-2022-epidemiology-prevention-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lutsey-2022-epidemiology-prevention-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lutsey-2022-epidemiology-prevention-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lutsey-2022-epidemiology-prevention-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/salazar-adum-2018-venous-thromboembolism-controversies 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/salazar-adum-2018-venous-thromboembolism-controversies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/salazar-adum-2018-venous-thromboembolism-controversies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/salazar-adum-2018-venous-thromboembolism-controversies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kekre-2018-venous-thromboembolism-incidence-hematologic-malignancies 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kekre-2018-venous-thromboembolism-incidence-hematologic-malignancies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kekre-2018-venous-thromboembolism-incidence-hematologic-malignancies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kekre-2018-venous-thromboembolism-incidence-hematologic-malignancies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/saitoh-2024-incidence-venous-thromboembolism-cardiovascular-surgery 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/saitoh-2024-incidence-venous-thromboembolism-cardiovascular-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/saitoh-2024-incidence-venous-thromboembolism-cardiovascular-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/saitoh-2024-incidence-venous-thromboembolism-cardiovascular-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/marschang-2025-epidemiology-venous-thromboembolism-implications-clinical 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/marschang-2025-epidemiology-venous-thromboembolism-implications-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/marschang-2025-epidemiology-venous-thromboembolism-implications-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/marschang-2025-epidemiology-venous-thromboembolism-implications-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/paulmann-2023-incidence-venous-thromboembolism-among-commonly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/paulmann-2023-incidence-venous-thromboembolism-among-commonly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/paulmann-2023-incidence-venous-thromboembolism-among-commonly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/paulmann-2023-incidence-venous-thromboembolism-among-commonly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sada-2023-incidence-venous-thromboembolism-following-adrenalectomy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sada-2023-incidence-venous-thromboembolism-following-adrenalectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sada-2023-incidence-venous-thromboembolism-following-adrenalectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sada-2023-incidence-venous-thromboembolism-following-adrenalectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/harry-2025-incidence-venous-thromboembolism-type-solid 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/harry-2025-incidence-venous-thromboembolism-type-solid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/harry-2025-incidence-venous-thromboembolism-type-solid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/harry-2025-incidence-venous-thromboembolism-type-solid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/na-2022-incidence-characteristics-risk-factors-venous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/na-2022-incidence-characteristics-risk-factors-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/na-2022-incidence-characteristics-risk-factors-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/na-2022-incidence-characteristics-risk-factors-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lankeit-2016-incidence-venous-thromboembolism-copd-linking 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lankeit-2016-incidence-venous-thromboembolism-copd-linking 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lankeit-2016-incidence-venous-thromboembolism-copd-linking 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lankeit-2016-incidence-venous-thromboembolism-copd-linking 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yang-2024-incidence-risk-factors-vte-lung 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yang-2024-incidence-risk-factors-vte-lung 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yang-2024-incidence-risk-factors-vte-lung 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yang-2024-incidence-risk-factors-vte-lung 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/draganich-2023-venous-thromboembolism-exploring-incidence-utility 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/draganich-2023-venous-thromboembolism-exploring-incidence-utility 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/draganich-2023-venous-thromboembolism-exploring-incidence-utility 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/draganich-2023-venous-thromboembolism-exploring-incidence-utility 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ikeda-2022-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ikeda-2022-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ikeda-2022-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ikeda-2022-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lampert-2024-higher-incidence-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lampert-2024-higher-incidence-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lampert-2024-higher-incidence-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lampert-2024-higher-incidence-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/okusaka-2023-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/okusaka-2023-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/okusaka-2023-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/okusaka-2023-incidence-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stein-2011-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stein-2011-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stein-2011-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stein-2011-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stein-2010-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stein-2010-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stein-2010-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stein-2010-epidemiology-incidence-scope-problem-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anijs-2023-venous-arterial-thromboembolism-colorectal-cancer 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anijs-2023-venous-arterial-thromboembolism-colorectal-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anijs-2023-venous-arterial-thromboembolism-colorectal-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anijs-2023-venous-arterial-thromboembolism-colorectal-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/felber-2018-venous-thromboembolism-urological-cancer-epidemiology 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/felber-2018-venous-thromboembolism-urological-cancer-epidemiology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/felber-2018-venous-thromboembolism-urological-cancer-epidemiology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/felber-2018-venous-thromboembolism-urological-cancer-epidemiology 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/boulet-2024-incidence-venous-thromboembolism-pediatric-orthopedics 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/boulet-2024-incidence-venous-thromboembolism-pediatric-orthopedics 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/boulet-2024-incidence-venous-thromboembolism-pediatric-orthopedics 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/boulet-2024-incidence-venous-thromboembolism-pediatric-orthopedics 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/konstantinides-2020-2019-esc-guidelines-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/konstantinides-2020-2019-esc-guidelines-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/konstantinides-2020-2019-esc-guidelines-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/konstantinides-2020-2019-esc-guidelines-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/khandait-2023-acute-pulmonary-embolism-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/khandait-2023-acute-pulmonary-embolism-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/khandait-2023-acute-pulmonary-embolism-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/khandait-2023-acute-pulmonary-embolism-diagnosis-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/duffett-2020-pulmonary-embolism-update-management-controversies 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/duffett-2020-pulmonary-embolism-update-management-controversies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/duffett-2020-pulmonary-embolism-update-management-controversies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/duffett-2020-pulmonary-embolism-update-management-controversies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guarnieri-2025-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guarnieri-2025-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guarnieri-2025-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guarnieri-2025-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/martinez-licha-2019-current-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/martinez-licha-2019-current-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/martinez-licha-2019-current-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/martinez-licha-2019-current-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ross-2021-acute-management-high-risk-intermediate 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ross-2021-acute-management-high-risk-intermediate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ross-2021-acute-management-high-risk-intermediate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ross-2021-acute-management-high-risk-intermediate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goldhaber-2012-pulmonary-embolism-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goldhaber-2012-pulmonary-embolism-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goldhaber-2012-pulmonary-embolism-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goldhaber-2012-pulmonary-embolism-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/de-wit-2023-risk-stratification-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/de-wit-2023-risk-stratification-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/de-wit-2023-risk-stratification-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/de-wit-2023-risk-stratification-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/virk-2018-systemic-thrombolysis-pulmonary-embolism-evidence 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/virk-2018-systemic-thrombolysis-pulmonary-embolism-evidence 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/virk-2018-systemic-thrombolysis-pulmonary-embolism-evidence 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/virk-2018-systemic-thrombolysis-pulmonary-embolism-evidence 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rali-2018-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rali-2018-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rali-2018-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rali-2018-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cox-2025-basics-diagnosis-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cox-2025-basics-diagnosis-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cox-2025-basics-diagnosis-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cox-2025-basics-diagnosis-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hecker-2015-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hecker-2015-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hecker-2015-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hecker-2015-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carroll-2023-percutaneous-management-high-risk-pulmonary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carroll-2023-percutaneous-management-high-risk-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carroll-2023-percutaneous-management-high-risk-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carroll-2023-percutaneous-management-high-risk-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tu-2019-prospective-single-arm-multicenter-catheter 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tu-2019-prospective-single-arm-multicenter-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tu-2019-prospective-single-arm-multicenter-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tu-2019-prospective-single-arm-multicenter-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tan-2020-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tan-2020-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tan-2020-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tan-2020-contemporary-management-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/serebriakoff-2022-pulmonary-embolism-management-emergency-department 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/serebriakoff-2022-pulmonary-embolism-management-emergency-department 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/serebriakoff-2022-pulmonary-embolism-management-emergency-department 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/serebriakoff-2022-pulmonary-embolism-management-emergency-department 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barco-2017-risk-adapted-management-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barco-2017-risk-adapted-management-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barco-2017-risk-adapted-management-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barco-2017-risk-adapted-management-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rivera-lebron-2019-diagnosis-treatment-follow-up-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rivera-lebron-2019-diagnosis-treatment-follow-up-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rivera-lebron-2019-diagnosis-treatment-follow-up-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rivera-lebron-2019-diagnosis-treatment-follow-up-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/furfaro-2018-catheter-directed-thrombolysis-intermediate-risk 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/furfaro-2018-catheter-directed-thrombolysis-intermediate-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/furfaro-2018-catheter-directed-thrombolysis-intermediate-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/furfaro-2018-catheter-directed-thrombolysis-intermediate-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bottega-2020-thrombolysis-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bottega-2020-thrombolysis-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bottega-2020-thrombolysis-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bottega-2020-thrombolysis-acute-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/allroggen-2000-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/allroggen-2000-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/allroggen-2000-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/allroggen-2000-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ohteki-2000-clinical-experience-argatroban-anticoagulation-cardiovascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ohteki-2000-clinical-experience-argatroban-anticoagulation-cardiovascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ohteki-2000-clinical-experience-argatroban-anticoagulation-cardiovascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ohteki-2000-clinical-experience-argatroban-anticoagulation-cardiovascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/seaver-2001-establishment-segment-polarity-ectoderm-leech 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/seaver-2001-establishment-segment-polarity-ectoderm-leech 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/seaver-2001-establishment-segment-polarity-ectoderm-leech 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/seaver-2001-establishment-segment-polarity-ectoderm-leech 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mosesson-2001-structure-biological-features-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mosesson-2001-structure-biological-features-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mosesson-2001-structure-biological-features-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mosesson-2001-structure-biological-features-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nieuwenhuizen-2001-fibrin-mediated-plasminogen-activation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nieuwenhuizen-2001-fibrin-mediated-plasminogen-activation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nieuwenhuizen-2001-fibrin-mediated-plasminogen-activation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nieuwenhuizen-2001-fibrin-mediated-plasminogen-activation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goldstein-2001-dorsal-snail-homologs-leech-development 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goldstein-2001-dorsal-snail-homologs-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goldstein-2001-dorsal-snail-homologs-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goldstein-2001-dorsal-snail-homologs-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-2002-micromere-lineages-glossiphoniid-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-2002-micromere-lineages-glossiphoniid-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-2002-micromere-lineages-glossiphoniid-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-2002-micromere-lineages-glossiphoniid-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/berg-2003-engineering-proteolytic-specificity-activated-protein 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/berg-2003-engineering-proteolytic-specificity-activated-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/berg-2003-engineering-proteolytic-specificity-activated-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/berg-2003-engineering-proteolytic-specificity-activated-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rand-2003-platelet-function-assays 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rand-2003-platelet-function-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rand-2003-platelet-function-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rand-2003-platelet-function-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lian-2003-engineering-staphylokinase-based-fibrinolytic-agent 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lian-2003-engineering-staphylokinase-based-fibrinolytic-agent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lian-2003-engineering-staphylokinase-based-fibrinolytic-agent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lian-2003-engineering-staphylokinase-based-fibrinolytic-agent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/le-bonniec-1992-interaction-thrombin-des-etw-antithrombin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/le-bonniec-1992-interaction-thrombin-des-etw-antithrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/le-bonniec-1992-interaction-thrombin-des-etw-antithrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/le-bonniec-1992-interaction-thrombin-des-etw-antithrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kuo-2003-distinct-patterning-mechanism-o-p 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kuo-2003-distinct-patterning-mechanism-o-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kuo-2003-distinct-patterning-mechanism-o-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kuo-2003-distinct-patterning-mechanism-o-p 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/williamson-2004-argatroban-dosing-intensive-care-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/williamson-2004-argatroban-dosing-intensive-care-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/williamson-2004-argatroban-dosing-intensive-care-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/williamson-2004-argatroban-dosing-intensive-care-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lowe-2004-plasma-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lowe-2004-plasma-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lowe-2004-plasma-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lowe-2004-plasma-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tang-2005-argatroban-renal-replacement-therapy-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tang-2005-argatroban-renal-replacement-therapy-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tang-2005-argatroban-renal-replacement-therapy-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tang-2005-argatroban-renal-replacement-therapy-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/miller-2005-cost-benefits-anticoagulation-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/miller-2005-cost-benefits-anticoagulation-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/miller-2005-cost-benefits-anticoagulation-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/miller-2005-cost-benefits-anticoagulation-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2005-applications-mrna-injections-analyzing-cell 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2005-applications-mrna-injections-analyzing-cell 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2005-applications-mrna-injections-analyzing-cell 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2005-applications-mrna-injections-analyzing-cell 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/weisel-2005-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/weisel-2005-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/weisel-2005-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/weisel-2005-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prince-2005-glucocorticosteroids-primary-biliary-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prince-2005-glucocorticosteroids-primary-biliary-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prince-2005-glucocorticosteroids-primary-biliary-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prince-2005-glucocorticosteroids-primary-biliary-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stam-2005-thrombosis-cerebral-veins-sinuses 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stam-2005-thrombosis-cerebral-veins-sinuses 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stam-2005-thrombosis-cerebral-veins-sinuses 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stam-2005-thrombosis-cerebral-veins-sinuses 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/franchini-2006-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/franchini-2006-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/franchini-2006-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/franchini-2006-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/laurens-2006-fibrin-structure-wound-healing 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/laurens-2006-fibrin-structure-wound-healing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/laurens-2006-fibrin-structure-wound-healing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/laurens-2006-fibrin-structure-wound-healing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/agee-2006-maternal-expression-nanos-homolog-required 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/agee-2006-maternal-expression-nanos-homolog-required 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/agee-2006-maternal-expression-nanos-homolog-required 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/agee-2006-maternal-expression-nanos-homolog-required 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bakhai-2006-economic-implications-bivalirudin-cardiac-catheterization 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bakhai-2006-economic-implications-bivalirudin-cardiac-catheterization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bakhai-2006-economic-implications-bivalirudin-cardiac-catheterization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bakhai-2006-economic-implications-bivalirudin-cardiac-catheterization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gruber-2007-relative-antithrombotic-antihemostatic-effects-protein 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gruber-2007-relative-antithrombotic-antihemostatic-effects-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gruber-2007-relative-antithrombotic-antihemostatic-effects-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gruber-2007-relative-antithrombotic-antihemostatic-effects-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/davenport-2007-anticoagulation-options-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/davenport-2007-anticoagulation-options-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/davenport-2007-anticoagulation-options-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/davenport-2007-anticoagulation-options-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/garces-2007-anticoagulation-continuous-renal-replacement-therapies 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/garces-2007-anticoagulation-continuous-renal-replacement-therapies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/garces-2007-anticoagulation-continuous-renal-replacement-therapies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/garces-2007-anticoagulation-continuous-renal-replacement-therapies 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/brand-2008-argatroban-therapy-hepatic-renal-impairment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/brand-2008-argatroban-therapy-hepatic-renal-impairment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/brand-2008-argatroban-therapy-hepatic-renal-impairment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/brand-2008-argatroban-therapy-hepatic-renal-impairment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dalainas-2008-pathogenesis-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dalainas-2008-pathogenesis-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dalainas-2008-pathogenesis-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dalainas-2008-pathogenesis-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/link-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/link-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/link-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/link-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/blanchette-1991-inherited-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/blanchette-1991-inherited-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/blanchette-1991-inherited-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/blanchette-1991-inherited-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/levi-2009-guidelines-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/levi-2009-guidelines-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/levi-2009-guidelines-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/levi-2009-guidelines-diagnosis-management-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reikvam-2009-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reikvam-2009-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reikvam-2009-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reikvam-2009-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mcglasson-2009-whole-blood-platelet-aggregometry-platelet 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mcglasson-2009-whole-blood-platelet-aggregometry-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mcglasson-2009-whole-blood-platelet-aggregometry-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mcglasson-2009-whole-blood-platelet-aggregometry-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tolwani-2009-anticoagulation-continuous-renal-replacement-therapy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tolwani-2009-anticoagulation-continuous-renal-replacement-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tolwani-2009-anticoagulation-continuous-renal-replacement-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tolwani-2009-anticoagulation-continuous-renal-replacement-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/keegan-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/keegan-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/keegan-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/keegan-2009-argatroban-anticoagulation-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2009-grandparental-stem-cells-leech-segmentation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2009-grandparental-stem-cells-leech-segmentation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2009-grandparental-stem-cells-leech-segmentation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2009-grandparental-stem-cells-leech-segmentation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/glauser-2009-anticoagulant-activity-sulfated-galactan-serpin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/glauser-2009-anticoagulant-activity-sulfated-galactan-serpin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/glauser-2009-anticoagulant-activity-sulfated-galactan-serpin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/glauser-2009-anticoagulant-activity-sulfated-galactan-serpin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cho-2010-evolutionary-dynamics-wnt-gene-family 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cho-2010-evolutionary-dynamics-wnt-gene-family 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cho-2010-evolutionary-dynamics-wnt-gene-family 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cho-2010-evolutionary-dynamics-wnt-gene-family 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mcrae-2010-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mcrae-2010-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mcrae-2010-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mcrae-2010-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/morel-kopp-2010-heparin-induced-thrombocytopenia-evaluation-igg 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/morel-kopp-2010-heparin-induced-thrombocytopenia-evaluation-igg 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/morel-kopp-2010-heparin-induced-thrombocytopenia-evaluation-igg 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/morel-kopp-2010-heparin-induced-thrombocytopenia-evaluation-igg 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kimmelstiel-2011-bivalirudin-dual-inhibitor-thrombin-collagen 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kimmelstiel-2011-bivalirudin-dual-inhibitor-thrombin-collagen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kimmelstiel-2011-bivalirudin-dual-inhibitor-thrombin-collagen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kimmelstiel-2011-bivalirudin-dual-inhibitor-thrombin-collagen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/forbes-2011-pediatric-catheterization-laboratory-anticoagulation-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/forbes-2011-pediatric-catheterization-laboratory-anticoagulation-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/forbes-2011-pediatric-catheterization-laboratory-anticoagulation-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/forbes-2011-pediatric-catheterization-laboratory-anticoagulation-bivalirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/masotti-2011-practical-management-intracerebral-hemorrhage-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/masotti-2011-practical-management-intracerebral-hemorrhage-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/masotti-2011-practical-management-intracerebral-hemorrhage-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/masotti-2011-practical-management-intracerebral-hemorrhage-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shaikh-2011-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shaikh-2011-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shaikh-2011-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shaikh-2011-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/coutinho-2011-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/coutinho-2011-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/coutinho-2011-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/coutinho-2011-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yates-2011-apixaban-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yates-2011-apixaban-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yates-2011-apixaban-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yates-2011-apixaban-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/alonso-de-lecinana-2011-guidelines-treatment-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/alonso-de-lecinana-2011-guidelines-treatment-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/alonso-de-lecinana-2011-guidelines-treatment-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/alonso-de-lecinana-2011-guidelines-treatment-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/caprio-2012-duration-anticoagulation-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/caprio-2012-duration-anticoagulation-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/caprio-2012-duration-anticoagulation-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/caprio-2012-duration-anticoagulation-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cortese-2012-bivalirudin-has-own-shelf-cath 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cortese-2012-bivalirudin-has-own-shelf-cath 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cortese-2012-bivalirudin-has-own-shelf-cath 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cortese-2012-bivalirudin-has-own-shelf-cath 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/coutinho-2012-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/coutinho-2012-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/coutinho-2012-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/coutinho-2012-anticoagulation-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/garner-2013-clinical-utility-bivalirudin-coronary-artery 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/garner-2013-clinical-utility-bivalirudin-coronary-artery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/garner-2013-clinical-utility-bivalirudin-coronary-artery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/garner-2013-clinical-utility-bivalirudin-coronary-artery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/donadini-2012-management-bleeding-receiving-conventional-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/donadini-2012-management-bleeding-receiving-conventional-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/donadini-2012-management-bleeding-receiving-conventional-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/donadini-2012-management-bleeding-receiving-conventional-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/martinelli-2012-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/martinelli-2012-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/martinelli-2012-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/martinelli-2012-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ferguson-2013-recurring-extracorporeal-circuit-clotting-continuous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ferguson-2013-recurring-extracorporeal-circuit-clotting-continuous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ferguson-2013-recurring-extracorporeal-circuit-clotting-continuous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ferguson-2013-recurring-extracorporeal-circuit-clotting-continuous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/singla-2013-protamine-induced-immune-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/singla-2013-protamine-induced-immune-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/singla-2013-protamine-induced-immune-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/singla-2013-protamine-induced-immune-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cayla-2013-management-cardiovascular-disease-haemophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cayla-2013-management-cardiovascular-disease-haemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cayla-2013-management-cardiovascular-disease-haemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cayla-2013-management-cardiovascular-disease-haemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nattel-2013-anticoagulation-atrial-fibrillation-state-art 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nattel-2013-anticoagulation-atrial-fibrillation-state-art 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nattel-2013-anticoagulation-atrial-fibrillation-state-art 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nattel-2013-anticoagulation-atrial-fibrillation-state-art 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hossain-2013-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hossain-2013-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hossain-2013-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hossain-2013-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dasararaju-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dasararaju-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dasararaju-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dasararaju-2013-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/klingele-2013-argatroban-experiences-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/klingele-2013-argatroban-experiences-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/klingele-2013-argatroban-experiences-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/klingele-2013-argatroban-experiences-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bhatty-2014-contemporary-anticoagulation-therapy-undergoing-percutaneous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bhatty-2014-contemporary-anticoagulation-therapy-undergoing-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bhatty-2014-contemporary-anticoagulation-therapy-undergoing-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bhatty-2014-contemporary-anticoagulation-therapy-undergoing-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kuntze-soderqvist-2014-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kuntze-soderqvist-2014-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kuntze-soderqvist-2014-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kuntze-soderqvist-2014-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/choi-2014-acute-coagulopathy-pediatric-trauma 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/choi-2014-acute-coagulopathy-pediatric-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/choi-2014-acute-coagulopathy-pediatric-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/choi-2014-acute-coagulopathy-pediatric-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/le-roux-2014-race-against-clock-overcoming-challenges 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/le-roux-2014-race-against-clock-overcoming-challenges 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/le-roux-2014-race-against-clock-overcoming-challenges 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/le-roux-2014-race-against-clock-overcoming-challenges 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/da-luz-2014-effect-thromboelastography-teg-xae-rotational 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/da-luz-2014-effect-thromboelastography-teg-xae-rotational 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/da-luz-2014-effect-thromboelastography-teg-xae-rotational 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/da-luz-2014-effect-thromboelastography-teg-xae-rotational 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yates-2015-reversal-anticoagulant-effects-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yates-2015-reversal-anticoagulant-effects-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yates-2015-reversal-anticoagulant-effects-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yates-2015-reversal-anticoagulant-effects-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vanden-daelen-2014-monitoring-reversal-strategies-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vanden-daelen-2014-monitoring-reversal-strategies-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vanden-daelen-2014-monitoring-reversal-strategies-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vanden-daelen-2014-monitoring-reversal-strategies-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gaglia-2014-glycoprotein-iib-iiia-inhibitors-increase 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gaglia-2014-glycoprotein-iib-iiia-inhibitors-increase 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gaglia-2014-glycoprotein-iib-iiia-inhibitors-increase 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gaglia-2014-glycoprotein-iib-iiia-inhibitors-increase 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/siegal-2015-managing-target-specific-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/siegal-2015-managing-target-specific-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/siegal-2015-managing-target-specific-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/siegal-2015-managing-target-specific-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hunt-2015-thromboelastography-teg-rotational-thromboelastometry-rotem 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hunt-2015-thromboelastography-teg-rotational-thromboelastometry-rotem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hunt-2015-thromboelastography-teg-rotational-thromboelastometry-rotem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hunt-2015-thromboelastography-teg-rotational-thromboelastometry-rotem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/weisblat-2014-developmental-biology-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/weisblat-2014-developmental-biology-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/weisblat-2014-developmental-biology-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/weisblat-2014-developmental-biology-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/erez-2015-disseminated-intravascular-coagulation-pregnancy-insights 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/erez-2015-disseminated-intravascular-coagulation-pregnancy-insights 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/erez-2015-disseminated-intravascular-coagulation-pregnancy-insights 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/erez-2015-disseminated-intravascular-coagulation-pregnancy-insights 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/israels-2015-laboratory-testing-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/israels-2015-laboratory-testing-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/israels-2015-laboratory-testing-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/israels-2015-laboratory-testing-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/valla-2015-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/valla-2015-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/valla-2015-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/valla-2015-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2015-bivalirudin-anticoagulant-therapy-without-platelet 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2015-bivalirudin-anticoagulant-therapy-without-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2015-bivalirudin-anticoagulant-therapy-without-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2015-bivalirudin-anticoagulant-therapy-without-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cosmi-2015-current-management-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cosmi-2015-current-management-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cosmi-2015-current-management-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cosmi-2015-current-management-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gonzalez-2016-goal-directed-hemostatic-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gonzalez-2016-goal-directed-hemostatic-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gonzalez-2016-goal-directed-hemostatic-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gonzalez-2016-goal-directed-hemostatic-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gando-2016-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gando-2016-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gando-2016-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gando-2016-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sie-2016-spotlight-idarucizumab-potential-reversal-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sie-2016-spotlight-idarucizumab-potential-reversal-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sie-2016-spotlight-idarucizumab-potential-reversal-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sie-2016-spotlight-idarucizumab-potential-reversal-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qi-2017-portal-vein-thrombosis-recent-advance 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qi-2017-portal-vein-thrombosis-recent-advance 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qi-2017-portal-vein-thrombosis-recent-advance 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qi-2017-portal-vein-thrombosis-recent-advance 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gonzalez-2017-management-trauma-induced-coagulopathy-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gonzalez-2017-management-trauma-induced-coagulopathy-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gonzalez-2017-management-trauma-induced-coagulopathy-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gonzalez-2017-management-trauma-induced-coagulopathy-thrombelastography 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/weisel-2017-fibrin-formation-structure-properties 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/weisel-2017-fibrin-formation-structure-properties 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/weisel-2017-fibrin-formation-structure-properties 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/weisel-2017-fibrin-formation-structure-properties 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kamel-2017-cardioembolic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kamel-2017-cardioembolic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kamel-2017-cardioembolic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kamel-2017-cardioembolic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gendron-2017-real-world-idarucizumab-dabigatran-reversal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gendron-2017-real-world-idarucizumab-dabigatran-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gendron-2017-real-world-idarucizumab-dabigatran-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gendron-2017-real-world-idarucizumab-dabigatran-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/luan-2017-joannsin-novel-kunitz-type-fxa 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/luan-2017-joannsin-novel-kunitz-type-fxa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/luan-2017-joannsin-novel-kunitz-type-fxa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/luan-2017-joannsin-novel-kunitz-type-fxa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/davenport-2001-management-heparin-induced-thrombocytopenia-renal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/davenport-2001-management-heparin-induced-thrombocytopenia-renal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/davenport-2001-management-heparin-induced-thrombocytopenia-renal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/davenport-2001-management-heparin-induced-thrombocytopenia-renal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sibbing-2017-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sibbing-2017-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sibbing-2017-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sibbing-2017-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/amri-2017-fibrinogen-mahdia-congenitally-abnormal-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/amri-2017-fibrinogen-mahdia-congenitally-abnormal-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/amri-2017-fibrinogen-mahdia-congenitally-abnormal-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/amri-2017-fibrinogen-mahdia-congenitally-abnormal-fibrinogen 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sriram-2017-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sriram-2017-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sriram-2017-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sriram-2017-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wang-2017-recombinant-chemo-bio-orthogonal-synthesis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wang-2017-recombinant-chemo-bio-orthogonal-synthesis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wang-2017-recombinant-chemo-bio-orthogonal-synthesis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wang-2017-recombinant-chemo-bio-orthogonal-synthesis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2017-spatiotemporal-expression-twist-homolog-leech 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2017-spatiotemporal-expression-twist-homolog-leech 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2017-spatiotemporal-expression-twist-homolog-leech 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2017-spatiotemporal-expression-twist-homolog-leech 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hvas-2017-platelet-function-analyzed-light-transmission 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hvas-2017-platelet-function-analyzed-light-transmission 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hvas-2017-platelet-function-analyzed-light-transmission 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hvas-2017-platelet-function-analyzed-light-transmission 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fritsma-2017-whole-blood-platelet-aggregometry 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fritsma-2017-whole-blood-platelet-aggregometry 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fritsma-2017-whole-blood-platelet-aggregometry 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fritsma-2017-whole-blood-platelet-aggregometry 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/koltai-2017-platelet-aggregometry-testing-molecular-mechanisms 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/koltai-2017-platelet-aggregometry-testing-molecular-mechanisms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/koltai-2017-platelet-aggregometry-testing-molecular-mechanisms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/koltai-2017-platelet-aggregometry-testing-molecular-mechanisms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tralhao-2017-dabigatran-reversal-idarucizumab-undergoing-heart 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tralhao-2017-dabigatran-reversal-idarucizumab-undergoing-heart 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tralhao-2017-dabigatran-reversal-idarucizumab-undergoing-heart 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tralhao-2017-dabigatran-reversal-idarucizumab-undergoing-heart 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cortese-2018-idarucizumab-what-should-know 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cortese-2018-idarucizumab-what-should-know 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cortese-2018-idarucizumab-what-should-know 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cortese-2018-idarucizumab-what-should-know 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2017-criteria-sepsis-induced-coagulopathy-sic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2017-criteria-sepsis-induced-coagulopathy-sic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2017-criteria-sepsis-induced-coagulopathy-sic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2017-criteria-sepsis-induced-coagulopathy-sic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/farley-2017-prevalence-overtesting-true-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/farley-2017-prevalence-overtesting-true-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/farley-2017-prevalence-overtesting-true-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/farley-2017-prevalence-overtesting-true-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tsai-2017-real-world-experience-idarucizumab-reverse 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tsai-2017-real-world-experience-idarucizumab-reverse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tsai-2017-real-world-experience-idarucizumab-reverse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tsai-2017-real-world-experience-idarucizumab-reverse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lopez-lopez-2017-oral-anticoagulants-prevention-stroke-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lopez-lopez-2017-oral-anticoagulants-prevention-stroke-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lopez-lopez-2017-oral-anticoagulants-prevention-stroke-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lopez-lopez-2017-oral-anticoagulants-prevention-stroke-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/levi-2017-how-i-treat-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/levi-2017-how-i-treat-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/levi-2017-how-i-treat-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/levi-2017-how-i-treat-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zapata-wainberg-2017-mechanical-thrombectomy-orally-anticoagulated-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zapata-wainberg-2017-mechanical-thrombectomy-orally-anticoagulated-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zapata-wainberg-2017-mechanical-thrombectomy-orally-anticoagulated-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zapata-wainberg-2017-mechanical-thrombectomy-orally-anticoagulated-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-2018-platelet-activating-antibodies-detectable-earliest 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-2018-platelet-activating-antibodies-detectable-earliest 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-2018-platelet-activating-antibodies-detectable-earliest 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-2018-platelet-activating-antibodies-detectable-earliest 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kuo-2018-duplicated-foxa-genes-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kuo-2018-duplicated-foxa-genes-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kuo-2018-duplicated-foxa-genes-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kuo-2018-duplicated-foxa-genes-leech-helobdella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cernik-2018-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cernik-2018-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cernik-2018-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cernik-2018-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/helten-2018-platelet-function-testing-dead-alive 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/helten-2018-platelet-function-testing-dead-alive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/helten-2018-platelet-function-testing-dead-alive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/helten-2018-platelet-function-testing-dead-alive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sauter-2018-how-i-manage-anticoagulation-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sauter-2018-how-i-manage-anticoagulation-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sauter-2018-how-i-manage-anticoagulation-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sauter-2018-how-i-manage-anticoagulation-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/akpan-2018-splanchnic-vein-thrombosis-myeloproliferative-neoplasms 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/akpan-2018-splanchnic-vein-thrombosis-myeloproliferative-neoplasms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/akpan-2018-splanchnic-vein-thrombosis-myeloproliferative-neoplasms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/akpan-2018-splanchnic-vein-thrombosis-myeloproliferative-neoplasms 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sanak-2018-intravenous-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sanak-2018-intravenous-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sanak-2018-intravenous-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sanak-2018-intravenous-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54